

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/77174 A2

(51) International Patent Classification⁷: **C07K 14/705**

(21) International Application Number: PCT/US01/11206

(22) International Filing Date: 6 April 2001 (06.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/195,595	6 April 2000 (06.04.2000)	US
60/196,872	12 April 2000 (12.04.2000)	US
60/199,020	20 April 2000 (20.04.2000)	US
60/200,552	28 April 2000 (28.04.2000)	US
60/202,348	5 May 2000 (05.05.2000)	US
60/203,495	11 May 2000 (11.05.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/195,595 (CIP)
Filed on	6 April 2000 (06.04.2000)
US	60/196,872 (CIP)
Filed on	12 April 2000 (12.04.2000)
US	60/199,020 (CIP)
Filed on	20 April 2000 (20.04.2000)
US	60/200,552 (CIP)
Filed on	28 April 2000 (28.04.2000)
US	60/202,348 (CIP)
Filed on	5 May 2000 (05.05.2000)
US	60/203,495 (CIP)
Filed on	11 May 2000 (11.05.2000)

(71) Applicant (for all designated States except US): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REDDY, Roopa** [IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA 94086 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062-2612 (US). **BOROWSKY, Mark, L.** [US/US]; 122 Orchard Avenue, Redwood City, CA 94061 (US). **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **KHAN, Farrah, A.** [IN/US]; 333 Escuela Avenue, #221, Mountain View, CA 94040 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street, #5, San Francisco, CA 94107 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue, #1, Menlo Park, CA 94025 (US). **YAO, Monique, G.**

[US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **SANJANWALA, Madhu, S.** [US/US]; 210 Sylvia Court, Los Altos, CA 94024 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **NGUYEN, Dannie, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **SEILHAMER, Jeffrey, J.** [US/US]; 12555 La Cresta, Los Altos Hills, CA 94022 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street, #205, San Leandro, CA 94577 (US). **LAL, Preeti** [IN/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). **KEARNEY, Liam** [IE/US]; 50 Woodside Avenue, San Francisco, CA 94127 (US). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **GREENE, Barrie, D.** [US/US]; 1332 10th Avenue, #104, San Francisco, CA 94122 (US). **RAUMANN, Brigitte, E.** [US/US]; 5801 South Dorchester Avenue, #3B, Chicago, IL 60637 (US). **PATTERSON, Chandra** [US/US]; 490 Sherwood Way, #1, Menlo Park, CA 94025 (US).

(74) Agents: **HAMLET-COX, Diana** et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSPORTERS AND ION CHANNELS

(57) Abstract: The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and encode TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.



WO 01/77174 A2

TRANSPORTERS AND ION CHANNELS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of transporters and ion channels and to the use of these sequences in the diagnosis, treatment, and prevention of transport, neurological, muscle, immunological, and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

BACKGROUND OF THE INVENTION

Eukaryotic cells are surrounded and subdivided into functionally distinct organelles by hydrophobic lipid bilayer membranes which are highly impermeable to most polar molecules. Cells and organelles require transport proteins to import and export essential nutrients and metal ions including K^+ , NH_4^+ , P_i , SO_4^{2-} , sugars, and vitamins, as well as various metabolic waste products. Transport proteins also play roles in antibiotic resistance, toxin secretion, ion balance, synaptic neurotransmission, kidney function, intestinal absorption, tumor growth, and other diverse cell functions (Griffith, J. and C. Sansom (1998) The Transporter Facts Book, Academic Press, San Diego CA, pp. 3-29). Transport can occur by a passive concentration-dependent mechanism, or can be linked to an energy source such as ATP hydrolysis or an ion gradient. Proteins that function in transport include carrier proteins, which bind to a specific solute and undergo a conformational change that translocates the bound solute across the membrane, and channel proteins, which form hydrophilic pores that allow specific solutes to diffuse through the membrane down an electrochemical solute gradient.

Carrier proteins which transport a single solute from one side of the membrane to the other are called uniporters. In contrast, coupled transporters link the transfer of one solute with simultaneous or sequential transfer of a second solute, either in the same direction (symport) or in the opposite direction (antiport). For example, intestinal and kidney epithelium contains a variety of symporter systems driven by the sodium gradient that exists across the plasma membrane. Sodium moves into the cell down its electrochemical gradient and brings the solute into the cell with it. The sodium gradient that provides the driving force for solute uptake is maintained by the ubiquitous Na^+/K^+ ATPase system. Sodium-coupled transporters include the mammalian glucose transporter (SGLT1), iodide transporter (NIS), and multivitamin transporter (SMVT). All three transporters have twelve putative transmembrane segments, extracellular glycosylation sites, and cytoplasmically-oriented N- and C-termini. NIS plays a crucial role in the evaluation, diagnosis, and treatment of various thyroid pathologies because it is the molecular basis for radioiodide thyroid-imaging

techniques and for specific targeting of radioisotopes to the thyroid gland (Levy, O. et al. (1997) Proc. Natl. Acad. Sci. USA 94:5568-5573). SMVT is expressed in the intestinal mucosa, kidney, and placenta, and is implicated in the transport of the water-soluble vitamins, e.g., biotin and pantothenate (Prasad, P.D. et al. (1998) J. Biol. Chem. 273:7501-7506).

5 One of the largest families of transporters is the major facilitator superfamily (MFS), also called the uniporter-symporter-antiporter family. MFS transporters are single polypeptide carriers that transport small solutes in response to ion gradients. Members of the MFS are found in all classes of living organisms, and include transporters for sugars, oligosaccharides, phosphates, nitrates, nucleosides, monocarboxylates, and drugs. MFS transporters found in eukaryotes all have a structure
10 comprising 12 transmembrane segments (Pao, S.S. et al. (1998) Microbiol. Molec. Biol. Rev. 62:1-34). The largest family of MFS transporters is the sugar transporter family, which includes the seven glucose transporters (GLUT1-GLUT7) found in humans that are required for the transport of glucose and other hexose sugars. These glucose transport proteins have unique tissue distributions and physiological functions. GLUT1 provides many cell types with their basal glucose requirements and
15 transports glucose across epithelial and endothelial barrier tissues; GLUT2 facilitates glucose uptake or efflux from the liver; GLUT3 regulates glucose supply to neurons; GLUT4 is responsible for insulin-regulated glucose disposal; and GLUT5 regulates fructose uptake into skeletal muscle. Defects in glucose transporters are involved in a recently identified neurological syndrome causing infantile seizures and developmental delay, as well as glycogen storage disease, Fanconi-Bickel
20 syndrome, and non-insulin-dependent diabetes mellitus (Mueckler, M. (1994) Eur. J. Biochem. 219:713-725; Longo, N. and L.J. Elsas (1998) Adv. Pediatr. 45:293-313).

Monocarboxylate anion transporters are proton-coupled symporters with a broad substrate specificity that includes L-lactate, pyruvate, and the ketone bodies acetate, acetoacetate, and beta-hydroxybutyrate. At least seven isoforms have been identified to date. The isoforms are
25 predicted to have twelve transmembrane (TM) helical domains with a large intracellular loop between TM6 and TM7, and play a critical role in maintaining intracellular pH by removing the protons that are produced stoichiometrically with lactate during glycolysis. The best characterized H⁺-monocarboxylate transporter is that of the erythrocyte membrane, which transports L-lactate and a wide range of other aliphatic monocarboxylates. Other cells possess H⁺-linked monocarboxylate
30 transporters with differing substrate and inhibitor selectivities. In particular, cardiac muscle and tumor cells have transporters that differ in their K_m values for certain substrates, including stereoselectivity for L- over D-lactate, and in their sensitivity to inhibitors. There are Na⁺-monocarboxylate cotransporters on the luminal surface of intestinal and kidney epithelia, which allow the uptake of lactate, pyruvate, and ketone bodies in these tissues. In addition, there are
35 specific and selective transporters for organic cations and organic anions in organs including the

kidney, intestine and liver. Organic anion transporters are selective for hydrophobic, charged molecules with electron-attracting side groups. Organic cation transporters, such as the ammonium transporter, mediate the secretion of a variety of drugs and endogenous metabolites, and contribute to the maintenance of intercellular pH (Poole, R.C. and A.P. Halestrap (1993) *Am. J. Physiol.*

- 5 264:C761-C782; Price, N.T. et al. (1998) *Biochem. J.* 329:321-328; and Martinelle, K. and I. Haggstrom (1993) *J. Biotechnol.* 30:339-350).

- ATP-binding cassette (ABC) transporters are members of a superfamily of membrane proteins that transport substances ranging from small molecules such as ions, sugars, amino acids, peptides, and phospholipids, to lipopeptides, large proteins, and complex hydrophobic drugs. ABC
- 10 transporters consist of four modules: two nucleotide-binding domains (NBD), which hydrolyze ATP to supply the energy required for transport, and two membrane-spanning domains (MSD), each containing six putative transmembrane segments. These four modules may be encoded by a single gene, as is the case for the cystic fibrosis transmembrane regulator (CFTR), or by separate genes. When encoded by separate genes, each gene product contains a single NBD and MSD. These "half-
- 15 molecules" form homo- and heterodimers, such as Tap1 and Tap2, the endoplasmic reticulum-based major histocompatibility (MHC) peptide transport system. Several genetic diseases are attributed to defects in ABC transporters, such as the following diseases and their corresponding proteins: cystic fibrosis (CFTR, an ion channel), adrenoleukodystrophy (adrenoleukodystrophy protein, ALDP), Zellweger syndrome (peroxisomal membrane protein-70, PMP70), and hyperinsulinemic
- 20 hypoglycemia (sulfonylurea receptor, SUR). Overexpression of the multidrug resistance (MDR) protein, another ABC transporter, in human cancer cells makes the cells resistant to a variety of cytotoxic drugs used in chemotherapy (Taglicht, D. and S. Michaelis (1998) *Meth. Enzymol.* 292:130-162).

- A number of metal ions such as iron, zinc, copper, cobalt, manganese, molybdenum,
- 25 selenium, nickel, and chromium are important as cofactors for a number of enzymes. For example, copper is involved in hemoglobin synthesis, connective tissue metabolism, and bone development, by acting as a cofactor in oxidoreductases such as superoxide dismutase, ferroxidase (ceruloplasmin), and lysyl oxidase. Copper and other metal ions must be provided in the diet, and are absorbed by transporters in the gastrointestinal tract. Plasma proteins transport the metal ions to the liver and
- 30 other target organs, where specific transporters move the ions into cells and cellular organelles as needed. Imbalances in metal ion metabolism have been associated with a number of disease states (Danks, D.M. (1986) *J. Med. Genet.* 23:99-106).

- Transport of fatty acids across the plasma membrane can occur by diffusion, a high capacity, low affinity process. However, under normal physiological conditions a significant fraction of fatty
- 35 acid transport appears to occur via a high affinity, low capacity protein-mediated transport process.

Fatty acid transport protein (FATP), an integral membrane protein with four transmembrane segments, is expressed in tissues exhibiting high levels of plasma membrane fatty acid flux, such as muscle, heart, and adipose. Expression of FATP is upregulated in 3T3-L1 cells during adipose conversion, and expression in COS7 fibroblasts elevates uptake of long-chain fatty acids (Hui, T.Y. et al. (1998) J. Biol. Chem. 273:27420-27429).

Mitochondrial carrier proteins are transmembrane-spanning proteins which transport ions and charged metabolites between the cytosol and the mitochondrial matrix. Examples include the ADP, ATP carrier protein; the 2-oxoglutarate/malate carrier; the phosphate carrier protein; the pyruvate carrier; the dicarboxylate carrier which transports malate, succinate, fumarate, and phosphate; the tricarboxylate carrier which transports citrate and malate; and the Grave's disease carrier protein, a protein recognized by IgG in patients with active Grave's disease, an autoimmune disorder resulting in hyperthyroidism. Proteins in this family consist of three tandem repeats of an approximately 100 amino acid domain, each of which contains two transmembrane regions (Stryer, L. (1995) Biochemistry, W.H. Freeman and Company, New York NY, p. 551; PROSITE PDOC00189 Mitochondrial energy transfer proteins signature; Online Mendelian Inheritance in Man (OMIM) *275000 Graves Disease).

This class of transporters also includes the mitochondrial uncoupling proteins, which create proton leaks across the inner mitochondrial membrane, thus uncoupling oxidative phosphorylation from ATP synthesis. The result is energy dissipation in the form of heat. Mitochondrial uncoupling proteins have been implicated as modulators of thermoregulation and metabolic rate, and have been proposed as potential targets for drugs against metabolic diseases such as obesity (Ricquier, D. et al. (1999) J. Int. Med. 245:637-642).

Ion Channels

The electrical potential of a cell is generated and maintained by controlling the movement of ions across the plasma membrane. The movement of ions requires ion channels, which form ion-selective pores within the membrane. There are two basic types of ion channels, ion transporters and gated ion channels. Ion transporters utilize the energy obtained from ATP hydrolysis to actively transport an ion against the ion's concentration gradient. Gated ion channels allow passive flow of an ion down the ion's electrochemical gradient under restricted conditions. Together, these types of ion channels generate, maintain, and utilize an electrochemical gradient that is used in 1) electrical impulse conduction down the axon of a nerve cell, 2) transport of molecules into cells against concentration gradients, 3) initiation of muscle contraction, and 4) endocrine cell secretion.

Ion Transporters

Ion transporters generate and maintain the resting electrical potential of a cell. Utilizing the energy derived from ATP hydrolysis, they transport ions against the ion's concentration gradient.

These transmembrane ATPases are divided into three families. The phosphorylated (P) class ion transporters, including Na⁺-K⁺ ATPase, Ca²⁺-ATPase, and H⁺-ATPase, are activated by a phosphorylation event. P-class ion transporters are responsible for maintaining resting potential distributions such that cytosolic concentrations of Na⁺ and Ca²⁺ are low and cytosolic concentration of K⁺ is high. The vacuolar (V) class of ion transporters includes H⁺ pumps on intracellular organelles, such as lysosomes and Golgi. V-class ion transporters are responsible for generating the low pH within the lumen of these organelles that is required for function. The coupling factor (F) class consists of H⁺ pumps in the mitochondria. F-class ion transporters utilize a proton gradient to generate ATP from ADP and inorganic phosphate (P_i).

The P-ATPases are hexamers of a 100 kD subunit with ten transmembrane domains and several large cytoplasmic regions that may play a role in ion binding (Scarborough, G.A. (1999) *Curr. Opin. Cell Biol.* 11:517-522). The V-ATPases are composed of two functional domains: the V₁ domain, a peripheral complex responsible for ATP hydrolysis; and the V₀ domain, an integral complex responsible for proton translocation across the membrane. The F-ATPases are structurally and evolutionarily related to the V-ATPases. The F-ATPase F₀ domain contains 12 copies of the c subunit, a highly hydrophobic protein composed of two transmembrane domains and containing a single buried carboxyl group in TM2 that is essential for proton transport. The V-ATPase V₀ domain contains three types of homologous c subunits with four or five transmembrane domains and the essential carboxyl group in TM4 or TM3. Both types of complex also contain a single a subunit that may be involved in regulating the pH dependence of activity (Forgac, M. (1999) *J. Biol. Chem.* 274:12951-12954).

The resting potential of the cell is utilized in many processes involving carrier proteins and gated ion channels. Carrier proteins utilize the resting potential to transport molecules into and out of the cell. Amino acid and glucose transport into many cells is linked to sodium ion co-transport (symport) so that the movement of Na⁺ down an electrochemical gradient drives transport of the other molecule up a concentration gradient. Similarly, cardiac muscle links transfer of Ca²⁺ out of the cell with transport of Na⁺ into the cell (antiport).

Gated Ion Channels

Gated ion channels control ion flow by regulating the opening and closing of pores. The ability to control ion flux through various gating mechanisms allows ion channels to mediate such diverse signaling and homeostatic functions as neuronal and endocrine signaling, muscle contraction, fertilization, and regulation of ion and pH balance. Gated ion channels are categorized according to the manner of regulating the gating function. Mechanically-gated channels open their pores in response to mechanical stress; voltage-gated channels (e.g., Na⁺, K⁺, Ca²⁺, and Cl⁻ channels) open their pores in response to changes in membrane potential; and ligand-gated channels (e.g.,

acetylcholine-, serotonin-, and glutamate-gated cation channels, and GABA- and glycine-gated chloride channels) open their pores in the presence of a specific ion, nucleotide, or neurotransmitter. The gating properties of a particular ion channel (i.e., its threshold for and duration of opening and closing) are sometimes modulated by association with auxiliary channel proteins and/or post

5 translational modifications, such as phosphorylation.

Mechanically-gated or mechanosensitive ion channels act as transducers for the senses of touch, hearing, and balance, and also play important roles in cell volume regulation, smooth muscle contraction, and cardiac rhythm generation. A stretch-inactivated channel (SIC) was recently cloned from rat kidney. The SIC channel belongs to a group of channels which are activated by pressure or stress on the cell membrane and conduct both Ca^{2+} and Na^+ (Suzuki, M. et al. (1999) J. Biol. Chem. 274:6330-6335).

The pore-forming subunits of the voltage-gated cation channels form a superfamily of ion channel proteins. The characteristic domain of these channel proteins comprises six transmembrane domains (S1-S6), a pore-forming region (P) located between S5 and S6, and intracellular amino and carboxy termini. In the Na^+ and Ca^{2+} subfamilies, this domain is repeated four times, while in the K^+ channel subfamily, each channel is formed from a tetramer of either identical or dissimilar subunits. The P region contains information specifying the ion selectivity for the channel. In the case of K^+ channels, a GYG tripeptide is involved in this selectivity (Ishii, T.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11651-11656).

20 Voltage-gated Na^+ and K^+ channels are necessary for the function of electrically excitable cells, such as nerve and muscle cells. Action potentials, which lead to neurotransmitter release and muscle contraction, arise from large, transient changes in the permeability of the membrane to Na^+ and K^+ ions. Depolarization of the membrane beyond the threshold level opens voltage-gated Na^+ channels. Sodium ions flow into the cell, further depolarizing the membrane and opening more voltage-gated Na^+ channels, which propagates the depolarization down the length of the cell. Depolarization also opens voltage-gated potassium channels. Consequently, potassium ions flow outward, which leads to repolarization of the membrane. Voltage-gated channels utilize charged residues in the fourth transmembrane segment (S4) to sense voltage change. The open state lasts only about 1 millisecond, at which time the channel spontaneously converts into an inactive state that cannot be opened irrespective of the membrane potential. Inactivation is mediated by the channel's N-terminus, which acts as a plug that closes the pore. The transition from an inactive to a closed state requires a return to resting potential.

Voltage-gated Na^+ channels are heterotrimeric complexes composed of a 260 kDa pore-forming α subunit that associates with two smaller auxiliary subunits, $\beta 1$ and $\beta 2$. The $\beta 2$ subunit is a 35 integral membrane glycoprotein that contains an extracellular Ig domain, and its association with α

and $\beta 1$ subunits correlates with increased functional expression of the channel, a change in its gating properties, as well as an increase in whole cell capacitance due to an increase in membrane surface area (Isom, L.L. et al. (1995) Cell 83:433-442).

Non voltage-gated Na^+ channels include the members of the amiloride-sensitive Na^+ channel/degenerin (NaC/DEG) family. Channel subunits of this family are thought to consist of two transmembrane domains flanking a long extracellular loop, with the amino and carboxyl termini located within the cell. The NaC/DEG family includes the epithelial Na^+ channel (ENaC) involved in Na^+ reabsorption in epithelia including the airway, distal colon, cortical collecting duct of the kidney, and exocrine duct glands. Mutations in ENaC result in pseudohypoaldosteronism type 1 and Liddle's syndrome (pseudohyperaldosteronism). The NaC/DEG family also includes the recently characterized H^+ -gated cation channels or acid-sensing ion channels (ASIC). ASIC subunits are expressed in the brain and form heteromultimeric Na^+ -permeable channels. These channels require acid pH fluctuations for activation. ASIC subunits show homology to the degenerins, a family of mechanically-gated channels originally isolated from *C. elegans*. Mutations in the degenerins cause neurodegeneration. ASIC subunits may also have a role in neuronal function, or in pain perception, since tissue acidosis causes pain (Waldmann, R. and M. Lazdunski (1998) Curr. Opin. Neurobiol. 8:418-424; Eglen, R.M. et al. (1999) Trends Pharmacol. Sci. 20:337-342).

K^+ channels are located in all cell types, and may be regulated by voltage, ATP concentration, or second messengers such as Ca^{2+} and cAMP. In non-excitabile tissue, K^+ channels are involved in protein synthesis, control of endocrine secretions, and the maintenance of osmotic equilibrium across membranes. In neurons and other excitable cells, in addition to regulating action potentials and repolarizing membranes, K^+ channels are responsible for setting resting membrane potential. The cytosol contains non-diffusible anions and, to balance this net negative charge, the cell contains a Na^+ - K^+ pump and ion channels that provide the redistribution of Na^+ , K^+ , and Cl^- . The pump actively transports Na^+ out of the cell and K^+ into the cell in a 3:2 ratio. Ion channels in the plasma membrane allow K^+ and Cl^- to flow by passive diffusion. Because of the high negative charge within the cytosol, Cl^- flows out of the cell. The flow of K^+ is balanced by an electromotive force pulling K^+ into the cell, and a K^+ concentration gradient pushing K^+ out of the cell. Thus, the resting membrane potential is primarily regulated by K^+ flow (Salkoff, L. and T. Jegla (1995) Neuron 15:489-492).

Potassium channel subunits of the Shaker-like superfamily all have the characteristic six transmembrane/1 pore domain structure. Four subunits combine as homo- or heterotetramers to form functional K channels. These pore-forming subunits also associate with various cytoplasmic β subunits that alter channel inactivation kinetics. The Shaker-like channel family includes the voltage-gated K^+ channels as well as the delayed rectifier type channels such as the human ether-a-go-go

related gene (HERG) associated with long QT, a cardiac dysrhythmia syndrome (Curran, M.E. (1998) *Curr. Opin. Biotechnol.* 9:565-572; Kaczorowski, G.J. and M.L. Garcia (1999) *Curr. Opin. Chem. Biol.* 3:448-458).

A second superfamily of K^+ channels is composed of the inward rectifying channels (Kir).

- 5 Kir channels have the property of preferentially conducting K^+ currents in the inward direction. These proteins consist of a single potassium selective pore domain and two transmembrane domains, which correspond to the fifth and sixth transmembrane domains of voltage-gated K^+ channels. Kir subunits also associate as tetramers. The Kir family includes ROMK1, mutations in which lead to Bartter syndrome, a renal tubular disorder. Kir channels are also involved in regulation of cardiac
- 10 pacemaker activity, seizures and epilepsy, and insulin regulation (Doupnik, C.A. et al. (1995) *Curr. Opin. Neurobiol.* 5:268-277; Curran, *supra*).

- The recently recognized TWIK K^+ channel family includes the mammalian TWIK-1, TREK-1 and TASK proteins. Members of this family possess an overall structure with four transmembrane domains and two P domains. These proteins are probably involved in controlling the resting potential
- 15 in a large set of cell types (Duprat, F. et al. (1997) *EMBO J* 16:5464-5471).

- The voltage-gated Ca^{2+} channels have been classified into several subtypes based upon their electrophysiological and pharmacological characteristics. L-type Ca^{2+} channels are predominantly expressed in heart and skeletal muscle where they play an essential role in excitation-contraction coupling. T-type channels are important for cardiac pacemaker activity, while N-type and P/Q-type
- 20 channels are involved in the control of neurotransmitter release in the central and peripheral nervous system. The L-type and N-type voltage-gated Ca^{2+} channels have been purified and, though their functions differ dramatically, they have similar subunit compositions. The channels are composed of three subunits. The α_1 subunit forms the membrane pore and voltage sensor, while the $\alpha_2\delta$ and β subunits modulate the voltage-dependence, gating properties, and the current amplitude of the
- 25 channel. These subunits are encoded by at least six α_1 , one $\alpha_2\delta$, and four β genes. A fourth subunit, γ , has been identified in skeletal muscle (Walker, D. et al. (1998) *J. Biol. Chem.* 273:2361-2367; McCleskey, E.W. (1994) *Curr. Opin. Neurobiol.* 4:304-312).

- The transient receptor family (Trp) of calcium ion channels are thought to mediate capacitative calcium entry (CCE). CCE is the Ca^{2+} influx into cells to resupply Ca^{2+} stores depleted
- 30 by the action of inositol triphosphate (IP3) and other agents in response to numerous hormones and growth factors. Trp and Trp-like were first cloned from *Drosophila* and have similarity to voltage gated Ca^{2+} channels in the S3 through S6 regions. This suggests that Trp and/or related proteins may form mammalian CCC entry channels (Zhu, X. et al. (1996) *Cell* 85:661-671; Boulay, G. et al. (1997) *J. Biol. Chem.* 272:29672-29680). Melastatin is a gene isolated in both the mouse and human, and
- 35 whose expression in melanoma cells is inversely correlated with melanoma aggressiveness in vivo.

The human cDNA transcript corresponds to a 1533-amino acid protein having homology to members of the Trp family. It has been proposed that the combined use of malastatin mRNA expression status and tumor thickness might allow for the determination of subgroups of patients at both low and high risk for developing metastatic disease (Duncan, L.M. et al (2001) J. Clin. Oncol. 19:568-576).

5 Chloride channels are necessary in endocrine secretion and in regulation of cytosolic and organelle pH. In secretory epithelial cells, Cl^- enters the cell across a basolateral membrane through an Na^+ , K^+/Cl^- cotransporter, accumulating in the cell above its electrochemical equilibrium concentration. Secretion of Cl^- from the apical surface, in response to hormonal stimulation, leads to flow of Na^+ and water into the secretory lumen. The cystic fibrosis transmembrane conductance
10 regulator (CFTR) is a chloride channel encoded by the gene for cystic fibrosis, a common fatal genetic disorder in humans. CFTR is a member of the ABC transporter family, and is composed of two domains each consisting of six transmembrane domains followed by a nucleotide-binding site. Loss of CFTR function decreases transepithelial water secretion and, as a result, the layers of mucus that coat the respiratory tree, pancreatic ducts, and intestine are dehydrated and difficult to clear. The
15 resulting blockage of these sites leads to pancreatic insufficiency, "meconium ileus", and devastating "chronic obstructive pulmonary disease" (Al-Awqati, Q. et al. (1992) J. Exp. Biol. 172:245-266).

The voltage-gated chloride channels (CLC) are characterized by 10-12 transmembrane domains, as well as two small globular domains known as CBS domains. The CLC subunits probably function as homotetramers. CLC proteins are involved in regulation of cell volume,
20 membrane potential stabilization, signal transduction, and transepithelial transport. Mutations in CLC-1, expressed predominantly in skeletal muscle, are responsible for autosomal recessive generalized myotonia and autosomal dominant myotonia congenita, while mutations in the kidney channel CLC-5 lead to kidney stones (Jentsch, T.J. (1996) Curr. Opin. Neurobiol. 6:303-310).

Ligand-gated channels open their pores when an extracellular or intracellular mediator binds
25 to the channel. Neurotransmitter-gated channels are channels that open when a neurotransmitter binds to their extracellular domain. These channels exist in the postsynaptic membrane of nerve or muscle cells. There are two types of neurotransmitter-gated channels. Sodium channels open in response to excitatory neurotransmitters, such as acetylcholine, glutamate, and serotonin. This opening causes an influx of Na^+ and produces the initial localized depolarization that activates the
30 voltage-gated channels and starts the action potential. Chloride channels open in response to inhibitory neurotransmitters, such as γ -aminobutyric acid (GABA) and glycine, leading to hyperpolarization of the membrane and the subsequent generation of an action potential. Neurotransmitter-gated ion channels have four transmembrane domains and probably function as pentamers (Jentsch, supra). Amino acids in the second transmembrane domain appear to be important
35 in determining channel permeation and selectivity (Sather, W.A. et al. (1994) Curr. Opin. Neurobiol.

4:313-323).

Ligand-gated channels can be regulated by intracellular second messengers. For example, calcium-activated K^+ channels are gated by internal calcium ions. In nerve cells, an influx of calcium during depolarization opens K^+ channels to modulate the magnitude of the action potential (Ishi et al., *supra*). The large conductance (BK) channel has been purified from brain and its subunit composition determined. The α subunit of the BK channel has seven rather than six transmembrane domains in contrast to voltage-gated K^+ channels. The extra transmembrane domain is located at the subunit N-terminus. A 28-amino-acid stretch in the C-terminal region of the subunit (the "calcium bowl" region) contains many negatively charged residues and is thought to be the region responsible for calcium binding. The β subunit consists of two transmembrane domains connected by a glycosylated extracellular loop, with intracellular N- and C-termini (Kaczorowski, *supra*; Vergara, C. et al. (1998) *Curr. Opin. Neurobiol.* 8:321-329).

Cyclic nucleotide-gated (CNG) channels are gated by cytosolic cyclic nucleotides. The best examples of these are the cAMP-gated Na^+ channels involved in olfaction and the cGMP-gated cation channels involved in vision. Both systems involve ligand-mediated activation of a G-protein coupled receptor which then alters the level of cyclic nucleotide within the cell. CNG channels also represent a major pathway for Ca^{2+} entry into neurons, and play roles in neuronal development and plasticity. CNG channels are tetramers containing at least two types of subunits, an α subunit which can form functional homomeric channels, and a β subunit, which modulates the channel properties. All CNG subunits have six transmembrane domains and a pore forming region between the fifth and sixth transmembrane domains, similar to voltage-gated K^+ channels. A large C-terminal domain contains a cyclic nucleotide binding domain, while the N-terminal domain confers variation among channel subtypes (Zufall, F. et al. (1997) *Curr. Opin. Neurobiol.* 7:404-412).

The activity of other types of ion channel proteins may also be modulated by a variety of intracellular signalling proteins. Many channels have sites for phosphorylation by one or more protein kinases including protein kinase A, protein kinase C, tyrosine kinase, and casein kinase II, all of which regulate ion channel activity in cells. Kir channels are activated by the binding of the $G\beta\gamma$ subunits of heterotrimeric G-proteins (Reimann, F. and F.M. Ashcroft (1999) *Curr. Opin. Cell. Biol.* 11:503-508). Other proteins are involved in the localization of ion channels to specific sites in the cell membrane. Such proteins include the PDZ domain proteins known as MAGUKs (membrane-associated guanylate kinases) which regulate the clustering of ion channels at neuronal synapses (Craven, S.E. and D.S. Brecht (1998) *Cell* 93:495-498).

Disease Correlation

The etiology of numerous human diseases and disorders can be attributed to defects in the

transport of molecules across membranes. Defects in the trafficking of membrane-bound transporters and ion channels are associated with several disorders, e.g., cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, von Gierke disease, and certain forms of diabetes mellitus. Single-gene defect diseases resulting in an inability to transport small molecules across
 5 membranes include, e.g., cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease (van't Hoff, W.G. (1996) *Exp. Nephrol.* 4:253-262; Talente, G.M. et al. (1994) *Ann. Intern. Med.* 120:218-226; and Chillon, M. et al. (1995) *New Engl. J. Med.* 332:1475-1480).

Human diseases caused by mutations in ion channel genes include disorders of skeletal muscle, cardiac muscle, and the central nervous system. Mutations in the pore-forming subunits of
 10 sodium and chloride channels cause myotonia, a muscle disorder in which relaxation after voluntary contraction is delayed. Sodium channel myotonias have been treated with channel blockers. Mutations in muscle sodium and calcium channels cause forms of periodic paralysis, while mutations in the sarcoplasmic calcium release channel, T-tubule calcium channel, and muscle sodium channel cause malignant hyperthermia. Cardiac arrhythmia disorders such as the long QT syndromes and
 15 idiopathic ventricular fibrillation are caused by mutations in potassium and sodium channels (Cooper, E.C. and L.Y. Jan (1998) *Proc. Natl. Acad. Sci. USA* 96:4759-4766). All four known human idiopathic epilepsy genes code for ion channel proteins (Berkovic, S.F. and I.E. Scheffer (1999) *Curr. Opin. Neurology* 12:177-182). Other neurological disorders such as ataxias, hemiplegic migraine and hereditary deafness can also result from mutations in ion channel genes (Jen, J. (1999) *Curr. Opin.*
 20 *Neurobiol.* 9:274-280; Cooper, *supra*).

Ion channels have been the target for many drug therapies. Neurotransmitter-gated channels have been targeted in therapies for treatment of insomnia, anxiety, depression, and schizophrenia. Voltage-gated channels have been targeted in therapies for arrhythmia, ischemic stroke, head trauma, and neurodegenerative disease (Taylor, C.P. and L.S. Narasimhan (1997) *Adv. Pharmacol.* 39:47-98).
 25 Various classes of ion channels also play an important role in the perception of pain, and thus are potential targets for new analgesics. These include the vanilloid-gated ion channels, which are activated by the vanilloid capsaicin, as well as by noxious heat. Local anesthetics such as lidocaine and mexiletine which blockade voltage-gated Na⁺ channels have been useful in the treatment of neuropathic pain (Eglen, *supra*).

30 Ion channels in the immune system have recently been suggested as targets for immunomodulation. T-cell activation depends upon calcium signaling, and a diverse set of T-cell specific ion channels has been characterized that affect this signaling process. Channel blocking agents can inhibit secretion of lymphokines, cell proliferation, and killing of target cells. A peptide antagonist of the T-cell potassium channel Kv1.3 was found to suppress delayed-type hypersensitivity
 35 and allogenic responses in pigs, validating the idea of channel blockers as safe and efficacious

immunosuppressants (Cahalan, M.D. and K.G. Chandy (1997) Curr. Opin. Biotechnol. 8:749-756).

The discovery of new transporters and ion channels and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of transport, neurological, muscle, immunological, and cell proliferative disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of transporters and ion channels.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, transporters and ion channels, referred to collectively as "TRICH" and individually as "TRICH-1," "TRICH-2," "TRICH-3," "TRICH-4," "TRICH-5," "TRICH-6," "TRICH-7," "TRICH-8," "TRICH-9," "TRICH-10," "TRICH-11," "TRICH-12," "TRICH-13," "TRICH-14," and "TRICH-15." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-15.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-15. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:16-30.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a

biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of

SEQ ID NO:16-30, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and
5 which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

10 The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID
15 NO:16-30, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

20 The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an
25 amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The invention additionally provides a method of treating a disease or condition associated with decreased
30 expression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring
35 polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence

selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

10 Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional TRICH, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino

acid sequence selected from the group consisting of SEQ ID NO:1-15, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:16-30, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of

hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

5

BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each
10 polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble
15 polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

20 Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

25 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

30 It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

35 Unless defined otherwise, all technical and scientific terms used herein have the same

meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing
5 the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

“TRICH” refers to the amino acid sequences of substantially purified TRICH obtained from
10 any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term “agonist” refers to a molecule which intensifies or mimics the biological activity of TRICH. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TRICH either by directly interacting with
15 TRICH or by acting on components of the biological pathway in which TRICH participates.

An “allelic variant” is an alternative form of the gene encoding TRICH. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to
20 allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding TRICH include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as TRICH or a
25 polypeptide with at least one functional characteristic of TRICH. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding TRICH, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding TRICH. The encoded protein may also be “altered,” and may contain deletions, insertions, or
30 substitutions of amino acid residues which produce a silent change and result in a functionally equivalent TRICH. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of TRICH is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged
35 amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having

similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of TRICH. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of TRICH either by directly interacting with TRICH or by acting on components of the biological pathway in which TRICH participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind TRICH polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified

sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring
5 nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic"
10 refers to the capability of the natural, recombinant, or synthetic TRICH, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement,
15 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding TRICH or fragments of TRICH may be
20 employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated
25 DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and
30 assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded
35 as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
5	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
10	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
15	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
20	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

A "fragment" is a unique portion of TRICH or the polynucleotide encoding TRICH which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid

residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:16-30 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:16-30, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:16-30 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:16-30 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:16-30 and the region of SEQ ID NO:16-30 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-15 is encoded by a fragment of SEQ ID NO:16-30. A fragment of SEQ ID NO:1-15 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-15. For example, a fragment of SEQ ID NO:1-15 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-15. The precise length of a fragment of SEQ ID NO:1-15 and the region of SEQ ID NO:1-15 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS

8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

- 5 Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence
- 10 analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
- 15 programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

- 20 *Penalty for mismatch: -2*

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

- 25 *Filter: on*

- Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
- 30 nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

- Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes
- 35 in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid

sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

The term "humanized antibody" refers to an antibody molecule in which the amino acid

sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A

hybridization complex may be formed in solution (e.g., C_{0t} or R_{0t} analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

5 The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

 "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect
10 cellular and systemic defense systems.

 An "immunogenic fragment" is a polypeptide or oligopeptide fragment of TRICH which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of TRICH which is useful in any of the antibody production methods disclosed herein or known in the
15 art.

 The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

 The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

20 The term "modulate" refers to a change in the activity of TRICH. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of TRICH.

 The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or
25 synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding
30 sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
35 PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript

elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an TRICH may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of TRICH.

"Probe" refers to nucleic acid sequences encoding TRICH, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3

primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection
5 programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both
10 unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

15 A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have
20 been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a
25 vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription,
30 translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

35 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear

sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing TRICH, nucleic acids encoding TRICH, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor
5 of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be
10 introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having
15 at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater
20 sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the
25 reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The
30 presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-
35 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at

least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

5 THE INVENTION

The invention is based on the discovery of new human transporters and ion channels (TRICH), the polynucleotides encoding TRICH, and the use of these compositions for the diagnosis, treatment, or prevention of transport, neurological, muscle, immunological, and cell proliferative disorders.

10 Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is
15 denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte
20 polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

25 Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the
30 MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these
35 properties establish that the claimed polypeptides are transporters and ion channels. For example,

SEQ ID NO:5 is 98% identical, from residue M1 to residue I1009, to Rattus norvegicus glutamate receptor delta-1 subunit (GenBank ID g475542) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:5 also contains a
 5 receptor family ligand binding region as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and additional BLAST analyses provide further corroborative evidence that SEQ ID NO:5 is a glutamate receptor. SEQ ID NO:1-4 and SEQ ID NO:6-15 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ
 10 ID NO:1-15 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide
 15 consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:16-30 or that distinguish between SEQ ID NO:16-30 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA
 20 sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective full length sequences.

25 The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 6431853H1 is the identification number of an Incyte cDNA sequence, and LUNGNON07 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71456748V1). Alternatively, the identification numbers in column 5
 30 may refer to GenBank cDNAs or ESTs (e.g., g5396013) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GBI.g6742097_000003.fasta.edit is the identification number of a Genscan-predicted coding sequence, with g6742097 being the GenBank identification number of the sequence to which Genscan
 35 was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See

Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

The invention also encompasses TRICH variants. A preferred TRICH variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the TRICH amino acid sequence, and which contains at least one functional or structural characteristic of TRICH.

The invention also encompasses polynucleotides which encode TRICH. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:16-30, which encodes TRICH. The polynucleotide sequences of SEQ ID NO:16-30, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding TRICH. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding TRICH. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:16-30 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:16-30. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of TRICH.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding TRICH, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide

sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring TRICH, and all such variations are to be considered as being specifically disclosed.

5 Although nucleotide sequences which encode TRICH and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring TRICH under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding TRICH or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide
10 occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TRICH and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

15 The invention also encompasses production of DNA sequences which encode TRICH and TRICH derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding TRICH or any fragment thereof.

20 Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:16-30 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in
25 "Definitions."

 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or
30 combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
35 sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system

(Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

- 5 The nucleic acid sequences encoding TRICH may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.)
- 10 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom,
- 15 M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries
- 20 (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of
- 25 about 68°C to 72°C.

- When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence
- 30 into 5' non-transcribed regulatory regions.

- Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the
- 35 emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate

software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

5 In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode TRICH may be cloned in recombinant DNA molecules that direct expression of TRICH, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express TRICH.

10 The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter TRICH-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-
15 mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

 The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) *Nat. Biotechnol.* 17:793-797; Christians, F.C. et al. (1999) *Nat.*
20 *Biotechnol.* 17:259-264; and Cramer, A. et al. (1996) *Nat. Biotechnol.* 14:315-319) to alter or improve the biological properties of TRICH, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired
25 properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of
30 homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

 In another embodiment, sequences encoding TRICH may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids*
35 *Symp. Ser.* 7:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser.* 7:225-232.)

Alternatively, TRICH itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis
5 may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of TRICH, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid
10 chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active TRICH, the nucleotide sequences encoding TRICH or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which
15 contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding TRICH. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences
20 encoding TRICH. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding TRICH and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG
25 initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression
30 vectors containing sequences encoding TRICH and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and
35 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding TRICH. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus);

5 plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO

10 J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di

15 Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending

20 upon the use intended for polynucleotide sequences encoding TRICH. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding TRICH can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding TRICH into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of

25 transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of TRICH are needed, e.g. for the production of

30 antibodies, vectors which direct high level expression of TRICH may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of TRICH. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable

35 integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel,

1995, *supra*; Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of TRICH. Transcription of sequences encoding TRICH may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding TRICH may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses TRICH in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of TRICH in cell lines is preferred. For example, sequences encoding TRICH can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine

phosphoribosyltransferase genes, for use in *tk⁻* and *apr⁻* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding TRICH is inserted within a marker gene sequence, transformed cells containing sequences encoding TRICH can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding TRICH under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding TRICH and that express TRICH may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of TRICH using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on TRICH is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding TRICH include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.

5 Alternatively, the sequences encoding TRICH, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega

10 (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding TRICH may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein

15 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode TRICH may be designed to contain signal sequences which direct secretion of TRICH through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the

20 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for

25 post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding TRICH may be ligated to a heterologous sequence resulting in translation of a

30 fusion protein in any of the aforementioned host systems. For example, a chimeric TRICH protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of TRICH activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),

35 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG,

c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the TRICH encoding sequence and the heterologous protein sequence, so that TRICH may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled TRICH may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

TRICH of the present invention or fragments thereof may be used to screen for compounds that specifically bind to TRICH. At least one and up to a plurality of test compounds may be screened for specific binding to TRICH. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of TRICH, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which TRICH binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express TRICH, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing TRICH or cell membrane fractions which contain TRICH are then contacted with a test compound and binding, stimulation, or inhibition of activity of either TRICH or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with TRICH, either in solution or affixed to a solid support, and detecting the binding of TRICH to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a

labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

TRICH of the present invention or fragments thereof may be used to screen for compounds
5 that modulate the activity of TRICH. Such compounds may include agonists, antagonists, or partial
or inverse agonists. In one embodiment, an assay is performed under conditions permissive for
TRICH activity, wherein TRICH is combined with at least one test compound, and the activity of
TRICH in the presence of a test compound is compared with the activity of TRICH in the absence of
the test compound. A change in the activity of TRICH in the presence of the test compound is
10 indicative of a compound that modulates the activity of TRICH. Alternatively, a test compound is
combined with an in vitro or cell-free system comprising TRICH under conditions suitable for
TRICH activity, and the assay is performed. In either of these assays, a test compound which
modulates the activity of TRICH may do so indirectly and need not come in direct contact with the
test compound. At least one and up to a plurality of test compounds may be screened.

15 In another embodiment, polynucleotides encoding TRICH or their mammalian homologs may
be "knocked out" in an animal model system using homologous recombination in embryonic stem
(ES) cells. Such techniques are well known in the art and are useful for the generation of animal
models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number
5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the
20 early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the
gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region
of the host genome by homologous recombination. Alternatively, homologous recombination takes
place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-
25 specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic
Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell
blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred
to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce
heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential
30 therapeutic or toxic agents.

Polynucleotides encoding TRICH may also be manipulated in vitro in ES cells derived from
human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell
lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate
into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
35 (1998) Science 282:1145-1147).

Polynucleotides encoding TRICH can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding TRICH is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress TRICH, e.g., by secreting TRICH in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of TRICH and transporters and ion channels. In addition, the expression of TRICH is closely associated with brain, prostate and thyroid tissues, neoplasms, and cancers of the small intestine. Therefore, TRICH appears to play a role in transport, neurological, muscle, immunological, and cell proliferative disorders. In the treatment of disorders associated with increased TRICH expression or activity, it is desirable to decrease the expression or activity of TRICH. In the treatment of disorders associated with decreased TRICH expression or activity, it is desirable to increase the expression or activity of TRICH.

Therefore, in one embodiment, TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis, cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., neurofibromatosis, postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter,

Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, cystinuria, iminoglycinuria, Hartup disease, and Fanconi disease; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms,

5 Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous

10 system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic

15 nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses,

20 postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic

25 myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder, ophthalmoplegia, and acid maltase deficiency (AMD, also known as Pompe's disease); an immunological disorder such as acquired immunodeficiency syndrome

30 (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis,

erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, 5 systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal 10 nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

15 In another embodiment, a vector capable of expressing TRICH or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified TRICH in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent 20 a disorder associated with decreased expression or activity of TRICH including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of TRICH may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of TRICH including, but not limited to, those listed above.

25 In a further embodiment, an antagonist of TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH. Examples of such disorders include, but are not limited to, those transport, neurological, muscle, immunological, and cell proliferative disorders described above. In one aspect, an antibody which specifically binds TRICH may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for 30 bringing a pharmaceutical agent to cells or tissues which express TRICH.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding TRICH may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of TRICH including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary

sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of TRICH may be produced using methods which are generally known in the art. In particular, purified TRICH may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind TRICH. Antibodies to TRICH may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with TRICH or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to TRICH have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of TRICH amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to TRICH may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.

Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce TRICH-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for TRICH may also be generated. For example, such fragments include, but are not limited to, $F(ab)_2$ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the $F(ab)_2$ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between TRICH and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering TRICH epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for TRICH. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of TRICH-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple TRICH epitopes, represents the average affinity, or avidity, of the antibodies for TRICH. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular TRICH epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the TRICH-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of TRICH,

preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to
 5 determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of TRICH-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g.,
 10 Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding TRICH, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene
 15 encoding TRICH. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding TRICH. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense
 20 sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral
 25 vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.*
 30 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding TRICH may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined
 35 immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency

(Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in TRICH expression or regulation causes disease, the expression of TRICH from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in TRICH are treated by constructing mammalian expression vectors encoding TRICH and introducing these vectors by mechanical means into TRICH-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J.-L. and H. R  capon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of TRICH include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). TRICH may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding TRICH from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to TRICH expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding TRICH under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding TRICH to cells which have one or more genetic abnormalities with respect to the expression of TRICH. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) *Transplantation* 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"),

hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) *Annu. Rev. Nutr.* 19:511-544 and Verma, I.M. and N. Somia (1997) *Nature* 18:389:239-242, both incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver
5 polynucleotides encoding TRICH to target cells which have one or more genetic abnormalities with respect to the expression of TRICH. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing TRICH to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has
10 been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a
15 cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple
20 plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding TRICH to target cells. The biology of the prototypic alphavirus,
25 Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity
30 (e.g., protease and polymerase). Similarly, inserting the coding sequence for TRICH into the alphavirus genome in place of the capsid-coding region results in the production of a large number of TRICH-coding RNAs and the synthesis of high levels of TRICH in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN)
35 indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy

application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of TRICH into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding TRICH.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding TRICH. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding TRICH. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased TRICH expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding TRICH may be therapeutically useful, and in the treatment of disorders associated with decreased TRICH expression or activity, a compound which specifically promotes expression of the polynucleotide encoding TRICH may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding TRICH is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding TRICH are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding TRICH. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without

exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of TRICH, antibodies to TRICH, and mimetics, agonists, antagonists, or inhibitors of TRICH.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the

lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active
5 ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising TRICH or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of
10 the macromolecule. Alternatively, TRICH or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell
15 culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example
20 TRICH or fragments thereof, antibodies of TRICH, and agonists, antagonists or inhibitors of TRICH, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the
25 therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the
30 patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the
35 subject, time and frequency of administration, drug combination(s), reaction sensitivities, and

response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind TRICH may be used for the diagnosis of disorders characterized by expression of TRICH, or in assays to monitor patients being treated with TRICH or agonists, antagonists, or inhibitors of TRICH. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for TRICH include methods which utilize the antibody and a label to detect TRICH in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring TRICH, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of TRICH expression. Normal or standard values for TRICH expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to TRICH under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of TRICH expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding TRICH may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of TRICH may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of TRICH, and to monitor regulation of TRICH levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding TRICH or closely related molecules may be used to identify nucleic acid sequences which encode TRICH. The specificity of the probe, whether it is

made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding TRICH, allelic variants, or related sequences.

5 Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the TRICH encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO: 16-30 or from genomic sequences including promoters, enhancers, and introns of the TRICH gene.

Means for producing specific hybridization probes for DNAs encoding TRICH include the
10 cloning of polynucleotide sequences encoding TRICH or TRICH derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels,
15 such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding TRICH may be used for the diagnosis of disorders associated with expression of TRICH. Examples of such disorders include, but are not limited to, a transport disorder such as akinesia, amyotrophic lateral sclerosis, ataxia telangiectasia, cystic fibrosis, Becker's muscular dystrophy, Bell's palsy, Charcot-Marie Tooth disease, diabetes mellitus, diabetes
20 insipidus, diabetic neuropathy, Duchenne muscular dystrophy, hyperkalemic periodic paralysis, normokalemic periodic paralysis, Parkinson's disease, malignant hyperthermia, multidrug resistance, myasthenia gravis, myotonic dystrophy, catatonia, tardive dyskinesia, dystonias, peripheral neuropathy, cerebral neoplasms, prostate cancer, cardiac disorders associated with transport, e.g., angina, bradyarrhythmia, tachyarrhythmia, hypertension, Long QT syndrome, myocarditis,
25 cardiomyopathy, nemaline myopathy, centronuclear myopathy, lipid myopathy, mitochondrial myopathy, thyrotoxic myopathy, ethanol myopathy, dermatomyositis, inclusion body myositis, infectious myositis, polymyositis, neurological disorders associated with transport, e.g., Alzheimer's disease, amnesia, bipolar disorder, dementia, depression, epilepsy, Tourette's disorder, paranoid psychoses, and schizophrenia, and other disorders associated with transport, e.g., neurofibromatosis,
30 postherpetic neuralgia, trigeminal neuropathy, sarcoidosis, sickle cell anemia, Wilson's disease, cataracts, infertility, pulmonary artery stenosis, sensorineural autosomal deafness, hyperglycemia, hypoglycemia, Grave's disease, goiter, Cushing's disease, Addison's disease, glucose-galactose malabsorption syndrome, hypercholesterolemia, adrenoleukodystrophy, Zellweger syndrome, Menkes disease, occipital horn syndrome, von Gierke disease, cystinuria, iminoglycinuria, Hartup
35 disease, and Fanconi disease; a neurological disorder such as epilepsy, ischemic cerebrovascular

disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain

5 abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental

10 disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic

15 disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a muscle disorder such as cardiomyopathy, myocarditis, Duchenne's muscular dystrophy, Becker's muscular dystrophy, myotonic dystrophy, central core disease, nemaline myopathy, centronuclear

20 myopathy, lipid myopathy, mitochondrial myopathy, infectious myositis, polymyositis, dermatomyositis, inclusion body myositis, thyrotoxic myopathy, ethanol myopathy, angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, pheochromocytoma, and myopathies including encephalopathy, epilepsy, Kearns-Sayre syndrome, lactic acidosis, myoclonic disorder,

25 ophthalmoplegia, and acid maltase deficiency (AMD, also known as Pompe's disease); an immunological disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact

30 dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis,

psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a
5 cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall
10 bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding TRICH may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered TRICH
15 expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding TRICH may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding TRICH may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a
20 suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding TRICH in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to
25 monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of TRICH, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding TRICH, under conditions suitable for hybridization or
30 amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

35 Once the presence of a disorder is established and a treatment protocol is initiated,

hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

5 With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development
10 or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding TRICH may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding TRICH, or a fragment of a polynucleotide complementary to the polynucleotide encoding
15 TRICH, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH may be used to detect single nucleotide polymorphisms (SNPs). SNPs are
20 substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding TRICH are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example,
25 from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis
30 methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry
35 using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of TRICH include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, TRICH, fragments of TRICH, or antibodies specific for TRICH may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo,

as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the

separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for TRICH to quantify the levels of TRICH expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoze, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic

response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding TRICH may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man

(OMIM) World Wide Web site. Correlation between the location of the gene encoding TRICH on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as
5 linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely
10 localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

15 In another embodiment of the invention, TRICH, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between TRICH and the agent being tested may be measured.

20 Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with TRICH, or fragments thereof, and washed. Bound TRICH is then detected by methods well known in the art. Purified TRICH can
25 also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding TRICH specifically compete with a test compound for binding TRICH.
30 In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with TRICH.

In additional embodiments, the nucleotide sequences which encode TRICH may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such
35 properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

5 The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/195,595, U.S. Ser. No. 60/196,872, U.S. Ser. No. 60/199,020, U.S. Ser. No. 60/200,552, U.S. Ser. No. 60/202,348, and U.S. Ser. No. 60/203,495, are expressly incorporated by reference herein.

10

EXAMPLES

I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a
15 suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
20 purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

25 In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic
30 oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g.,
35 PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid

(Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

5

II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an
5 AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a
10 high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

15 III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the
20 MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the
25 ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

30 The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and
35 BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family

databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.

- 5 Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive
- 10 the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length
- 15 polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
- 20 Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column
- 25 presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ

30 ID NO:16-30. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative transporters and ion channels were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is

35 a general-purpose gene identification program which analyzes genomic DNA sequences from a

variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode transporters and ion channels, the encoded polypeptides were analyzed by querying against PFAM models for transporters and ion channels. Potential transporters and ion channels were also identified by homology to Incyte cDNA sequences that had been annotated as transporters and ion channels. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data
"Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or

genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended
 5 with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

"Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases
 10 using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The
 15 GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of TRICH Encoding Polynucleotides

20 The sequences which were used to assemble SEQ ID NO:16-30 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:16-30 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available
 25 from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map
 30 position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation
 35 hybrid markers whose sequences were included in each of the clusters. Human genome maps and

other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

VII. Analysis of Polynucleotide Expression

- 5 Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

- 10 Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$15 \quad \frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

- The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is
20 calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate
25 the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79%
30 identity and 100% overlap.

- Alternatively, polynucleotide sequences encoding TRICH are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is
35 classified into one of the following organ/tissue categories: cardiovascular system; connective tissue;

digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding TRICH. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

VIII. Extension of TRICH Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II

(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

5 The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones
10 were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

15 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
20 recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

 In like manner, full length polynucleotide sequences are verified using the above procedure or
25 are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

 Hybridization probes derived from SEQ ID NO:16-30 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base
30 pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a
35 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).

An aliquot containing 10^7 counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

10 X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is

reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ μ l oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/ μ l RNase inhibitor, 500 μ M dATP, 500 μ M dGTP, 500 μ M dTTP, 40 μ M dCTP, 40 μ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with

5 GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc.

10 (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μ l 5X SSC/0.2% SDS.

Microarray Preparation

15 Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia

20 Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water,

25 and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US Patent No. 5,807,522, incorporated herein by reference. 1 μ l of the array element DNA, at an average concentration of 100 ng/ μ l, is loaded into the open capillary printing element by a high-speed robotic

30 apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in

0.2% SDS and distilled water as before.

Hybridization

Hybridization reactions contain 9 μ l of sample mixture consisting of 0.2 μ g each of Cy3 and Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

Sequences complementary to the TRICH-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring TRICH. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of TRICH. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the TRICH-encoding transcript.

XII. Expression of TRICH

Expression and purification of TRICH is achieved using bacterial or virus-based expression systems. For expression of TRICH in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express TRICH upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of TRICH in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding TRICH by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to

infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

- 5 In most expression systems, TRICH is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham
10 Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from TRICH at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995,
15 supra, ch. 10 and 16). Purified TRICH obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

XIII. Functional Assays

- TRICH function is assessed by expressing the sequences encoding TRICH at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression
20 vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a
25 marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate
30 the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake;
35 alterations in expression of cell surface and intracellular proteins as measured by reactivity with

specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of TRICH on gene expression can be assessed using highly purified
5 populations of cells transfected with sequences encoding TRICH and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in
10 the art. Expression of mRNA encoding TRICH and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of TRICH Specific Antibodies

TRICH substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to
15 immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the TRICH amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well
20 described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the
25 oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-TRICH activity by, for example, binding the peptide or TRICH to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring TRICH Using Specific Antibodies

30 Naturally occurring or recombinant TRICH is substantially purified by immunoaffinity chromatography using antibodies specific for TRICH. An immunoaffinity column is constructed by covalently coupling anti-TRICH antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

35 Media containing TRICH are passed over the immunoaffinity column, and the column is

washed under conditions that allow the preferential absorbance of TRICH (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/TRICH binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and TRICH is collected.

5 XVI. Identification of Molecules Which Interact with TRICH

Molecules which interact with TRICH may include transporter substrates, agonists or antagonists, modulatory proteins such as G $\beta\gamma$ proteins (Reimann, *supra*) or proteins involved in TRICH localization or clustering such as MAGUKs (Craven, *supra*). TRICH, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled TRICH, washed, and any wells with labeled TRICH complex are assayed. Data obtained using different concentrations of TRICH are used to calculate values for the number, affinity, and association of TRICH with the candidate molecules.

Alternatively, proteins that interact with TRICH are isolated using the yeast 2-hybrid system (Fields, S. and O. Song (1989) *Nature* 340:245-246). TRICH, or fragments thereof, are expressed as fusion proteins with the DNA binding domain of Gal4 or *lexA*, and potential interacting proteins are expressed as fusion proteins with an activation domain. Interactions between the TRICH fusion protein and the TRICH interacting proteins (fusion proteins with an activation domain) reconstitute a transactivation function that is observed by expression of a reporter gene. Yeast 2-hybrid systems are commercially available, and methods for use of the yeast 2-hybrid system with ion channel proteins are discussed in Niethammer, M. and M. Sheng (1998, *Meth. Enzymol.* 293:104-122).

TRICH may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential TRICH agonists or antagonists may be tested for activation or inhibition of TRICH ion channel activity using the assays described in section XVIII.

XVII. Demonstration of TRICH Activity

Ion channel activity of TRICH is demonstrated using an electrophysiological assay for ion conductance. TRICH can be expressed by transforming a mammalian cell line such as COS7, HeLa or CHO with a eukaryotic expression vector encoding TRICH. Eukaryotic expression vectors are commercially available, and the techniques to introduce them into cells are well known to those skilled in the art. A second plasmid which expresses any one of a number of marker genes, such as β -galactosidase, is co-transformed into the cells to allow rapid identification of those cells which have taken up and expressed the foreign DNA. The cells are incubated for 48-72 hours after

transformation under conditions appropriate for the cell line to allow expression and accumulation of TRICH and β -galactosidase.

Transformed cells expressing β -galactosidase are stained blue when a suitable colorimetric substrate is added to the culture media under conditions that are well known in the art. Stained cells
5 are tested for differences in membrane conductance by electrophysiological techniques that are well known in the art. Untransformed cells, and/or cells transformed with either vector sequences alone or β -galactosidase sequences alone, are used as controls and tested in parallel. Cells expressing TRICH will have higher anion or cation conductance relative to control cells. The contribution of TRICH to conductance can be confirmed by incubating the cells using antibodies specific for TRICH. The
10 antibodies will bind to the extracellular side of TRICH, thereby blocking the pore in the ion channel, and the associated conductance.

Alternatively, ion channel activity of TRICH is measured as current flow across a TRICH-containing Xenopus laevis oocyte membrane using the two-electrode voltage-clamp technique (Ishi et al., supra; Jegla, T. and L. Salkoff (1997) J. Neurosci. 17:32-44). TRICH is subcloned into an
15 appropriate Xenopus oocyte expression vector, such as pBF, and 0.5-5 ng of mRNA is injected into mature stage IV oocytes. Injected oocytes are incubated at 18 °C for 1-5 days. Inside-out macropatches are excised into an intracellular solution containing 116 mM K-gluconate, 4 mM KCl, and 10 mM Hepes (pH 7.2). The intracellular solution is supplemented with varying concentrations of the TRICH mediator, such as cAMP, cGMP, or Ca^{+2} (in the form of CaCl_2), where appropriate.
20 Electrode resistance is set at 2-5 M Ω and electrodes are filled with the intracellular solution lacking mediator. Experiments are performed at room temperature from a holding potential of 0 mV. Voltage ramps (2.5 s) from -100 to 100 mV are acquired at a sampling frequency of 500 Hz. Current measured is proportional to the activity of TRICH in the assay.

Transport activity of TRICH is assayed by measuring uptake of labeled substrates into
25 Xenopus laevis oocytes. Oocytes at stages V and VI are injected with TRICH mRNA (10 ng per oocyte) and incubated for 3 days at 18°C in OR2 medium (82.5mM NaCl, 2.5 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 1mM Na_2HPO_4 , 5 mM Hepes, 3.8 mM NaOH , 50 $\mu\text{g/ml}$ gentamycin, pH 7.8) to allow expression of TRICH. Oocytes are then transferred to standard uptake medium (100mM NaCl, 2 mM KCl, 1mM CaCl_2 , 1mM MgCl_2 , 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g.,
30 amino acids, sugars, drugs, ions, and neurotransmitters) is initiated by adding labeled substrate (e.g. radiolabeled with ^3H , fluorescently labeled with rhodamine, etc.) to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na^+ -free medium, measuring the incorporated label, and comparing with controls. TRICH activity is proportional to the level of internalized labeled substrate.

ATPase activity associated with TRICH can be measured by hydrolysis of radiolabeled ATP- $[\gamma\text{-}^{32}\text{P}]$, separation of the hydrolysis products by chromatographic methods, and quantitation of the recovered ^{32}P using a scintillation counter. The reaction mixture contains ATP- $[\gamma\text{-}^{32}\text{P}]$ and varying amounts of TRICH in a suitable buffer incubated at 37°C for a suitable period of time. The reaction is terminated by acid precipitation with trichloroacetic acid and then neutralized with base, and an aliquot of the reaction mixture is subjected to membrane or filter paper-based chromatography to separate the reaction products. The amount of ^{32}P liberated is counted in a scintillation counter. The amount of radioactivity recovered is proportional to the ATPase activity of TRICH in the assay.

XVIII. Identification of TRICH Agonists and Antagonists

TRICH is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293. Ion channel activity of the transformed cells is measured in the presence and absence of candidate agonists or antagonists. Ion channel activity is assayed using patch clamp methods well known in the art or as described in Example XVII. Alternatively, ion channel activity is assayed using fluorescent techniques that measure ion flux across the cell membrane (Velicelebi, G. et al. (1999) *Meth. Enzymol.* 294:20-47; West, M.R. and C.R. Molloy (1996) *Anal. Biochem.* 241:51-58). These assays may be adapted for high-throughput screening using microplates. Changes in internal ion concentration are measured using fluorescent dyes such as the Ca^{2+} indicator Fluo-4 AM, sodium-sensitive dyes such as SBFI and sodium green, or the Cl^- indicator MQAE (all available from Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In a more generic version of this assay, changes in membrane potential caused by ionic flux across the plasma membrane are measured using oxonol dyes such as DiBAC₄ (Molecular Probes). DiBAC₄ equilibrates between the extracellular solution and cellular sites according to the cellular membrane potential. The dye's fluorescence intensity is 20-fold greater when bound to hydrophobic intracellular sites, allowing detection of DiBAC₄ entry into the cell (Gonzalez, J.E. and P.A. Negulescu (1998) *Curr. Opin. Biotechnol.* 9:624-631). Candidate agonists or antagonists may be selected from known ion channel agonists or antagonists, peptide libraries, or combinatorial chemical libraries.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
1784775	1	1784775CD1	16	1784775CB1
7473034	2	7473034CD1	17	7473034CB1
1878581	3	1878581CD1	18	1878581CB1
2246292	4	2246292CD1	19	2246292CB1
5151730	5	5151730CD1	20	5151730CB1
7472584	6	7472584CD1	21	7472584CB1
7472536	7	7472536CD1	22	7472536CB1
7473422	8	7473422CD1	23	7473422CB1
2864715	9	2864715CD1	24	2864715CB1
1734724	10	1734724CD1	25	1734724CB1
1563237	11	1563237CD1	26	1563237CB1
7473443	12	7473443CD1	27	7473443CB1
7473438	13	7473438CD1	28	7473438CB1
7474286	14	7474286CD1	29	7474286CB1
7472589	15	7472589CD1	30	7472589CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
1	1784775CD1	g4902730	4.00E-94	[Homo sapiens] multidrug resistance-associated protein 7
2	7473034CD1	g2317274	9.00E-168	[Homo sapiens] aquaporin adipose Kuriyama, H. et al. (1997) Biochem. Biophys. Res. Commun. 241, 53-58
3	1878581CD1	g545998	1.10E-164	[Rattus sp.] tricarboxylate carrier rats, liver, Peptide Mitochondrial Partial, 357 aa Azzi, A. et al. (1993) J. Bioenerg. Biomembr. 25, 515-524
4	2246292CD1	g6045150	0	[Rattus norvegicus] TAP-like ABC transporter Yamaguchi, Y. et al. (1999) FEBS Lett. 457, 231-236
5	5151730CD1	g475542	0	[Rattus norvegicus] glutamate receptor delta-1 subunit
		g220418	0	[Mus musculus] glutamate receptor channel subunit delta-1 Yamazaki, M. et al. (1992) Biochem. Biophys. Res. Commun. 183:886-892
6	7472584CD1	g7546839	0	[Cavia porcellus] potassium channel TASK3 Rajan, S. et al. (2000) J. Biol. Chem. 275:16650-16657
7	7472536CD1	g2687858	4.30E-129	[Pseudopleuronectes americanus] renal organic anion transporter Wolff, N.A. et al. (1997) Expression cloning and characterization of a renal organic anion transporter from winter flounder, FEBS Lett 417:287-291
8	7473422CD1	g9950945	0	[Pseudomonas aeruginosa] iron (III)-transport system permease HitB Stover, C.K. et al. (2000) Nature 406:959-964

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
9	2864715CD1	g531469	0	[Rattus norvegicus] renal osmotic stress-induced Na-Cl organic solute cotransporter
		g3347922	5.00E-190	[Mus musculus] orphan transporter isoform A12 Nash, S.R. et al. (1998) Cloning, gene structure and genomic localization of an orphan transporter from mouse kidney with six alternatively-spliced isoforms, Receptors Channels 6:113-128
10	1734724CD1	g3980315	5.00E-46	[Oryctolagus cuniculus] hepatic sodium-dependent bile acid
11	1563237CD1	g2208839	2.00E-125	[Rattus norvegicus] peptide/histidine transporter Yamashita, T. et al. (1997) Cloning and functional expression of a brain peptide/histidine transporter, J. Biol. Chem. 272:10205-10211
		g7415511	0	[Homo sapiens] peptide transporter 3
12	7473443CD1	g4186073	3.20E-280	[Mus musculus] calcium channel alpha-2-delta-C subunit
13	7473438CD1	g2465542	7.60E-84	[Homo sapiens] TWIK-related acid-sensitive K ⁺ channel Duprat, F. et al. (1997) TASK, a human background K ⁺ channel to sense external pH variations near physiological pH, EMBO J. 16:5464-5471
		g11228686	0	[Homo sapiens] two pore potassium channel KT3.3

Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability score	GenBank Homolog
14	7474286CD1	g306473	1.90E-39	[Homo sapiens] calcium channel gamma subunit Powers, P.A. et al. (1993) Molecular characterization of the gene encoding the gamma subunit of the human skeletal muscle 1,4- dihydropyridine-sensitive Ca ²⁺ channel (CACNLG), cDNA sequence, gene structure, and chromosomal location, J. Biol. Chem. 268:9275- 9279
15	7472589CD1	g11177514	0	[Homo sapiens] tandem pore domain potassium channel THIK-2 Rajan, S. et al. (2001) J. Biol. Chem. 276:7302-7311

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	1784775CD1	520	T343 S354 S404 T496 S345		Transmembrane domains: L25-L42; P120-Y142; L277-L297 L365-P392; Y465-M485 ABC transporter transmembrane region: Y242-E499 RESISTANCE; MULTIDRUG; SAUROLEISHMANIA; C3F10.11C; DM01742 P33527 195-653; P160-P201; Q221-V483	HMMER HMMER-PFAM BLAST-DOMO
2	7473034CD1	346	Y297 T11 S146 T192 T194 S252 S10	N65 N327	transmembrane domain: M46-L64 Major intrinsic protein (MIP): E31-Y276 MIP family proteins BL00221A:A43-V53 BL00221B:I92-T102 BL00221C:E179-D195 BL00221D:T225-I239 BL00221E:W258-G268 MAJOR INTRINSIC PROTEIN PR00783A:R39-S58 PR00783B:F78-T102 PR00783C:K115-I134 PR00783D:N178-Q196 PR00783E:G79-V101 PR00783F:W259-F279 AQUAPORIN ADIPOSE AQPAP TRANSPORT TRANSMEMBRANE PD078705:L277-F346 MIP FAMILY DM00228 P47862 15-263:K36-Y276 DM00228 I59266 15-263:K36-Y276 DM00228 P43549 340-587:R35-F279 DM00228 P11244 1-253:L42-Y276	HMMER HMMER-PFAM BLIMPS_BLOCKS BLIMPS_PRINTS BLAST_PRODOM BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
3	1878581CD1	322	T30 T64 T143 T296 S309 S46 T134	N100 N124 N132 N135	PROTEIN TRANSMEMBRANE CHROMOSOME PUTATIVE TRANSPORTER PD006986:L5-L251	BLAST_PRODOM
4	2246292CD1	723	T139 S161 T209 T311 T377 T469 S500 S720 S354 Y559 S28 S33 S46 T153 T181 S275 T367 S528 S552 S628 S659	N280 N465 N481 N556 N718	ABC transporter: L600-L614 ATP/GTP-binding site motif A: G496-S503 transmembrane domain V85-F104, V185-F204, L328- G347 ABC transporter: G489-G673 ABC transporter transmembrane region: L188-G450	MOTIFS HMMER HMMER_PFAM
					ABC transporters family BL00211A:L494-C505 BL00211B:L600-D631 ABC transporters family signature: I582-D631 ATP-BINDING TRANSPORT PROTEIN TRANSMEMBRANE GLYCOPROTEIN TRANSPORTER: PD000130:V229- A406	BLIMPS_BLOCKS PROFILES SCAN BLAST_PRODOM
					MT2 PROTEIN DM07894 Q03519 1-685:L395-V675 DM07894 S25577 1-703:V422-M699 ABC TRANSPORTERS FAMILY DM00008 Q03518 502-717:V461- G673 DM00008 S13426 479-695:V461- G673	BLAST_DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
6	7472584CD1	374	S31, S55, S127, S179, S251, S319, S331, T341, S360, S373,	N53	TASK K+ channel signature: PR01095A: V6-V25, PR01095B: F26-K51, PR01095C: E63-Q77, PR01095D: Q126-K145, PR01095E: C146-T161, PR01095F: Q209-V230, PR01095G: G236-E254, PR01095H: R283-D306, PR01095K: F348-V374, CHANNEL IONIC TWIKRELATED ACIDSENSITIVE K+ CTBAK F34D6.3 PROTEIN PUTATIVE POTASSIUM: PD013020: M1-A74 Signal Peptide (signal_peptide): M1-V25 Transmembrane Domain (transmembrane_domain): F225-V243 TASK K+ channel (TWIK_channel): M1-V374 Ion Transport Protein (ion_trans): I54-L244 Sugar transport proteins: DM00135 P38142 145-478: R230-E488 (p = 6.1e-06) Transmembrane domain: G400-M425; T424-A447 Sugar (and other) transporter: S133-A553	BLIMPS-PRINTS
7	7472536CD1	589	S94, T121, T170, S192, S246, S308, S362, T376, T433, T513, S563, S564	N54, N74, N89, N96, N131, N149	Transporter: organic cation transport protein: putative ion renal cationic transmembrane protein: PD003661: M34-W125	BLAST-PRODOM HMMER-SIGPEPT HMMER-TRANSMEMBRANE HMMER-PFAM BLAST-DOMO HMMER-TRANSMEMBRANE HMMER-PFAM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
8	7473422CD1	549	S3, S19, S49, S155, T182, T188, S189, S193 T449, T541		Binding-protein-dependent transport signature: BPD_transp: T182-E252	HMMEP-PFAM
					Binding-protein-dependent transport systems inner membrane component: bpd_transp_inn_membr.prf: L432-E231	PROFILESAN
					Protein: iron iron III transport system, permease transport, transmembrane inner membrane HITB PD031934: K46-L183	BLAST-PRODOR
					DOMAIN: SFUB; IRON; TRANSPORT; PERIPLASMIC; DM05963 D64048 210-473: A316-L540	BLAST-DOMO
					BPD Transporter Integral Membraneprotein signature: L183-P211, L443-P471	MOTIFS
					Transmembrane domain: P48-V70; N97-A117; M262-L279; V315-S334; V356-V375	HMMEP-TRANSMEMBRANE

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	2864715CD1	634	S17, S30, S100, S143, S170, S186, T212, T219, T243, T267, T330, S483, T533, S561, S573	N158 N182 N258 N354 N368	SODIUM:NEUROTRANSMITTER SYMPORTER FAMILY: DM00572 S50998 19-616:S31-G614	BLAST-DOMO
					Sodium:neurotransmitter: BL00610A: Q40-E89; BL00610B: W104-W153; BL00610C: W195-G246; BL00610D: E261-T313; BL00610E: A406-V448; BL00610F: M502-Q556; BL00610G: I576-P598	BLIMPS-BLOCKS
					Sodium:neurotransmitter symporter family signature: neurotransm_transp_1: D36-F90	PROFILESCAN
					SODIUM/NEUROTRANSMITTER: PR00176A: Q40-L61; PR00176B: A69-L88; PR00176C: G113-Y139; PR00176D: A222-I239; PR00176E: V304-V324; PR00176F: M410-L429; PR00176G: S491-V511; PR00176H: Q531-V551	BLIMPS-PRINTS
					TRANSPORTER NEUROTRANSMITTER TRANSPORT TRANSMEMBRANE SYMPORT GLYCOPROTEIN SODIUM CHLORIDEDEPENDENT SODIUMDEPENDENT GABA: PD000448:C383-I606	BLAST-PRODOM
					Transmembrane domain: F70-L88, F123-F141, I305-V324, S417-V440, I462-Y480, T533-F550	HMME-TRANSMEMBRANE
					Sodium neurotransmitter symporter family (SNF): R32-R332, L378-N608	HMME-PFAM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
10	1734724CD1	491	T227, S233, S459, T475	N6, N18, N24, N180	SODIUM; ACID; BILE; TRANSPORTER DOMAIN; DM03972 I38655 8-318:S251-Y439 Transmembrane domain: V241-L261, L288-F307, W325-G343, M416-I435 Sodium Bile acid symporter family (SBF): L113-E345 (score=6.0, e-value=0.00017) ACID COTRANSPORTING POLYPEPTIDE; SODIUM/BILE COTRANSPORTER; NA+/BILE SODIUM/TAUROCHOLATE TRANSMEMBRANE TRANSPORT SYMPORTER: PD007533:L342-Y439	BLAST-DOMO HMMER HMMER-PFAM BLAST-PRODOR
					PTR2 family (putative protein transp.), proton/oligo: BL01022A:E42-L60; BL01022B:A72-L117; BL01022C:G164-V187; BL01022D:F199-V211; BL01022E:E416-S451 Glucose transporter signature: PR00172C: V241-L261.	BLIMPS-BLOCKS BLIMPS-PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
11	1563237CD1	525	S281, S302, S367, S174, T195, S281, S371	N61, N66, N178, N223, N356, N383	PEPTIDE OLIGOPEPTIDE TRANSPORTER; PROTEIN SYMPORT ISOFORM H+/PEPTIDE COTRANSPORTER: PD001550: Y101-S262	BLAST-PRODOM
					PTR2 FAMILY PROTON/OLIGOPEPTIDE SYMPORTERS: M01990 P46032 46-551:E42-L269	BLAST-DOMO
					POT family (putative protein transporter) PTR2:Y101-S259; PTR2:N396-S447	HMMER-PFAM
12	7473443CD1	1310	S52, T81, T96, S108, S109, S119, S176, S213, S330, T375, S410, S426, S459, S511, S550, S601, T725, S748, S761, T776, T780, S897, T918, S976, S1026, S1052, S1062, T1125, S1126, T1150, S1160, T1170, T1235, T1239, T1245, T1287	N16, N457, N661, N979, 1124, 1206	Similarity to calcium channels: DM06895 P54289 261-693:S759-L1187 CHANNEL CALCIUM PRECURSOR; IONIC TRANSMEMBRANE ION TRANSPORT; VOLTAGE-GATED DIHYDROPYRIDINESENSITIVE LTYPE: PD013837:I631-K750	BLAST-DOMO BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13	7473438CD1	400	S75 S101 S125 T162 S197 S249 S7 S105 S175 S332		Transmembrane domains: S75-F96; F295-V313 TASK K+ channel domain: M71-I400 TASK K+ channel signature PR01095: V76-V95; F96-K121; E133-Q147; Q196-C215; C216- V231; Q279-L300; G306-P324 CHANNEL PROTEIN IONIC POTASSIUM SUBUNIT K+ PUTATIVE SUBFAMILY K MEMBER PD021430: L229-V312	HMMER HMMER-PFAM BLIMPS-PRINTS BLAST-PRODOM
14	7474286CD1	260	T121 T133 T67 T88 T132 S195	N71 N113	Signal peptide: M1-A53 Transmembrane domains: V146-S164; F169-V187; V225- T242 CALCIUM CHANNEL GAMMA SUBUNIT DIHYDROPYRIDINESENSITIVE LTYPE SKELETAL MUSCLE IONIC TRANSMEMBRANE PD016829: L31-C223	SPSCAN HMMER BLAST-PRODOM
15	7472589CD1	489	S257 S373 S424 S58 S62 S260 T295 S416 S429 S2 S5 S13 T36 T75 T149 T156 T252 S436	N78	Transmembrane domains: F204-F223; P270-M293; F340- I359 TASK K+ channel domain: L32-E484 (Score = -115.2; E-value = 0.0078)	HMMER HMMER-PFAM

Table 4

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment (s)	Sequence Fragments	5' Position	3' Position
16	1784775CB1	1735	233-901, 1- 59, 1252- 1513	60118407D2	948	1303
				60209102U1	1053	1416
				6756053J1 (SINTFER02)	1057	1735
				6431853H1 (LUNGNON07)	324	1021
				GBI:g6850429_000023. fasta.edit.comp	1	771
17	7473034CB1	1041	158-280	GBI:g6742097_000003. fasta.edit	1	1041
18	1878581CB1	2367	1-42, 1275- 2367	71456748V1	228	852
				71461790V1	1602	2235
				71465463V1	300	863
				71464816V1	1499	2193
				71465977V1	807	1533
				71456476V1	1723	2367
				71466268V1	908	1564
				4202150H1 (BRAITUT29)	1	280
19	2246292CB1	3343	1-867, 2606-2809, 1501-1983, 960-1013	5531403F6 (HEARFET05)	1747	2162
				60111369D2	1	473
				95396013	2884	3343
				3811252F6 (CONTTUT01)	1387	1948
				2246292R6 (HIPONON02)	2978	3333
				6890917J1 (BRAITDR03)	650	1293
				7168417H1 (MCLRNOC01)	100	648
				4691312T6 (BRAENOT02)	2689	3320
				6120730H1 (BRAHNON05)	2365	3044
				3334167H1 (BRAIFET01)	549	818
				4691312F6 (BRAENOT02)	1959	2552
				5014991H1 (BRAXNOT03)	1713	1968
				2395385F6 (THP1AZT01)	1026	1490

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
20	5151730CB1	3517	863-1689, 1-113, 3288-3339	6885903J1 (BRAHTDR03) 5151730F6 (HEARFET03) 1675978T6 (BLADNOT05) 3907290H1 (LUNGNOT23) 4406394H1 (PROSDIT01) 6974079F8 (BRAHTDR04) 7288330H1 (BRAIFER06) 6250428F8 (LUNPTUT02) 7326591H2 (SPLNTUE01) 7174088H1 (BRSTTMC01) 3486391T6 (EPIGNOT01) 6891842H1 (BRAITDR03) 449149H1 (TLYMNOT02) GBL.g6164987.raw g2001843 7693385H2 (LNODTUE01) 7693385J2 (LNODTUE01) GNN.g5776606_000002_002 .edit GNN.g5525050_000002_ 004 70870289V1 70529541V1 6783918H1 (SINITMC01) 6829267J1 (SINTNOR01) 70792490V1 6783311H1 (SINITMC01) 6783435H2 (SINITMC01) 1734724F6 (COLNNOT22) 60123116D1 4222214H1 (PANCNOT07) 3495639T7 (ADRETUT07) 3495639F6 (ADRETUT07) GNN.g7344269_000021_002 6147668H1 (BRANDIT03)	2374 604 2973 3381 2229 1 1855 183 804 1082 2821 1458 959 1 946 1 253 1 1 1771 550 1254 1088 2213 1710 1 1063 902 1942 1525 963 69 1	2952 927 3502 3517 2485 582 2316 856 1409 1683 3440 1993 1128 1122 1248 743 879 1770 2544 2335 1154 1738 1616 2871 2261 466 1704 987 2141 2120 1551 1544 545
21	7472584CB1	1248	751-945, 96-219			
22	7472536CB1	1770	1-481, 1136-1770, 573-1030			
23	7473422CB1	2544	1-2544			
24	2864715CB1	2871	1-32, 750- 1421, 1950- 2871			
25	1734724CB1	2141	658-817			

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragment(s)	Sequence Fragments	5' Position	3' Position
26	1563237CB1	1902	1-1283	7127258H1 (COLNDIY01) 2207658F6 (SINTFET03) 1563237T6 (SPLNNOT04) 2118071T6 (BRSTTUT02) 7679862H1 (BRAFTUE01)	689 818 1332 1410 1	1258 1379 1899 1902 722
27	7473443CB1	4125	1-41, 3763- 4125, 407- 435, 491- 2446	71153376V1 FL722155_00001.raw 71395953V1 GBI.g3810573.raw 71151716V1 71158575V1	3186 1864 3713 1 3338 2741	3857 2161 4125 804 3892 3346
28	7473438CB1	2460	1628-1717, 1-374, 998- 1020, 515- 540, 2181- 2460, 1182- 1278	GBI.g3810573.edit 6758949H1 (HEAONOR01) 2230573F6 (PROSNOT16) FL767399_00001 CpG_991027_B15_masked_ fa.Contig52563	634 1907 1541 722 1	3099 2460 2120 1974 1162
29	7474286CB1	896	86-487	GNN.g7523629_000001_ 002	1	896
30	7472589CB1	2080	1-492, 1002-1177, 618-691	7289171H1 (BRAIFER06) GNN.g6560849_000001_ 002	1 285	599 2080

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
16	1784775CB1	BRAINOT10
18	1878581CB1	SPLNFET02
19	2246292CB1	HIPONON02
20	5151730CB1	PROSTM07
21	7472584CB1	TYMNOT02
22	7472536CB1	LNODTUE01
24	2864715CB1	SINITUT03
25	1734724CB1	ADRETUT07
26	1563237CB1	DRGLNOT01
27	7473443CB1	THP1AZS08
28	7473438CB1	PROSNOT16
29	7474286CB1	PTHYNOT03
30	7472589CB1	BRAIFER06

Table 6

Library	Vector	Library Description
ADRETUT07	pINCY	Library was constructed using RNA isolated from adrenal tumor tissue removed from a 43-year-old Caucasian female during a unilateral adrenalectomy. Pathology indicated pheochromocytoma.
BRAIFER06	PCDNA2.1	This random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. Serologies were negative.
BRAINOT10	pINCY	Library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 74-year-old Caucasian male, who died from Alzheimer's disease.
DRGLNOT01	pINCY	Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus, infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. Surgeries included colonoscopy, large intestine biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy; treatment included radiation therapy.
HIPONON02	PSPORT1	This normalized hippocampus library was constructed from 1.13M independent clones from a hippocampus tissue library. RNA was isolated from the hippocampus tissue of a 72-year-old Caucasian female who died from an intracranial bleed. Patient history included nose cancer, hypertension, and arthritis. The normalization and hybridization conditions were adapted from Soares et al. (PNAS (1994) 91:9228).
LNODTUE01	PCDNA2.1	This 5' biased random primed library was constructed using RNA isolated from lymph node tumor tissue removed from a 67-year-old Caucasian male during regional lymph node excision, open biopsy of tongue, and partial glossectomy. Pathology indicated metastatic basaloid squamous cell carcinoma. Pathology for the associated tumor tissue indicated basaloid squamous cell carcinoma forming an ulcerated mass in the base of the tongue. Tumor deeply invaded the underlying skeletal muscle. The patient presented with tongue cancer. Patient history included benign hypertension and alcohol abuse. The patient was not taking any medications. Family history included diabetes in the son.

Table 6 (cont.)

Library	Vector	Library Description
PROSNOT16	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 68-year-old Caucasian male during a radical prostatectomy. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3+4). The patient presented with elevated prostate specific antigen (PSA). During this hospitalization, the patient was diagnosed with myasthenia gravis. Patient history included osteoarthritis, and type II diabetes. Family history included benign hypertension, acute myocardial infarction, hyperlipidemia, and arteriosclerotic coronary artery disease.
PROSTWT07	pINCY	The library was constructed using RNA isolated from diseased prostate tissue removed from a 73-year-old Caucasian male during radical prostatectomy, closed prostatic biopsy, and regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated adenocarcinoma, Gleason 3+3, involving the left side peripherally and anteriorly. The tumor perforated the capsule to involve periprostatic tissue and anterior surgical margin on the left. The patient presented with elevated prostate-specific antigen. Patient history included bladder cancer, speech disturbance and acquired spondylolisthesis. Family history included benign hypertension and acquired cerebrovascular disease.
PTHYNOT03	pINCY	Library was constructed using RNA isolated from the left parathyroid tissue of a 69-year-old Caucasian female during a partial parathyroidectomy. Pathology indicated hyperplasia. The patient presented with primary hyperparathyroidism.
SINITUT03	pINCY	Library was constructed using RNA isolated from ileal tumor tissue obtained from a 49-year-old Caucasian female during destruction of peritoneal tissue, peritoneal adhesiolysis, ileum resection, and permanent colostomy. Pathology indicated grade 4 adenocarcinoma. Patient history included benign hypertension. Previous surgeries included total abdominal hysterectomy, bilateral salpingo-oophorectomy, regional lymph node excision, an incidental appendectomy, and dilation and curettage. Family history included benign hypertension, cerebrovascular disease, hyperlipidemia, atherosclerotic coronary artery disease, hyperlipidemia, type II diabetes, and stomach cancer.
SPLNFET02	pINCY	Library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation.

Table 6 (cont.)

Library	Vector	Library Description
THP1AZS08	PSPORT1	This subtracted THP-1 promonocyte cell line library was constructed using 5.76 x 1e6 clones from a 5-aza-2'-deoxycytidine (AZ) treated THP-1 cell library. Starting RNA was made from THP-1 promonocyte cells treated for three days with 0.8 micromolar AZ. The donor had acute monocytic leukemia. The hybridization probe for subtraction was derived from a similarly constructed library, made from 1 microgram of polyA RNA isolated from untreated THP-1 cells. 5.76 million clones from the AZ-treated THP-1 cell library were then subjected to two rounds of subtractive hybridization with 5 million clones from the untreated THP-1 cell library. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR (1991) 19:1954, and Bonaldo et al., Genome Research (1996) 6:791.
TLYMN0T02	Lambda UnizAP	Library was constructed using RNA isolated from non-adherent peripheral blood mononuclear cells. The blood was obtained from unrelated male and female donors and treated with LPS for 0 hours. Cells from each donor were purified on Ficoll Hypaque, then harvested by centrifugation, lysed in a buffer containing GUSCN, and spun through CsCl to obtain RNA for library construction. PolyA RNA was isolated using a Qiagen Oligotex kit. cDNA synthesis was initiated using an XhoI-oligo(dT) primer. Double-stranded cDNA was blunted, ligated to EcoRI adaptors, digested with XhoI, size-selected, and cloned into the XhoI and EcoRI sites of the Lambda UnizAP vector.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising an amino acid sequence selected from the group consisting of
5 SEQ ID NO:1-15,
 - b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4 and SEQ ID NO:6-15,
 - c) a naturally occurring polypeptide comprising an amino acid sequence at least 92%
10 identical to the amino acid sequence of SEQ ID NO:2,
 - d) a naturally occurring polypeptide comprising an amino acid sequence at least 96% identical to the amino acid sequence of SEQ ID NO:3,
 - e) a naturally occurring polypeptide comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:5,
15 f) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, and
g) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.
 - 20 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-15.
 3. An isolated polynucleotide encoding a polypeptide of claim 1.
 - 25 4. An isolated polynucleotide encoding a polypeptide of claim 2.
 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:16-30.
 - 30 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
 7. A cell transformed with a recombinant polynucleotide of claim 6.

8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said
5 cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide
comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of
claim 1, and
- b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
11. An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting
of SEQ ID NO:16-30,
- 15 b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:16-30,
c) a polynucleotide complementary to the polynucleotide of a),
d) a polynucleotide complementary to the polynucleotide of b), and
e) an RNA equivalent of a)-d).
- 20 12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a
polynucleotide of claim 11.
13. A method for detecting a target polynucleotide in a sample, said target polynucleotide
25 having a sequence of a polynucleotide of claim 11, the method comprising:
- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides
comprising a sequence complementary to said target polynucleotide in the sample, and which probe
specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
complex is formed between said probe and said target polynucleotide or fragments thereof, and
- 30 b) detecting the presence or absence of said hybridization complex, and, optionally, if
present, the amount thereof.
14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- 5 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

10

17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.

18. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- 20 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

25

21. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- 30 a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional TRICH, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;

b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim

5 11 or fragment thereof;

c) quantifying the amount of hybridization complex; and

d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test

10 compound.

29. A diagnostic test for a condition or disease associated with the expression of TRICH in a biological sample comprising the steps of:

a) combining the biological sample with an antibody of claim 10, under conditions suitable
15 for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and

b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

30. The antibody of claim 10, wherein the antibody is:

- 20 a) a chimeric antibody,
b) a single chain antibody,
c) a Fab fragment,
d) a F(ab')₂ fragment, or
e) a humanized antibody.

25

31. A composition comprising an antibody of claim 10 and an acceptable excipient.

32. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the composition of claim

30 31.

33. A composition of claim 31, wherein the antibody is labeled.

34. A method of diagnosing a condition or disease associated with the expression of TRICH

in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 5 10 comprising:

a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibodies from said animal; and

10 c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.

36. An antibody produced by a method of claim 35.

15

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:

20 a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15, or an immunogenic fragment thereof, under conditions to elicit an antibody response;

b) isolating antibody producing cells from the animal;

25 c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;

d) culturing the hybridoma cells; and

e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.

30 39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

41. The antibody of claim 10, wherein the antibody is produced by screening a Fab

expression library.

42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

5

43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 in a sample, comprising the steps of:

a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

10 b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 in the sample.

44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15 from a sample, the method comprising:

15 a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and

b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-15.

20

45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

25 47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

30

50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
- 5 54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
- 10 57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
- 15 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
60. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:16.
- 20 61. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:17.
62. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:18.
- 25 63. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:19.
64. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:20.
- 30 65. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:21.

66. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:22.

67. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
5 NO:23.

68. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:24.

10 69. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:25.

70. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:26.
15

71. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:27.

72. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
20 NO:28.

73. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:29.

25 74. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:30.

<110> INCYTE GENOMICS, INC.
 REDDY, Roopa
 THORNTON, Michael
 BOROWSKY, Mark L.
 TANG, Y. Tom
 KHAN, Farrah A.
 TRIBOULEY, Catherine M.
 GANDHI, Aameena R.
 YAO, Monique G.
 SANJANWALA, Madhu S.
 BAUGHN, Mariah R.
 NGUYEN, Danniel B.
 POLICKY, Jennifer L.
 YUE, Henry
 SEILHAMER, Jeffrey J.
 WALIA, Narinder K.
 LAL, Preeti
 KEARNEY, Liam
 WALSH, Roderick T.
 LU, Dyung Aina M.
 LU, Yan
 GREENE, Barrie D.
 RAUMANN, Brigitte E.
 PATTERSON, Chandra

<120> TRANSPORTERS AND ION CHANNELS

<130> PI-0067 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/195,595; 60/196,872; 60/199,020; 60/200,552; 60/202,348;
 60/203,495

<151> 2000-04-06; 2000-04-12; 2000-04-20; 2000-04-28; 2000-05-05;
 2000-05-11

<160> 30

<170> PERL Program

<210> 1

<211> 520

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1784775CD1

<400> 1

Met	Cys	Leu	Leu	Val	Phe	Pro	Leu	Val	Pro	Arg	Ser	Pro	Asp	Tyr
1				5					10					15
Ile	Leu	Pro	Cys	Ser	Pro	Gly	Trp	Arg	Leu	Arg	Leu	Ala	Ala	Ser
				20					25					30
Phe	Leu	Leu	Ser	Val	Phe	Pro	Leu	Leu	Asp	Leu	Leu	Pro	Val	Ala
				35					40					45
Leu	Pro	Pro	Gly	Ala	Gly	Pro	Gly	Pro	Ile	Gly	Leu	Glu	Val	Leu
				50					55					60
Ala	Gly	Cys	Val	Ala	Ala	Val	Ala	Trp	Ile	Ser	His	Ser	Leu	Ala
				65					70					75
Leu	Trp	Val	Leu	Ala	His	Ser	Pro	His	Gly	His	Ser	Arg	Gly	Pro
				80					85					90

Leu	Ala	Leu	Ala	Leu	Val	Ala	Leu	Leu	Pro	Ala	Pro	Ala	Leu	Val
				95					100					105
Leu	Thr	Val	Leu	Trp	His	Cys	Gln	Arg	Gly	Thr	Leu	Leu	Pro	Pro
				110					115					120
Leu	Leu	Pro	Gly	Pro	Met	Ala	Arg	Leu	Cys	Leu	Leu	Ile	Leu	Gln
				125					130					135
Leu	Ala	Ala	Leu	Leu	Ala	Tyr	Ala	Leu	Gly	Trp	Ala	Ala	Pro	Gly
				140					145					150
Gly	Pro	Arg	Glu	Pro	Trp	Ala	Gln	Glu	Pro	Leu	Leu	Pro	Glu	Asp
				155					160					165
Gln	Glu	Pro	Glu	Val	Ala	Glu	Asp	Gly	Glu	Ser	Trp	Leu	Ser	Arg
				170					175					180
Phe	Ser	Tyr	Ala	Trp	Leu	Ala	Pro	Leu	Leu	Ala	Arg	Gly	Ala	Cys
				185					190					195
Gly	Glu	Leu	Arg	Gln	Pro	Gln	Asp	Ile	Cys	Arg	Leu	Pro	His	Arg
				200					205					210
Leu	Gln	Pro	Thr	Tyr	Leu	Ala	Arg	Val	Phe	Gln	Ala	His	Trp	Gln
				215					220					225
Glu	Gly	Ala	Arg	Leu	Trp	Arg	Ala	Leu	Tyr	Gly	Ala	Phe	Gly	Arg
				230					235					240
Cys	Tyr	Leu	Ala	Leu	Gly	Leu	Leu	Lys	Leu	Val	Gly	Thr	Met	Leu
				245					250					255
Gly	Phe	Ser	Gly	Pro	Leu	Leu	Leu	Ser	Leu	Leu	Val	Gly	Phe	Leu
				260					265					270
Glu	Glu	Gly	Gln	Glu	Pro	Leu	Ser	His	Gly	Leu	Leu	Tyr	Ala	Leu
				275					280					285
Gly	Leu	Ala	Gly	Gly	Ala	Val	Leu	Gly	Ala	Val	Leu	Gln	Asn	Gln
				290					295					300
Tyr	Gly	Tyr	Glu	Val	Tyr	Lys	Val	Thr	Leu	Gln	Ala	Arg	Gly	Ala
				305					310					315
Val	Leu	Asn	Ile	Leu	Tyr	Cys	Lys	Ala	Leu	Gln	Leu	Gly	Pro	Ser
				320					325					330
Arg	Pro	Pro	Thr	Gly	Glu	Ala	Leu	Asn	Leu	Leu	Gly	Thr	Asp	Ser
				335					340					345
Glu	Arg	Leu	Leu	Asn	Phe	Ala	Gly	Ser	Phe	His	Glu	Ala	Trp	Gly
				350					355					360
Leu	Pro	Leu	Gln	Leu	Ala	Ile	Thr	Leu	Tyr	Leu	Leu	Tyr	Gln	Gln
				365					370					375
Val	Gly	Val	Ala	Phe	Val	Gly	Gly	Leu	Ile	Leu	Ala	Leu	Leu	Leu
				380					385					390
Val	Pro	Val	Asn	Lys	Val	Ile	Ala	Thr	Arg	Ile	Met	Ala	Ser	Asn
				395					400					405
Gln	Glu	Met	Leu	Gln	His	Lys	Asp	Ala	Arg	Val	Lys	Leu	Val	Thr
				410					415					420
Glu	Leu	Leu	Ser	Gly	Ile	Arg	Val	Ile	Lys	Phe	Cys	Gly	Trp	Glu
				425					430					435
Gln	Ala	Leu	Gly	Ala	Arg	Val	Glu	Ala	Cys	Arg	Ala	Arg	Glu	Leu
				440					445					450
Gly	Arg	Leu	Arg	Val	Ile	Lys	Tyr	Leu	Asp	Ala	Ala	Cys	Val	Tyr
				455					460					465
Leu	Trp	Ala	Ala	Leu	Pro	Val	Val	Ile	Ser	Ile	Val	Ile	Phe	Ile
				470					475					480
Thr	Tyr	Val	Leu	Met	Gly	His	Gln	Leu	Thr	Ala	Thr	Lys	Val	Arg
				485					490					495
Thr	Arg	Lys	Glu	Gly	Asp	Gln	His	Gln	Gly	Asp	Phe	Ser	Glu	Val
				500					505					510
Lys	Thr	Glu	Ala	Trp	Ala	Leu	Ser	Ala	Gly					
				515					520					

<210> 2

<211> 346

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473034CD1

<400> 2

Met	Val	Gln	Ala	Ser	Gly	His	Arg	Arg	Ser	Thr	Arg	Gly	Ser	Lys
1				5					10					15
Met	Val	Ser	Trp	Ser	Val	Ile	Ala	Lys	Ile	Gln	Glu	Ile	Trp	Cys
				20					25					30
Glu	Glu	Asp	Glu	Arg	Lys	Met	Val	Arg	Glu	Phe	Leu	Ala	Glu	Phe
				35					40					45
Met	Ser	Thr	Tyr	Val	Met	Met	Val	Phe	Gly	Leu	Gly	Ser	Val	Ala
				50					55					60
His	Met	Val	Leu	Asn	Lys	Thr	Tyr	Gly	Ser	Tyr	Leu	Gly	Val	Asn
				65					70					75
Leu	Gly	Phe	Gly	Phe	Gly	Val	Thr	Met	Gly	Val	His	Val	Ala	Gly
				80					85					90
Arg	Ile	Ser	Gly	Ala	His	Met	Asn	Ala	Ala	Val	Thr	Phe	Thr	Asn
				95					100					105
Cys	Ala	Leu	Gly	Arg	Val	Pro	Trp	Arg	Lys	Phe	Pro	Val	His	Val
				110					115					120
Leu	Gly	Gln	Phe	Leu	Gly	Ser	Phe	Leu	Ala	Ala	Ala	Thr	Ile	Tyr
				125					130					135
Ser	Leu	Phe	Tyr	Ser	Ala	Ile	Leu	His	Phe	Ser	Gly	Gly	Glu	Leu
				140					145					150
Met	Val	Thr	Gly	Pro	Phe	Ala	Thr	Ala	Gly	Ile	Phe	Ala	Thr	Tyr
				155					160					165
Leu	Pro	Asp	His	Met	Thr	Leu	Trp	Arg	Gly	Phe	Leu	Asn	Glu	Glu
				170					175					180
Trp	Leu	Thr	Arg	Met	Leu	Gln	Leu	Cys	Leu	Phe	Thr	Ile	Thr	Asp
				185					190					195
Gln	Glu	Asn	Asn	Pro	Ala	Leu	Pro	Gly	Thr	His	Ala	Leu	Val	Ile
				200					205					210
Ser	Ile	Leu	Val	Val	Ile	Ile	Arg	Val	Ser	His	Gly	Ile	Asn	Thr
				215					220					225
Gly	Tyr	Ala	Ile	Asn	Pro	Ser	Arg	Asp	Pro	Pro	Pro	Ser	Ile	Phe
				230					235					240
Thr	Phe	Ile	Ala	Gly	Trp	Gly	Lys	Gln	Val	Phe	Ser	Asp	Gly	Glu
				245					250					255
Asn	Trp	Trp	Trp	Val	Pro	Val	Val	Ala	Pro	Leu	Leu	Gly	Ala	Ser
				260					265					270
Leu	Gly	Gly	Ile	Ile	Tyr	Leu	Val	Phe	Ile	Gly	Ser	Thr	Ile	Pro
				275					280					285
Arg	Glu	Pro	Leu	Lys	Leu	Glu	Asp	Ser	Val	Ala	Tyr	Glu	Asp	His
				290					295					300
Gly	Ile	Thr	Val	Leu	Pro	Lys	Met	Gly	Ser	His	Glu	Pro	Met	Ile
				305					310					315
Ser	Pro	Leu	Thr	Leu	Ile	Ser	Val	Ser	Leu	Ala	Asn	Arg	Ser	Ser
				320					325					330
Val	His	Ser	Ala	Pro	Pro	Leu	His	Glu	Ser	Met	Ala	Leu	Glu	His
				335					340					345

Phe

<210> 3

<211> 322

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1878581CD1

<400> 3

```

Met Ser Gly Glu Leu Pro Pro Asn Ile Asn Ile Lys Glu Pro Arg
 1      5      10      15
Trp Asp Gln Ser Thr Phe Ile Gly Arg Ala Asn His Phe Phe Thr
      20      25      30
Val Thr Asp Pro Arg Asn Ile Leu Leu Thr Asn Glu Gln Leu Glu
      35      40      45
Ser Ala Arg Lys Ile Val His Asp Tyr Arg Gln Gly Ile Val Pro
      50      55      60
Pro Gly Leu Thr Glu Asn Glu Leu Trp Arg Ala Lys Tyr Ile Tyr
      65      70      75
Asp Ser Ala Phe His Pro Asp Thr Gly Glu Lys Met Ile Leu Ile
      80      85      90
Gly Arg Met Ser Ala Gln Val Pro Met Asn Met Thr Ile Thr Gly
      95      100      105
Cys Met Met Thr Phe Tyr Arg Thr Thr Pro Ala Val Leu Phe Trp
      110      115      120
Gln Trp Ile Asn Gln Ser Phe Asn Ala Val Val Asn Tyr Thr Asn
      125      130      135
Arg Ser Gly Asp Ala Pro Leu Thr Val Asn Glu Leu Gly Thr Ala
      140      145      150
Tyr Val Ser Ala Thr Thr Gly Ala Val Ala Thr Ala Leu Gly Leu
      155      160      165
Asn Ala Leu Thr Lys His Val Ser Pro Leu Ile Gly Arg Phe Val
      170      175      180
Pro Phe Ala Ala Val Ala Ala Ala Asn Cys Ile Asn Ile Pro Leu
      185      190      195
Met Arg Gln Arg Glu Leu Lys Val Gly Ile Pro Val Thr Asp Glu
      200      205      210
Asn Gly Asn Arg Leu Gly Glu Ser Ala Asn Ala Ala Lys Gln Ala
      215      220      225
Ile Thr Gln Val Val Val Ser Arg Ile Leu Met Ala Ala Pro Gly
      230      235      240
Met Ala Ile Pro Pro Phe Ile Met Asn Thr Leu Glu Lys Lys Ala
      245      250      255
Phe Leu Lys Arg Phe Pro Trp Met Ser Ala Pro Ile Gln Val Gly
      260      265      270
Leu Val Gly Phe Cys Leu Val Phe Ala Thr Pro Leu Cys Cys Ala
      275      280      285
Leu Phe Pro Gln Lys Ser Ser Met Ser Val Thr Ser Leu Glu Ala
      290      295      300
Glu Leu Gln Ala Lys Ile Gln Glu Ser His Pro Glu Leu Arg Arg
      305      310      315
Val Tyr Phe Asn Lys Gly Leu
      320

```

<210> 4

<211> 723

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2246292CD1

<400> 4

```

Met Arg Leu Trp Lys Ala Val Val Val Thr Leu Ala Phe Met Ser
 1      5      10      15
Val Asp Ile Cys Val Thr Thr Ala Ile Tyr Val Phe Ser His Leu
      20      25      30
Asp Arg Ser Leu Leu Glu Asp Ile Arg His Phe Asn Ile Phe Asp
      35      40      45
Ser Val Leu Asp Leu Trp Ala Ala Cys Leu Tyr Arg Ser Cys Leu

```

				50					55				60
Leu	Leu	Gly	Ala	Thr	Ile	Gly	Val	Ala	Lys	Asn	Ser	Ala	Leu
				65					70				75
Pro	Arg	Arg	Leu	Arg	Ala	Ser	Trp	Leu	Val	Ile	Ser	Leu	Val
				80					85				90
Leu	Phe	Val	Gly	Ile	Tyr	Ala	Met	Val	Lys	Leu	Leu	Leu	Phe
				95					100				105
Glu	Val	Arg	Arg	Pro	Ile	Arg	Asp	Pro	Trp	Phe	Trp	Ala	Leu
				110					115				120
Val	Trp	Thr	Tyr	Ile	Ser	Leu	Gly	Ala	Ser	Phe	Leu	Leu	Trp
				125					130				135
Leu	Leu	Ser	Thr	Val	Arg	Pro	Gly	Thr	Gln	Ala	Leu	Glu	Pro
				140					145				150
Ala	Ala	Thr	Glu	Ala	Glu	Gly	Phe	Pro	Gly	Ser	Gly	Arg	Pro
				155					160				165
Pro	Glu	Gln	Ala	Ser	Gly	Ala	Thr	Leu	Gln	Lys	Leu	Leu	Ser
				170					175				180
Thr	Lys	Pro	Asp	Val	Ala	Phe	Leu	Val	Ala	Ala	Ser	Phe	Phe
				185					190				195
Ile	Val	Ala	Ala	Leu	Gly	Glu	Thr	Phe	Leu	Pro	Tyr	Tyr	Thr
				200					205				210
Arg	Ala	Ile	Asp	Gly	Ile	Val	Ile	Gln	Lys	Ser	Met	Asp	Gln
				215					220				225
Ser	Thr	Ala	Val	Val	Ile	Val	Cys	Leu	Leu	Ala	Ile	Gly	Ser
				230					235				240
Phe	Ala	Ala	Gly	Ile	Arg	Gly	Gly	Ile	Phe	Thr	Leu	Ile	Phe
				245					250				255
Arg	Leu	Asn	Ile	Arg	Leu	Arg	Asn	Cys	Leu	Phe	Arg	Ser	Leu
				260					265				270
Ser	Gln	Glu	Thr	Ser	Phe	Phe	Asp	Glu	Asn	Arg	Thr	Gly	Asp
				275					280				285
Ile	Ser	Arg	Leu	Thr	Ser	Asp	Thr	Thr	Met	Val	Ser	Asp	Leu
				290					295				300
Ser	Gln	Asn	Ile	Asn	Val	Phe	Leu	Arg	Asn	Thr	Val	Lys	Val
				305					310				315
Gly	Val	Val	Val	Phe	Met	Phe	Ser	Leu	Ser	Trp	Gln	Leu	Ser
				320					325				330
Val	Thr	Phe	Met	Gly	Phe	Pro	Ile	Ile	Met	Met	Val	Ser	Asn
				335					340				345
Tyr	Gly	Lys	Tyr	Tyr	Lys	Arg	Leu	Ser	Lys	Glu	Val	Gln	Asn
				350					355				360
Leu	Ala	Arg	Ala	Ser	Asn	Thr	Ala	Glu	Glu	Thr	Ile	Ser	Ala
				365					370				375
Lys	Thr	Val	Arg	Ser	Phe	Ala	Asn	Glu	Glu	Glu	Glu	Ala	Glu
				380					385				390
Tyr	Leu	Arg	Lys	Leu	Gln	Gln	Val	Tyr	Lys	Leu	Asn	Arg	Lys
				395					400				405
Ala	Ala	Ala	Tyr	Met	Tyr	Tyr	Val	Trp	Gly	Ser	Gly	Ser	Val
				410					415				420
Ser	Val	Tyr	Ser	Gly	Leu	Met	Gln	Gly	Val	Gly	Ala	Ala	Glu
				425					430				435
Val	Phe	Glu	Phe	Ile	Asp	Arg	Gln	Pro	Thr	Met	Val	His	Asp
				440					445				450
Ser	Leu	Ala	Pro	Asp	His	Leu	Glu	Gly	Arg	Val	Asp	Phe	Glu
				455					460				465
Val	Thr	Phe	Thr	Tyr	Arg	Thr	Arg	Pro	His	Thr	Gln	Val	Leu
				470					475				480
Asn	Val	Ser	Phe	Ser	Leu	Ser	Pro	Gly	Lys	Val	Thr	Ala	Leu
				485					490				495
Gly	Pro	Ser	Gly	Ser	Gly	Lys	Ser	Ser	Cys	Val	Asn	Ile	Leu
				500					505				510
Asn	Phe	Tyr	Pro	Leu	Glu	Gly	Gly	Arg	Val	Leu	Leu	Asp	Gly
				515					520				525

```

Pro Ile Ser Ala Tyr Asp His Lys Tyr Leu His Arg Val Ile Ser
530 535 540
Leu Val Ser Gln Glu Pro Val Leu Phe Ala Arg Ser Ile Thr Asp
545 550 555
Asn Ile Ser Tyr Gly Leu Pro Thr Val Pro Phe Glu Met Val Val
560 565 570
Glu Ala Ala Gln Lys Ala Asn Ala His Gly Phe Ile Met Glu Leu
575 580 585
Gln Asp Gly Tyr Ser Thr Glu Thr Gly Glu Lys Gly Ala Gln Leu
590 595 600
Ser Gly Gly Gln Lys Gln Arg Val Ala Met Ala Arg Ala Leu Val
605 610 615
Arg Asn Pro Pro Val Leu Ile Leu Asp Glu Ala Thr Ser Ala Leu
620 625 630
Asp Ala Glu Ser Glu Tyr Leu Ile Gln Gln Ala Ile His Gly Asn
635 640 645
Leu Gln Lys His Thr Val Leu Ile Ile Ala His Arg Leu Ser Thr
650 655 660
Val Glu His Ala His Leu Ile Val Val Leu Asp Lys Gly Arg Val
665 670 675
Val Gln Gln Gly Thr His Gln Gln Leu Leu Ala Gln Gly Gly Leu
680 685 690
Tyr Ala Lys Leu Val Gln Arg Gln Met Leu Gly Leu Gln Pro Ala
695 700 705
Ala Asp Phe Thr Ala Gly His Asn Glu Pro Val Ala Asn Gly Ser
710 715 720
His Lys Ala

```

<210> 5

<211> 1009

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5151730CD1

<400> 5

```

Met Glu Ala Leu Thr Leu Trp Leu Leu Pro Trp Ile Cys Gln Cys
1 5 10 15
Val Ser Val Arg Ala Asp Ser Ile Ile His Ile Gly Ala Ile Phe
20 25 30
Glu Glu Asn Ala Ala Lys Asp Asp Arg Val Phe Gln Leu Ala Val
35 40 45
Ser Asp Leu Ser Leu Asn Asp Asp Ile Leu Gln Ser Glu Lys Ile
50 55 60
Thr Tyr Ser Ile Lys Val Ile Glu Ala Asn Asn Pro Phe Gln Ala
65 70 75
Val Gln Glu Ala Cys Asp Leu Met Thr Gln Gly Ile Leu Ala Leu
80 85 90
Val Thr Ser Thr Gly Cys Ala Ser Ala Asn Ala Leu Gln Ser Leu
95 100 105
Thr Asp Ala Met His Ile Pro His Leu Phe Val Gln Arg Asn Pro
110 115 120
Gly Gly Ser Pro Arg Thr Ala Cys His Leu Asn Pro Ser Pro Asp
125 130 135
Gly Glu Ala Tyr Thr Leu Ala Ser Arg Pro Pro Val Arg Leu Asn
140 145 150
Asp Val Met Leu Arg Leu Val Thr Glu Leu Arg Trp Gln Lys Phe
155 160 165
Val Met Phe Tyr Asp Ser Glu Tyr Asp Ile Arg Gly Leu Gln Ser
170 175 180

```

Phe	Leu	Asp	Gln	Ala	Ser	Arg	Leu	Gly	Leu	Asp	Val	Ser	Leu	Gln
				185					190					195
Lys	Val	Asp	Lys	Asn	Ile	Ser	His	Val	Phe	Thr	Ser	Leu	Phe	Thr
				200					205					210
Thr	Met	Lys	Thr	Glu	Glu	Leu	Asn	Arg	Tyr	Arg	Asp	Thr	Leu	Arg
				215					220					225
Arg	Ala	Ile	Leu	Leu	Leu	Ser	Pro	Gln	Gly	Ala	His	Ser	Phe	Ile
				230					235					240
Asn	Glu	Ala	Val	Glu	Thr	Asn	Leu	Ala	Ser	Lys	Asp	Ser	His	Trp
				245					250					255
Val	Phe	Val	Asn	Glu	Glu	Ile	Ser	Asp	Pro	Glu	Ile	Leu	Asp	Leu
				260					265					270
Val	His	Ser	Ala	Leu	Gly	Arg	Met	Thr	Val	Val	Arg	Gln	Ile	Phe
				275					280					285
Pro	Ser	Ala	Lys	Asp	Asn	Gln	Lys	Cys	Thr	Arg	Asn	Asn	His	Arg
				290					295					300
Ile	Ser	Ser	Leu	Leu	Cys	Asp	Pro	Gln	Glu	Gly	Tyr	Leu	Gln	Met
				305					310					315
Leu	Gln	Ile	Ser	Asn	Leu	Tyr	Leu	Tyr	Asp	Ser	Val	Leu	Met	Leu
				320					325					330
Ala	Asn	Ala	Phe	His	Arg	Lys	Leu	Glu	Asp	Arg	Lys	Trp	His	Ser
				335					340					345
Met	Ala	Ser	Leu	Asn	Cys	Ile	Arg	Lys	Ser	Thr	Lys	Pro	Trp	Asn
				350					355					360
Gly	Gly	Arg	Ser	Met	Leu	Asp	Thr	Ile	Lys	Lys	Gly	His	Ile	Thr
				365					370					375
Gly	Leu	Thr	Gly	Val	Met	Glu	Phe	Arg	Glu	Asp	Ser	Ser	Asn	Pro
				380					385					390
Tyr	Val	Gln	Phe	Glu	Ile	Leu	Gly	Thr	Thr	Tyr	Ser	Glu	Thr	Phe
				395					400					405
Gly	Lys	Asp	Met	Arg	Lys	Leu	Ala	Thr	Trp	Asp	Ser	Glu	Lys	Gly
				410					415					420
Leu	Asn	Gly	Ser	Leu	Gln	Glu	Arg	Pro	Met	Gly	Ser	Arg	Leu	Gln
				425					430					435
Gly	Leu	Thr	Leu	Lys	Val	Val	Thr	Val	Leu	Glu	Glu	Pro	Phe	Val
				440					445					450
Met	Val	Ala	Glu	Asn	Ile	Leu	Gly	Gln	Pro	Lys	Arg	Tyr	Lys	Gly
				455					460					465
Phe	Ser	Ile	Asp	Val	Leu	Asp	Ala	Leu	Ala	Lys	Ala	Leu	Gly	Phe
				470					475					480
Lys	Tyr	Glu	Ile	Tyr	Gln	Ala	Pro	Asp	Gly	Arg	Tyr	Gly	His	Gln
				485					490					495
Leu	His	Asn	Thr	Ser	Trp	Asn	Gly	Met	Ile	Gly	Glu	Leu	Ile	Ser
				500					505					510
Lys	Arg	Ala	Asp	Leu	Ala	Ile	Ser	Ala	Ile	Thr	Ile	Thr	Pro	Glu
				515					520					525
Arg	Glu	Ser	Val	Val	Asp	Phe	Ser	Lys	Arg	Tyr	Met	Asp	Tyr	Ser
				530					535					540
Val	Gly	Ile	Leu	Ile	Lys	Lys	Pro	Glu	Glu	Lys	Ile	Ser	Ile	Phe
				545					550					555
Ser	Leu	Phe	Ala	Pro	Phe	Asp	Phe	Ala	Val	Trp	Ala	Cys	Ile	Ala
				560					565					570
Ala	Ala	Ile	Pro	Val	Val	Gly	Val	Leu	Ile	Phe	Val	Leu	Asn	Arg
				575					580					585
Ile	Gln	Ala	Val	Arg	Ala	Gln	Ser	Ala	Ala	Gln	Pro	Arg	Pro	Ser
				590					595					600
Ala	Ser	Ala	Thr	Leu	His	Ser	Ala	Ile	Trp	Ile	Val	Tyr	Gly	Ala
				605					610					615
Phe	Val	Gln	Gln	Gly	Gly	Glu	Ser	Ser	Val	Asn	Ser	Met	Ala	Met
				620					625					630
Arg	Ile	Val	Met	Gly	Ser	Trp	Trp	Leu	Phe	Thr	Leu	Ile	Val	Cys
				635					640					645
Ser	Ser	Tyr	Thr	Ala	Asn	Leu	Ala	Ala	Phe	Leu	Thr	Val	Ser	Arg

Met Asp Asn Pro	650	655	660
Ile Arg Thr Phe Gln Asp Leu Ser Lys Gln Val	665	670	675
Glu Met Ser Tyr Gly Thr Val Arg Asp Ser Ala Val Tyr Glu Tyr	680	685	690
Phe Arg Ala Lys Gly Thr Asn Pro Leu Glu Gln Asp Ser Thr Phe	695	700	705
Ala Glu Leu Trp Arg Thr Ile Ser Lys Asn Gly Gly Ala Asp Asn	710	715	720
Cys Val Ser Ser Pro Ser Glu Gly Ile Arg Lys Ala Lys Lys Gly	725	730	735
Asn Tyr Ala Phe Leu Trp Asp Val Ala Val Val Glu Tyr Ala Ser	740	745	750
Leu Thr Asp Asp Asp Cys Ser Val Thr Val Ile Gly Asn Ser Ile	755	760	765
Ser Ser Lys Gly Tyr Gly Ile Ala Leu Gln His Gly Ser Pro Tyr	770	775	780
Arg Asp Leu Phe Ser Gln Arg Ile Leu Glu Leu Gln Asp Thr Gly	785	790	795
Asp Leu Asp Val Leu Lys Gln Lys Trp Trp Pro His Met Gly Arg	800	805	810
Cys Asp Leu Thr Ser His Ala Ser Ala Gln Ala Asp Gly Lys Ser	815	820	825
Leu Lys Leu His Ser Phe Ala Gly Val Phe Cys Ile Leu Ala Ile	830	835	840
Gly Leu Leu Leu Ala Cys Leu Val Ala Ala Leu Glu Leu Trp Trp	845	850	855
Asn Ser Asn Arg Cys His Gln Glu Thr Pro Lys Glu Asp Lys Glu	860	865	870
Val Asn Leu Glu Gln Val His Arg Arg Met Asn Ser Leu Met Asp	875	880	885
Glu Asp Ile Ala His Lys Gln Ile Ser Pro Ala Ser Ile Glu Leu	890	895	900
Ser Ala Leu Glu Met Gly Gly Leu Ala Pro Thr Gln Thr Leu Glu	905	910	915
Pro Thr Arg Glu Tyr Gln Asn Thr Gln Leu Ser Val Ser Thr Phe	920	925	930
Leu Pro Glu Gln Ser Ser His Gly Thr Ser Arg Thr Leu Ser Ser	935	940	945
Gly Pro Ser Ser Asn Leu Pro Leu Pro Leu Ser Ser Ser Ala Thr	950	955	960
Met Pro Ser Met Gln Cys Lys His Arg Ser Pro Asn Gly Gly Leu	965	970	975
Phe Arg Gln Ser Pro Val Lys Thr Pro Ile Pro Met Ser Phe Gln	980	985	990
Pro Val Pro Gly Gly Val Leu Pro Glu Ala Leu Asp Thr Ser His	995	1000	1005
Gly Thr Ser Ile			

<210> 6

<211> 374

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472584CD1

<400> 6

Met Lys Arg Gln Asn Val Arg Thr Leu Ser Leu Ile Val Cys Thr	1	5	10	15
Phe Thr Tyr Leu Leu Val Gly Ala Ala Val Phe Asp Ala Leu Glu				

				20						25				30
Ser	Asp	His	Glu	Met	Arg	Glu	Glu	Glu	Lys	Leu	Lys	Ala	Glu	Glu
				35						40				45
Ile	Arg	Ile	Lys	Gly	Lys	Tyr	Asn	Ile	Ser	Ser	Glu	Asp	Tyr	Arg
				50						55				60
Gln	Leu	Glu	Leu	Val	Ile	Leu	Gln	Ser	Glu	Pro	His	Arg	Ala	Gly
				65						70				75
Val	Gln	Trp	Lys	Phe	Ala	Gly	Ser	Phe	Tyr	Phe	Ala	Ile	Thr	Val
				80						85				90
Ile	Thr	Thr	Ile	Gly	Tyr	Gly	His	Ala	Ala	Pro	Gly	Thr	Asp	Ala
				95						100				105
Gly	Lys	Ala	Phe	Cys	Met	Phe	Tyr	Ala	Val	Leu	Gly	Ile	Pro	Leu
				110						115				120
Thr	Leu	Val	Met	Phe	Gln	Ser	Leu	Gly	Glu	Arg	Met	Asn	Thr	Phe
				125						130				135
Val	Arg	Tyr	Leu	Leu	Lys	Arg	Ile	Lys	Lys	Cys	Cys	Gly	Met	Arg
				140						145				150
Asn	Thr	Asp	Val	Ser	Met	Glu	Asn	Met	Val	Thr	Val	Gly	Phe	Phe
				155						160				165
Ser	Cys	Met	Gly	Thr	Leu	Cys	Ile	Gly	Ala	Ala	Ala	Phe	Ser	Gln
				170						175				180
Cys	Glu	Glu	Trp	Ser	Phe	Phe	His	Ala	Tyr	Tyr	Tyr	Cys	Phe	Ile
				185						190				195
Thr	Leu	Thr	Thr	Ile	Gly	Phe	Gly	Asp	Tyr	Val	Ala	Leu	Gln	Thr
				200						205				210
Lys	Gly	Ala	Leu	Gln	Lys	Lys	Pro	Leu	Tyr	Val	Ala	Phe	Ser	Phe
				215						220				225
Met	Tyr	Ile	Leu	Val	Gly	Leu	Thr	Val	Ile	Gly	Ala	Phe	Leu	Asn
				230						235				240
Leu	Val	Val	Leu	Arg	Phe	Leu	Thr	Met	Asn	Ser	Glu	Asp	Glu	Arg
				245						250				255
Arg	Asp	Ala	Glu	Glu	Arg	Ala	Ser	Leu	Ala	Gly	Asn	Arg	Asn	Ser
				260						265				270
Met	Val	Ile	His	Ile	Pro	Glu	Glu	Pro	Arg	Pro	Ser	Arg	Pro	Arg
				275						280				285
Tyr	Lys	Ala	Asp	Val	Pro	Asp	Leu	Gln	Ser	Val	Cys	Ser	Cys	Thr
				290						295				300
Cys	Tyr	Arg	Ser	Gln	Asp	Tyr	Gly	Gly	Arg	Ser	Val	Ala	Pro	Gln
				305						310				315
Asn	Ser	Phe	Ser	Ala	Lys	Leu	Ala	Pro	His	Tyr	Phe	His	Ser	Ile
				320						325				330
Ser	Tyr	Lys	Ile	Glu	Glu	Ile	Ser	Pro	Ser	Thr	Leu	Lys	Asn	Ser
				335						340				345
Leu	Phe	Pro	Ser	Pro	Ile	Ser	Ser	Ile	Ser	Pro	Gly	Leu	His	Ser
				350						355				360
Phe	Thr	Asp	His	Gln	Arg	Leu	Met	Lys	Arg	Arg	Lys	Ser	Val	
				365						370				

<210> 7

<211> 589

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472536CD1

<400> 7

Met	Ser	Ala	Val	Leu	Thr	Pro	Gly	Leu	Phe	Leu	Pro	Leu	Pro	Gly
1				5					10					15
Pro	Leu	Pro	Ala	Ser	Leu	His	Lys	Ala	Gly	Gly	Thr	Gly	Pro	Gln
				20					25					30
Val	Arg	Pro	Met	Ala	Met	Ala	Phe	Thr	Asp	Leu	Leu	Asp	Ala	Leu

				35					40					45
Gly	Ser	Met	Gly	Arg	Phe	Gln	Leu	Asn	His	Thr	Ala	Leu	Leu	Leu
				50					55					60
Leu	Pro	Cys	Gly	Leu	Leu	Ala	Cys	His	Asn	Phe	Leu	Gln	Asn	Phe
				65					70					75
Thr	Ala	Ala	Val	Pro	His	His	Cys	Arg	Gly	Pro	Ala	Asn	His	
				80					85					90
Thr	Glu	Ala	Ser	Thr	Asn	Asp	Ser	Gly	Ala	Trp	Leu	Arg	Ala	Thr
				95					100					105
Ile	Pro	Leu	Asp	Gln	Leu	Gly	Ala	Pro	Glu	Pro	Cys	Arg	Arg	Phe
				110					115					120
Thr	Lys	Pro	Gln	Trp	Ala	Leu	Leu	Ser	Pro	Asn	Ser	Ser	Ile	Pro
				125					130					135
Gly	Ala	Ala	Thr	Glu	Gly	Cys	Lys	Asp	Gly	Trp	Val	Tyr	Asn	Arg
				140					145					150
Ser	Val	Phe	Pro	Ser	Thr	Ile	Val	Met	Glu	Gln	Trp	Asp	Leu	Val
				155					160					165
Cys	Glu	Ala	Arg	Thr	Leu	Arg	Asp	Leu	Ala	Gln	Ser	Val	Tyr	Ile
				170					175					180
Ala	Gly	Val	Leu	Val	Gly	Ala	Ala	Val	Phe	Gly	Ser	Leu	Ala	Asp
				185					190					195
Arg	Leu	Gly	Cys	Lys	Gly	Pro	Leu	Val	Trp	Ser	Tyr	Leu	Gln	Leu
				200					205					210
Ala	Ala	Ser	Gly	Ala	Ala	Thr	Ala	Tyr	Phe	Ser	Ser	Phe	Ser	Ala
				215					220					225
Tyr	Cys	Val	Phe	Arg	Phe	Leu	Met	Gly	Met	Thr	Phe	Ser	Gly	Ile
				230					235					240
Ile	Leu	Asn	Ser	Val	Ser	Leu	Val	Glu	Trp	Met	Pro	Thr	Arg	Gly
				245					250					255
Arg	Thr	Val	Ala	Gly	Ile	Leu	Leu	Gly	Tyr	Ser	Phe	Thr	Leu	Gly
				260					265					270
Gln	Leu	Ile	Leu	Ala	Gly	Val	Ala	Tyr	Leu	Ile	Arg	Pro	Trp	Arg
				275					280					285
Cys	Leu	Gln	Phe	Ala	Ile	Ser	Ala	Pro	Phe	Leu	Ile	Phe	Phe	Leu
				290					295					300
Tyr	Ser	Trp	Trp	Leu	Pro	Glu	Ser	Ser	Arg	Trp	Leu	Leu	Leu	His
				305					310					315
Gly	Lys	Ser	Gln	Leu	Ala	Val	Gln	Asn	Leu	Gln	Lys	Val	Ala	Ala
				320					325					330
Met	Asn	Gly	Arg	Lys	Gln	Glu	Gly	Glu	Arg	Leu	Thr	Lys	Glu	Val
				335					340					345
Met	Ser	Ser	Tyr	Ile	Gln	Ser	Glu	Phe	Ala	Ser	Val	Cys	Thr	Ser
				350					355					360
Asn	Ser	Ile	Leu	Asp	Leu	Phe	Arg	Thr	Pro	Ala	Ile	Arg	Lys	Val
				365					370					375
Thr	Cys	Cys	Pro	Ala	Leu	Arg	Phe	Ser	Asn	Ser	Val	Ala	Tyr	Tyr
				380					385					390
Gly	Leu	Ala	Met	Asp	Leu	Gln	Lys	Phe	Gly	Leu	Ser	Leu	Tyr	Leu
				395					400					405
Val	Gln	Ala	Leu	Phe	Gly	Ile	Ile	Asn	Ile	Pro	Ala	Met	Leu	Val
				410					415					420
Ala	Thr	Ala	Thr	Met	Ile	Tyr	Val	Gly	Arg	Arg	Ala	Thr	Val	Ala
				425					430					435
Ser	Phe	Leu	Ile	Leu	Ala	Gly	Leu	Met	Val	Ile	Ala	Asn	Met	Phe
				440					445					450
Val	Pro	Glu	Gly	Thr	Gln	Ile	Leu	Cys	Thr	Ala	Gln	Ala	Ala	Leu
				455					460					465
Gly	Lys	Gly	Cys	Leu	Ala	Ser	Ser	Phe	Ile	Cys	Val	Tyr	Leu	Phe
				470					475					480
Thr	Gly	Glu	Leu	Tyr	Pro	Thr	Glu	Ile	Arg	Gln	Met	Gly	Met	Gly
				485					490					495
Phe	Ala	Ser	Val	His	Ala	Arg	Leu	Gly	Gly	Leu	Thr	Ala	Pro	Leu
				500					505					510

Val Thr Thr Leu	Gly Glu Tyr Ser Thr	Ile Leu Pro Pro Val	Ser
	515	520	525
Phe Gly Ala Thr	Ala Ile Leu Ala Gly	Leu Ala Val Cys Phe	Leu
	530	535	540
Thr Glu Thr Arg	Asn Met Pro Leu Val	Glu Thr Ile Ala Ala	Met
	545	550	555
Glu Arg Arg Val	Lys Glu Gly Ser Ser	Lys Lys His Val Glu	Glu
	560	565	570
Lys Ser Glu Glu	Ile Ser Leu Gln Gln	Leu Arg Ala Ser Pro	Leu
	575	580	585
Lys Glu Thr Ile			

<210> 8

<211> 549

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473422CD1

<400> 8

Met Val Ser Asp Arg	Gly Leu Lys Pro	Phe Glu Asp Leu Arg	Pro
1	5	10	15
Pro Lys Ile Ser	Pro Ala Asp Leu Gly	Asn Ala Glu Glu Ala	Ile
	20	25	30
Glu Leu Glu Arg	Pro Ala Pro Val	Arg Phe Val Pro Arg	Arg
	35	40	45
Lys Arg Pro Ser	Ile Trp Val Val Leu	Pro Val Leu Phe Leu	Val
	50	55	60
Ala Met Ser Leu	Leu Pro Leu Leu Tyr	Val Ala Ile Lys Ala	Trp
	65	70	75
Glu Ala Gly Trp	Arg Glu Ala Leu His	Leu Leu Trp Arg Pro	Phe
	80	85	90
Val Trp Gly Leu	Met Arg Asn Thr Leu	Met Leu Met Val Gly	Val
	95	100	105
Thr Leu Ala Cys	Met Val Val Gly Leu	Ala Leu Ala Trp Leu	Leu
	110	115	120
Glu Arg Ser Asn	Leu Ala Gly Arg Arg	Leu Trp Gly Val Val	Leu
	125	130	135
Cys Leu Pro Phe	Ala Val Pro Ser Phe	Val Ser Ser Phe Thr	Trp
	140	145	150
Val Ser Leu Ser	Ser Asp Phe Glu Gly	Leu Gly Gly Ala Ile	Leu
	155	160	165
Val Met Ala Leu	Ser Lys Tyr Pro Leu	Val Phe Leu Pro Val	Ala
	170	175	180
Ala Thr Leu Arg	Asn Leu Asp Thr Ser	Leu Glu Glu Ser Ala	Arg
	185	190	195
Thr Leu Gly Cys	Ser Arg Trp Gly Val	Phe Ile Lys Val Thr	Leu
	200	205	210
Pro Leu Leu Trp	Pro Ser Met Leu Gly	Gly Ala Leu Leu Ile	Ala
	215	220	225
Leu His Met Leu	Val Glu Phe Gly Ala	Leu Ser Ile Leu Gly	Leu
	230	235	240
Gln Thr Phe Thr	Thr Ala Ile Tyr Gln	Gln Phe Glu Leu Glu	Phe
	245	250	255
Ser Asn Ala Asn	Ala Ala Met Leu Ser	Ala Val Leu Leu Ala	Met
	260	265	270
Cys Leu Val Met	Leu Trp Leu Glu Leu	Arg Val Arg Gly Lys	Ala
	275	280	285
Arg His Val Arg	Ile Gly Gln Gly Val	Ala Arg Arg Ala Gln	Pro
	290	295	300

```

Val Arg Leu Arg Gly Trp Ala Val Pro Ala Gln Leu Leu Cys Val
305 310 315
Ala Leu Ala Val Leu Gly Ser Gly Ile Pro Leu Ala Met Leu Gly
320 325 330
Tyr Trp Leu Ser Val Gly Ser Ser Ala Ala Phe Pro Val Gly Ala
335 340 345
Ile Ser Lys Ala Leu Phe Thr Ser Leu Ser Val Ser Leu Gly Gly
350 355 360
Ala Gly Phe Cys Val Leu Leu Ala Leu Pro Ile Ser Phe Leu Val
365 370 375
Val Arg Tyr Lys Gly Arg Leu Ala Ile Trp Ala Glu Arg Leu Pro
380 385 390
Tyr Leu Leu His Ala Leu Pro Gly Leu Val Ile Ala Leu Thr Leu
395 400 405
Val Phe Phe Ala Leu His Tyr Val Pro Ala Leu Tyr Gln Thr Thr
410 415 420
Ala Leu Leu Leu Leu Ala Tyr Ala Leu Leu Phe Leu Pro Leu Ala
425 430 435
Gln Ser Pro Val Arg Thr Ala Leu Asn Lys Ala Ser Pro Thr Leu
440 445 450
Glu Glu Ala Ala Arg Thr Leu Gly Ala Ser Ser Phe Thr Ala Phe
455 460 465
Cys Arg Val Thr Leu Pro Ile Ile Phe Pro Ala Met Ala Ala Ala
470 475 480
Phe Ala Leu Val Phe Leu Asp Ala Met Lys Glu Leu Thr Ala Thr
485 490 495
Leu Leu Leu Ser Pro Thr Gly Met Thr Thr Leu Ala Thr Glu Val
500 505 510
Trp Ala His Thr Ala Asn Val Glu Phe Ala Ala Ala Ala Pro Tyr
515 520 525
Ala Ala Leu Leu Ile Val Val Ser Gly Leu Pro Val Tyr Leu Leu
530 535 540
Thr Thr Arg Met Tyr Leu Asn Lys Ala
545

```

<210> 9

<211> 634

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2864715CD1

<400> 9

```

Met Val Arg Leu Val Leu Pro Asn Pro Gly Leu Asp Ala Arg Ile
1 5 10 15
Pro Ser Leu Ala Glu Leu Glu Thr Ile Glu Gln Glu Glu Ala Ser
20 25 30
Ser Arg Pro Lys Trp Asp Asn Lys Ala Gln Tyr Met Leu Thr Cys
35 40 45
Leu Gly Phe Cys Val Gly Leu Gly Asn Val Trp Arg Phe Pro Tyr
50 55 60
Leu Cys Gln Ser His Gly Gly Gly Ala Phe Met Ile Pro Phe Leu
65 70 75
Ile Leu Leu Val Leu Glu Gly Ile Pro Leu Leu Tyr Leu Glu Phe
80 85 90
Ala Ile Gly Gln Arg Leu Arg Arg Gly Ser Leu Gly Val Trp Ser
95 100 105
Ser Ile His Pro Ala Leu Lys Gly Leu Gly Leu Ala Ser Met Leu
110 115 120
Thr Ser Phe Met Val Gly Leu Tyr Tyr Asn Thr Ile Ile Ser Trp
125 130 135

```

Ile Met Trp Tyr	Leu Phe Asn Ser Phe	Gln Glu Pro Leu Pro	Trp
140	145	150	
Ser Asp Trp Pro	Leu Asn Glu Asn Gln	Thr Gly Tyr Val Asp	Glu
155	160	165	
Cys Ala Arg Ser	Ser Pro Val Asp Tyr	Phe Trp Tyr Arg Glu	Thr
170	175	180	
Leu Asn Ile Ser	Thr Ser Ile Ser Asp	Ser Gly Ser Ile Gln	Trp
185	190	195	
Trp Met Leu Leu	Cys Leu Ala Cys Ala	Trp Ser Val Leu Tyr	Met
200	205	210	
Cys Thr Ile Arg	Gly Ile Glu Thr Thr	Gly Lys Ala Val Tyr	Ile
215	220	225	
Thr Ser Thr Leu	Pro Tyr Val Val Leu	Thr Ile Phe Leu Ile	Arg
230	235	240	
Gly Leu Thr Leu	Lys Gly Ala Thr Asn	Gly Ile Val Phe Leu	Phe
245	250	255	
Thr Pro Asn Val	Thr Glu Leu Ala Gln	Pro Asp Thr Trp Leu	Asp
260	265	270	
Ala Gly Ala Gln	Val Phe Phe Ser Phe	Ser Leu Ala Phe Gly	Gly
275	280	285	
Leu Ile Ser Phe	Ser Ser Tyr Asn Ser	Val His Asn Asn Cys	Glu
290	295	300	
Lys Asp Ser Val	Ile Val Ser Ile Ile	Asn Gly Phe Thr Ser	Val
305	310	315	
Tyr Val Ala Ile	Val Val Tyr Ser Val	Ile Gly Phe Arg Ala	Thr
320	325	330	
Gln Arg Tyr Asp	Asp Cys Phe Ser Thr	Asn Ile Leu Thr Leu	Ile
335	340	345	
Asn Gly Phe Asp	Leu Pro Glu Gly Asn	Val Thr Gln Glu Asn	Phe
350	355	360	
Val Asp Met Gln	Gln Arg Cys Asn Ala	Ser Asp Pro Ala Ala	Tyr
365	370	375	
Ala Gln Leu Val	Phe Gln Thr Cys Asp	Ile Asn Ala Phe Leu	Ser
380	385	390	
Glu Ala Val Glu	Gly Thr Gly Leu Ala	Phe Ile Val Phe Thr	Glu
395	400	405	
Ala Ile Thr Lys	Met Pro Leu Ser Pro	Leu Trp Ser Val Leu	Phe
410	415	420	
Phe Ile Met Leu	Phe Cys Leu Gly Leu	Ser Ser Met Phe Gly	Asn
425	430	435	
Met Glu Gly Val	Val Val Pro Leu Gln	Asp Leu Arg Val Ile	Pro
440	445	450	
Pro Lys Trp Pro	Lys Glu Val Leu Thr	Gly Leu Ile Cys Leu	Gly
455	460	465	
Thr Phe Leu Ile	Gly Phe Ile Phe Thr	Leu Asn Ser Gly Gln	Tyr
470	475	480	
Trp Leu Ser Leu	Leu Asp Ser Tyr Ala	Gly Ser Ile Pro Leu	Leu
485	490	495	
Ile Ile Ala Phe	Cys Glu Met Phe Ser	Val Val Tyr Val Tyr	Gly
500	505	510	
Val Asp Arg Phe	Asn Lys Asp Ile Glu	Phe Met Ile Gly His	Lys
515	520	525	
Pro Asn Ile Phe	Trp Gln Val Thr Trp	Arg Val Val Ser Pro	Leu
530	535	540	
Leu Met Leu Ile	Ile Phe Leu Phe Phe	Phe Val Val Glu Val	Ser
545	550	555	
Gln Glu Leu Thr	Tyr Ser Ile Trp Asp	Pro Gly Tyr Glu Glu	Phe
560	565	570	
Pro Lys Ser Gln	Lys Ile Ser Tyr Pro	Asn Trp Val Tyr Val	Val
575	580	585	
Val Val Ile Val	Ala Gly Val Pro Ser	Leu Thr Ile Pro Gly	Tyr
590	595	600	
Ala Ile Tyr Lys	Leu Ile Arg Asn His	Cys Gln Lys Pro Gly	Asp

	605		610		615
His Gln Gly Leu	Val Ser Thr Leu Ser	Thr Ala Ser Met Asn	Gly		
	620	625	630		
Asp Leu Lys Tyr					

<210> 10
 <211> 491
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1734724CD1

<400> 10
 Met Asp Gly Asn Asp Asn Val Thr Leu Leu Phe Ala Pro Leu Leu
 1 5 10 15
 Arg Asp Asn Tyr Thr Leu Ala Pro Asn Ala Ser Ser Leu Gly Pro
 20 25 30
 Gly Thr Asn Leu Ala Leu Ala Pro Ala Ser Ser Ala Gly Pro Gly
 35 40 45
 Pro Gly Leu Ser Leu Gly Pro Val Pro Ser Phe Gly Phe Ser Pro
 50 55 60
 Gly Pro Thr Pro Thr Pro Glu Pro Thr Thr Ser Gly Leu Ala Gly
 65 70 75
 Gly Ala Ala Ser His Gly Pro Ser Pro Val Pro Ser Ala Leu Gly
 80 85 90
 Ala Pro Arg Ala Pro Val Leu Gly His Ala Ala Glu Pro Arg Ala
 95 100 105
 Glu Arg Val Arg Gly Arg Arg Leu Cys Ile Thr Met Leu Gly Leu
 110 115 120
 Gly Cys Thr Val Asp Val Asn His Phe Gly Ala His Val Arg Arg
 125 130 135
 Pro Val Ala Ala Leu Leu Ala Ala Leu Pro Val Arg Pro Pro Ala
 140 145 150
 Ala Ala Gly Leu Pro Ala Gly Pro Arg Leu Gln Ala Gly Arg Gly
 155 160 165
 Gly Arg Arg Gly Leu Leu Leu Cys Gly Cys Cys Pro Gly Gly Asn
 170 175 180
 Leu Ser Asn Leu Met Ser Leu Leu Val Asp Gly Asp Met Asn Leu
 185 190 195
 Arg Arg Ala Ala Leu Leu Ala Leu Ser Ser Asp Val Gly Ser Ala
 200 205 210
 Gln Thr Ser Thr Pro Gly Leu Ala Val Ser Pro Phe His Leu Tyr
 215 220 225
 Ser Thr Tyr Lys Lys Lys Val Ser Trp Leu Phe Asp Ser Lys Leu
 230 235 240
 Val Leu Ile Ser Ala His Ser Leu Phe Cys Ser Ile Ile Met Thr
 245 250 255
 Ile Ser Ser Thr Leu Leu Ala Leu Val Leu Met Pro Leu Cys Leu
 260 265 270
 Trp Ile Tyr Ser Trp Ala Trp Ile Asn Thr Pro Ile Val Gln Leu
 275 280 285
 Leu Pro Leu Gly Thr Val Thr Leu Thr Leu Cys Ser Thr Leu Ile
 290 295 300
 Pro Ile Gly Leu Gly Val Phe Ile Arg Tyr Lys Tyr Ser Arg Val
 305 310 315
 Ala Asp Tyr Ile Val Lys Val Ser Leu Trp Ser Leu Leu Val Thr
 320 325 330
 Leu Val Val Leu Phe Ile Met Thr Gly Thr Met Leu Gly Pro Glu
 335 340 345
 Leu Leu Ala Ser Ile Pro Ala Ala Val Tyr Val Ile Ala Ile Phe

	350		355		360
Met Pro Leu Ala	Gly Tyr Ala Ser Gly	Tyr Gly Leu Ala Thr	Leu		
	365		370		375
Phe His Leu Pro	Pro Asn Cys Lys Arg	Thr Val Cys Leu Glu	Thr		
	380		385		390
Gly Ser Gln Asn	Val Gln Leu Cys Thr	Ala Ile Leu Lys Leu	Ala		
	395		400		405
Phe Pro Pro Gln	Phe Ile Gly Ser Met	Tyr Met Phe Pro Leu	Leu		
	410		415		420
Tyr Ala Leu Phe	Gln Ser Ala Glu Ala	Gly Ile Phe Val Leu	Ile		
	425		430		435
Tyr Lys Met Tyr	Gly Ser Glu Met Leu	His Lys Arg Asp Pro	Leu		
	440		445		450
Asp Glu Asp Glu	Asp Thr Asp Ile Ser	Tyr Lys Lys Leu Lys	Glu		
	455		460		465
Glu Glu Met Ala	Asp Thr Ser Tyr Gly	Thr Val Lys Ala Glu	Asn		
	470		475		480
Ile Ile Met Met	Glu Thr Ala Gln Thr	Ser Leu			
	485		490		

<210> 11

<211> 525

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1563237CD1

<400> 11

Met Pro Ala Pro Arg	Ala Arg Glu Gln Pro	Arg Val Pro Gly Glu	
1	5	10	15
Arg Gln Pro Leu Leu	Pro Arg Gly Ala Arg	Gly Pro Arg Arg Trp	
	20	25	30
Arg Arg Ala Ala Gly	Ala Ala Val Leu Leu	Val Glu Met Leu Glu	
	35	40	45
Arg Ala Ala Phe Phe	Gly Val Thr Ala Asn	Leu Val Leu Tyr Leu	
	50	55	60
Asn Ser Thr Asn Phe	Asn Trp Thr Gly Glu	Gln Ala Thr Arg Ala	
	65	70	75
Ala Leu Val Phe Leu	Gly Ala Ser Tyr Leu	Leu Ala Pro Val Gly	
	80	85	90
Gly Trp Leu Ala Asp	Val Tyr Leu Gly Arg	Tyr Arg Ala Val Ala	
	95	100	105
Leu Ser Leu Leu Leu	Tyr Leu Ala Ala Ser	Gly Leu Leu Pro Ala	
	110	115	120
Thr Ala Phe Pro Asp	Gly Arg Ser Ser Phe	Cys Gly Glu Met Pro	
	125	130	135
Ala Ser Pro Leu Gly	Pro Ala Cys Pro Ser	Ala Gly Cys Pro Arg	
	140	145	150
Ser Ser Pro Ser Pro	Tyr Cys Ala Pro Val	Leu Tyr Ala Gly Leu	
	155	160	165
Leu Leu Leu Gly Leu	Ala Ala Ser Ser Val	Arg Ser Asn Leu Thr	
	170	175	180
Ser Phe Gly Ala Asp	Gln Val Met Asp Leu	Gly Arg Asp Ala Thr	
	185	190	195
Arg Arg Phe Phe Asn	Trp Phe Tyr Trp Ser	Ile Asn Leu Gly Ala	
	200	205	210
Val Leu Ser Leu Leu	Val Val Ala Phe Ile	Gln Gln Asn Ile Ser	
	215	220	225
Phe Leu Leu Gly Tyr	Ser Ile Pro Val Gly	Cys Val Gly Leu Ala	
	230	235	240
Phe Phe Ile Phe Leu	Phe Ala Thr Pro Val	Phe Ile Thr Lys Pro	

Pro Met Gly Ser	245	250	255
Gln Val Ser Ser Met	260	265	270
Leu Lys Leu Ala Leu	275	280	285
Asn Cys Cys Pro Gln	290	295	300
Leu Trp Gln Arg His	305	310	315
Val Leu Ala Asp Glu	320	325	330
Arg Ser Pro Gln Pro	335	340	345
Gln Cys Ala Arg Val	350	355	360
Leu Ala Asp Glu Arg	365	370	375
Ala Ser Pro Gln Glu	380	385	390
Asp Ile Ala Asn Phe	395	400	405
Gln Val Leu Val Lys	410	415	420
Ile Leu Pro Val Met	425	430	435
Val Thr Leu Val Pro	440	445	450
Tyr Trp Met Val Tyr	455	460	465
Phe Gln Met Gln Ser	470	475	480
Thr Tyr Val Leu Gln	485	490	495
Gly Leu His Leu His	500	505	510
Ile Pro Asn Ile Phe	515	520	525
Pro Ala Asn Pro Ala			
Asn Ile Ser Val Ala			
Leu Arg Ala Gln Gly			
Ser Ser Tyr Thr Glu			
Ser Trp Arg Trp Ser			
Ala Leu His Tyr Ile			
His His Asn Glu Thr			
Val Ser Gln Gln Ile			
Gly Glu Val Leu Tyr			
Asn Ala Ala Pro Leu			
Ser Ile Trp Trp Gln			
Ile Pro Gln Tyr Leu			
Ile Ile Gly Ile Ser			
Glu Ile Phe Ala Ser			
Ile Pro Gly Leu Glu			
Phe Ala Tyr Ser Glu			
Ala Pro Arg Ser Met			
Gln Gly Ala Ile Met			
Gly Ile Phe Phe Cys			
Leu Ser Gly Val Gly			
Ser Leu Leu Gly Ser			
Ser Leu Val Ala Leu			
Leu Ser Leu Pro Gly			
Gly Trp Leu His Cys			
Pro Lys Asp Phe Gly			
Asn Ile Asn Asn Cys			
Arg Met Asp Leu Tyr			
Phe Phe Leu Leu Ala			
Gly Ile Gln Ala Val			
Thr Ala Leu Leu Phe			
Val Trp Ile Ala Gly			
Arg Tyr Glu Arg Ala			
Ser Gln Gly Pro Ala			
Ser His Ser Arg Phe			
Ser Arg Asp Arg Gly			

<210> 12

<211> 1310

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473443CD1

<400> 12

Met Gly Lys Lys Gln	Cys Lys Lys Ala	Lys Asn Ser Lys Asn Gln
1	5	10
Asn Ala Ser Ser Pro	Pro Lys Asp His	Asn Ser Ser Pro Ala Gly
20	25	30
Glu Gln Asn Trp Met	Glu Asn Glu Leu Thr	Glu Ala Gly Phe Arg
35	40	45
Arg Trp Val Val Ile	Asn Ser Cys Lys	Leu Lys Glu His Val Leu
50	55	60
Thr Gln Cys Lys Glu	Ala Lys Asn Leu	Glu Lys Arg Leu Gly Glu
65	70	75
Leu Leu Thr Arg Ile	Thr Ser Leu Glu	Lys Asn Ile Asn Asp Leu
80	85	90
Met Glu Leu Lys Asn	Thr Ala Arg Glu	Leu Arg Asp Ala Tyr Ile
95	100	105

Ser	Ile	Ser	Ser	Arg	Ile	Asp	Gln	Ala	Glu	Lys	Arg	Ile	Ser	Glu
				110					115					120
Ile	Glu	Asp	Gln	Leu	Asn	Glu	Ile	Lys	Arg	Glu	Asp	Lys	Ile	Arg
				125					130					135
Glu	Lys	Asn	Glu	Lys	Asp	Glu	Gln	Gly	Leu	Gln	Glu	Ile	Trp	Asp
				140					145					150
Tyr	Val	Lys	Arg	Pro	Asn	Leu	His	Leu	Ile	Gly	Val	Pro	Gly	Leu
				155					160					165
Leu	Tyr	Ser	Asp	Met	Cys	Arg	Leu	Leu	Pro	Ser	Pro	Arg	Asn	Gln
				170					175					180
Pro	Ala	Leu	Gln	Ala	Leu	Glu	Arg	Gly	Val	Ile	Leu	Glu	Val	Lys
				185					190					195
Cys	Val	Val	Cys	Ser	Thr	Gln	Ala	Gly	Ala	Ala	Arg	Arg	Gly	Val
				200					205					210
Lys	Ile	Ser	Ile	Lys	Gly	Lys	Gly	Phe	Ser	Val	Val	Ser	Val	Val
				215					220					225
Gly	Thr	Leu	Gln	Trp	Leu	Leu	Trp	Ala	Arg	Ala	Ala	His	Ala	Pro
				230					235					240
His	Trp	Arg	Phe	Leu	Arg	Trp	Met	Ala	Ala	Leu	Trp	Asp	Val	Pro
				245					250					255
Gly	Lys	Thr	Gly	Pro	Ser	Pro	Ile	Ser	Leu	Thr	Gly	Gln	Arg	Gly
				260					265					270
Asn	Arg	Gly	Pro	Glu	Ser	Ser	Ser	Ile	Leu	Arg	Gly	Val	Pro	Lys
				275					280					285
Asp	Phe	Ser	Thr	Gly	Thr	Ser	Ala	Gln	Leu	Arg	Arg	Ala	Met	Gly
				290					295					300
Leu	Ala	Pro	Glu	Gly	Gly	Phe	Gln	Ala	Phe	Phe	Pro	Arg	Pro	Pro
				305					310					315
Thr	Met	Pro	Ala	Thr	Pro	Asn	Phe	Leu	Ala	Asn	Pro	Ser	Ser	Ser
				320					325					330
Ser	Arg	Trp	Ile	Pro	Leu	Gln	Pro	Met	Pro	Val	Ala	Trp	Ala	Phe
				335					340					345
Val	Gln	Lys	Thr	Ser	Ala	Leu	Leu	Trp	Leu	Leu	Leu	Leu	Gly	Thr
				350					355					360
Ser	Leu	Ser	Pro	Ala	Trp	Gly	Gln	Ala	Lys	Ile	Pro	Leu	Glu	Thr
				365					370					375
Val	Lys	Leu	Trp	Ala	Asp	Thr	Phe	Gly	Gly	Asp	Leu	Tyr	Asn	Thr
				380					385					390
Val	Thr	Lys	Tyr	Ser	Gly	Ser	Leu	Leu	Leu	Gln	Lys	Lys	Tyr	Lys
				395					400					405
Asp	Val	Glu	Ser	Ser	Leu	Lys	Ile	Glu	Glu	Val	Asp	Gly	Leu	Glu
				410					415					420
Leu	Val	Arg	Lys	Phe	Ser	Glu	Asp	Met	Glu	Asn	Met	Leu	Arg	Arg
				425					430					435
Lys	Val	Glu	Ala	Val	Gln	Asn	Leu	Val	Glu	Ala	Ala	Glu	Glu	Ala
				440					445					450
Asp	Leu	Asn	His	Glu	Phe	Asn	Glu	Ser	Leu	Val	Glu	Pro	Gly	Val
				455					460					465
Gly	Val	Gly	Val	Gly	Met	Ser	Val	Thr	Gln	Ser	Gly	Val	Gly	Val
				470					475					480
Gly	Val	Gly	Met	Ser	Val	Thr	Gln	Ser	Gly	Val	Gly	Val	Gly	Val
				485					490					495
Gly	Met	Ser	Ile	Thr	Leu	Ser	Gly	Val	Gly	Val	Gly	Val	Gly	Met
				500					505					510
Ser	Val	Arg	Gln	Ser	Gly	Val	Gly	Val	Gly	Val	Gly	Met	Ser	Val
				515					520					525
Thr	Gln	Ser	Gly	Val	Gly	Val	Gly	Val	Gly	Met	Ser	Val	Thr	Gln
				530					535					540
Ser	Gly	Val	Gly	Val	Gly	Val	Gly	Met	Ser	Val	Arg	Gln	Ser	Gly
				545					550					555
Val	Gly	Val	Gly	Val	Gly	Met	Ser	Val	Thr	Gln	Ser	Trp	Gly	Val
				560					565					570
Phe	Ser	Ala	Gln	Arg	Ala	Ala	Ala	Gly	Ala	Cys	Val	Asp	Ser	Asp

	575		580		585
Gly Arg Pro Ala	Pro Ala Leu Ser Ser	Ser His Leu Arg Arg	Phe		
	590		595		600
Ser Ser Ser Leu	Ser Ala Cys Pro Gly	Ala Arg Ala Ala Ser	Val		
	605		610		615
Gly Leu Thr Arg	Pro Pro Gln Phe Asp	Tyr Tyr Asn Ser Val	Leu		
	620		625		630
Ile Asn Glu Arg	Asp Glu Lys Gly Asn	Phe Val Glu Leu Gly	Ala		
	635		640		645
Glu Phe Leu Leu	Glu Ser Asn Ala His	Phe Ser Asn Leu Pro	Val		
	650		655		660
Asn Thr Ser Ile	Ser Ser Val Gln Leu	Pro Thr Asn Val Tyr	Asn		
	665		670		675
Lys Asp Pro Asp	Ile Leu Asn Gly Val	Tyr Met Ser Glu Ala	Leu		
	680		685		690
Asn Ala Val Phe	Val Glu Asn Phe Gln	Arg Asp Pro Thr Leu	Thr		
	695		700		705
Trp Gln Tyr Phe	Gly Ser Ala Thr Gly	Phe Phe Arg Ile Tyr	Pro		
	710		715		720
Gly Ile Lys Trp	Thr Pro Asp Glu Asn	Gly Val Ile Thr Phe	Asp		
	725		730		735
Cys Arg Asn Arg	Gly Trp Tyr Ile Gln	Ala Ala Thr Ser Pro	Lys		
	740		745		750
Asp Ile Val Ile	Leu Val Asp Val Ser	Gly Ser Met Lys Gly	Leu		
	755		760		765
Arg Met Thr Ile	Ala Lys His Thr Ile	Thr Thr Ile Leu Asp	Thr		
	770		775		780
Leu Gly Glu Asn	Asp Phe Ile Asn Ile	Ile Ala Tyr Asn Asp	Tyr		
	785		790		795
Val His Tyr Ile	Glu Pro Cys Phe Lys	Gly Ile Leu Val Gln	Ala		
	800		805		810
Asp Arg Asp Asn	Arg Glu His Phe Lys	Leu Leu Val Glu Glu	Leu		
	815		820		825
Met Val Lys Gly	Val Gly Val Val Asp	Gln Ala Leu Arg Glu	Ala		
	830		835		840
Phe Gln Ile Leu	Lys Gln Phe Gln Glu	Ala Lys Gln Gly Ser	Leu		
	845		850		855
Cys Asn Gln Ala	Ile Met Leu Ile Ser	Asp Gly Ala Val Glu	Asp		
	860		865		870
Tyr Glu Pro Val	Phe Glu Lys Tyr Asn	Trp Pro Asp Cys Lys	Val		
	875		880		885
Arg Val Phe Thr	Tyr Leu Ile Gly Arg	Glu Val Ser Phe Ala	Asp		
	890		895		900
Arg Met Lys Trp	Ile Ala Cys Asn Asn	Lys Gly Tyr Tyr Thr	Gln		
	905		910		915
Ile Ser Thr Leu	Ala Asp Thr Gln Glu	Asn Val Met Glu Tyr	Leu		
	920		925		930
His Val Leu Ser	Arg Pro Met Val Ile	Asn His Asp His Asp	Ile		
	935		940		945
Ile Trp Thr Glu	Ala Tyr Met Asp Ser	Lys Leu Leu Ser Ser	Gln		
	950		955		960
Ala Gln Ser Leu	Thr Leu Leu Thr Thr	Val Ala Met Pro Val	Phe		
	965		970		975
Ser Lys Lys Asn	Glu Thr Arg Ser His	Gly Ile Leu Leu Gly	Val		
	980		985		990
Val Gly Ser Asp	Val Ala Leu Arg Glu	Leu Met Lys Leu Ala	Pro		
	995		1000		1005
Arg Tyr Lys Leu	Gly Val His Gly Tyr	Ala Phe Leu Asn Thr	Asn		
	1010		1015		1020
Asn Gly Tyr Ile	Leu Ser His Pro Asp	Leu Arg Pro Leu Tyr	Arg		
	1025		1030		1035
Glu Gly Lys Lys	Leu Lys Pro Lys Pro	Asn Tyr Asn Ser Val	Asp		
	1040		1045		1050

Leu Ser Glu Val Glu Trp Glu Asp Gln Ala Glu Ser Leu Arg Thr
 1055 1060 1065
 Ala Met Ile Asn Arg Glu Thr Gly Thr Leu Ser Met Asp Val Lys
 1070 1075 1080
 Val Pro Met Asp Lys Gly Lys Arg Val Leu Phe Leu Thr Asn Asp
 1085 1090 1095
 Tyr Phe Phe Thr Asp Ile Ser Asp Thr Pro Phe Ser Leu Gly Val
 1100 1105 1110
 Val Leu Ser Arg Gly His Gly Glu Tyr Ile Leu Leu Gly Asn Thr
 1115 1120 1125
 Ser Val Glu Glu Gly Leu His Asp Leu Leu His Pro Asp Leu Ala
 1130 1135 1140
 Leu Ala Gly Asp Trp Ile Tyr Cys Ile Thr Asp Ile Asp Pro Asp
 1145 1150 1155
 His Arg Lys Leu Ser Gln Leu Glu Ala Met Ile Arg Phe Leu Thr
 1160 1165 1170
 Arg Lys Asp Pro Asp Leu Glu Cys Asp Glu Glu Leu Val Arg Glu
 1175 1180 1185
 Val Leu Phe Asp Ala Val Val Thr Ala Pro Met Glu Ala Tyr Trp
 1190 1195 1200
 Thr Ala Leu Ala Leu Asn Met Ser Glu Glu Ser Glu His Val Val
 1205 1210 1215
 Asp Met Ala Phe Leu Gly Thr Arg Ala Gly Leu Leu Arg Ser Ser
 1220 1225 1230
 Leu Phe Val Gly Ser Glu Lys Val Ser Asp Arg Lys Phe Leu Thr
 1235 1240 1245
 Pro Glu Asp Glu Ala Ser Val Phe Thr Leu Asp Arg Phe Pro Leu
 1250 1255 1260
 Trp Tyr Arg Gln Ala Ser Glu His Pro Ala Gly Ser Phe Val Phe
 1265 1270 1275
 Asn Leu Arg Trp Ala Glu Gly Pro Gly Arg Pro Ser Ala Lys Gly
 1280 1285 1290
 Leu Pro Pro Pro Leu Cys Gln Thr Ile Leu Lys Arg Arg Asp Gly
 1295 1300 1305
 Lys Met Ser Trp Ser
 1310

<210> 13

<211> 400

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473438CD1

<400> 13

Met Asn Pro Gly Gln Ala Ser Gly Arg Arg Thr Gly Glu Arg Phe
 1 5 10 15
 Phe Arg Pro Pro Pro Val Ala Ile Pro Ala Ser Arg Phe Pro Ala
 20 25 30
 Val Ala Pro Pro Arg Pro Ser Gln Pro Cys Arg Val Gly Pro Gly
 35 40 45
 Leu Glu Gly Ala Glu Arg Ala Val Arg Ala His Gly Ala Gly Trp
 50 55 60
 Asp Arg Gly Gly Tyr Arg Gly Arg Gly Ala Met Arg Arg Pro Ser
 65 70 75
 Val Arg Ala Ala Gly Leu Val Leu Cys Thr Leu Cys Tyr Leu Leu
 80 85 90
 Val Gly Ala Ala Val Phe Asp Ala Leu Glu Ser Glu Ala Glu Ser
 95 100 105
 Gly Arg Gln Arg Leu Leu Val Gln Lys Arg Gly Ala Leu Arg Arg
 110 115 120

Lys Phe Gly Phe Ser Ala Glu Asp Tyr Arg Glu Leu Glu Arg Leu
 125 130 135
 Ala Leu Gln Ala Glu Pro His Arg Ala Gly Arg Gln Trp Lys Phe
 140 145 150
 Pro Gly Ser Phe Tyr Phe Ala Ile Thr Val Ile Thr Thr Ile Glu
 155 160 165
 Tyr Gly His Ala Ala Pro Gly Thr Asp Ser Gly Lys Val Phe Cys
 170 175 180
 Met Phe Tyr Ala Leu Leu Gly Ile Pro Leu Thr Leu Val Thr Phe
 185 190 195
 Gln Ser Leu Gly Glu Arg Leu Asn Ala Val Val Arg Arg Leu Leu
 200 205 210
 Leu Ala Ala Lys Cys Cys Leu Gly Leu Arg Trp Thr Cys Val Ser
 215 220 225
 Thr Glu Asn Leu Val Val Ala Gly Leu Leu Ala Cys Ala Ala Thr
 230 235 240
 Leu Ala Leu Gly Ala Val Ala Phe Ser His Phe Glu Gly Trp Thr
 245 250 255
 Phe Phe His Ala Tyr Tyr Tyr Cys Phe Ile Thr Leu Thr Thr Ile
 260 265 270
 Gly Phe Gly Asp Phe Val Ala Leu Gln Ser Gly Glu Ala Leu Gln
 275 280 285
 Arg Lys Leu Pro Tyr Val Ala Phe Ser Phe Leu Tyr Ile Leu Leu
 290 295 300
 Gly Leu Thr Val Ile Gly Ala Phe Leu Asn Leu Val Val Leu Arg
 305 310 315
 Phe Leu Val Ala Ser Ala Asp Trp Pro Glu Arg Ala Ala Arg Thr
 320 325 330
 Pro Ser Pro Arg Pro Pro Gly Ala Pro Glu Ser Arg Gly Leu Trp
 335 340 345
 Leu Pro Arg Arg Pro Ala Arg Ser Val Gly Ser Ala Ser Val Phe
 350 355 360
 Cys His Val His Lys Leu Glu Arg Cys Ala Arg Asp Asn Leu Gly
 365 370 375
 Phe Ser Pro Pro Ser Ser Pro Gly Val Val Arg Gly Gly Gln Ala
 380 385 390
 Pro Arg Leu Gly Ala Arg Trp Lys Ser Ile
 395 400

<210> 14

<211> 260

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7474286CD1

<400> 14

Met Met Trp Ser Asn Phe Phe Leu Gln Glu Glu Asn Arg Arg Arg
 1 5 10 15
 Gly Ala Ala Gly Arg Arg Arg Ala His Gly Gln Gly Arg Ser Gly
 20 25 30
 Leu Thr Pro Glu Arg Glu Gly Lys Val Lys Leu Ala Leu Leu Leu
 35 40 45
 Ala Ala Val Gly Ala Thr Leu Ala Val Leu Ser Val Gly Thr Glu
 50 55 60
 Phe Trp Val Glu Leu Asn Thr Tyr Lys Ala Asn Gly Ser Ala Val
 65 70 75
 Cys Glu Ala Ala His Leu Gly Leu Trp Lys Ala Cys Thr Lys Arg
 80 85 90
 Leu Trp Gln Ala Asp Val Pro Val Asp Arg Asp Thr Cys Gly Pro
 95 100 105

Ala	Glu	Leu	Pro	Gly	Glu	Ala	Asn	Cys	Thr	Tyr	Phe	Lys	Phe	Phe
				110					115					120
Thr	Thr	Gly	Glu	Asn	Ala	Arg	Ile	Phe	Gln	Arg	Thr	Thr	Lys	Lys
				125					130					135
Glu	Val	Asn	Leu	Ala	Ala	Val	Ile	Ala	Val	Leu	Gly	Leu	Ala	
				140					145					150
Val	Met	Ala	Leu	Gly	Cys	Leu	Cys	Ile	Ile	Met	Val	Leu	Ser	Lys
				155					160					165
Gly	Ala	Glu	Phe	Leu	Leu	Arg	Val	Gly	Ala	Val	Cys	Phe	Gly	Leu
				170					175					180
Ser	Gly	Leu	Leu	Leu	Leu	Val	Ser	Leu	Glu	Val	Phe	Arg	His	Ser
				185					190					195
Val	Arg	Ala	Leu	Leu	Gln	Arg	Val	Ser	Pro	Glu	Pro	Pro	Pro	Ala
				200					205					210
Pro	Arg	Leu	Thr	Tyr	Glu	Tyr	Ser	Trp	Ser	Leu	Gly	Cys	Gly	Val
				215					220					225
Gly	Ala	Gly	Leu	Ile	Leu	Leu	Leu	Gly	Ala	Gly	Cys	Phe	Leu	Leu
				230					235					240
Leu	Thr	Leu	Pro	Ser	Trp	Pro	Trp	Gly	Ser	Leu	Cys	Pro	Lys	Arg
				245					250					255
Gly	His	Arg	Ala	Thr										
				260										

<210> 15

<211> 489

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472589CD1

<400> 15

Met	Ser	Ser	Arg	Ser	Pro	Arg	Pro	Pro	Pro	Arg	Arg	Ser	Arg	Arg
1				5					10					15
Arg	Leu	Pro	Arg	Pro	Ser	Cys	Cys	Cys	Cys	Cys	Cys	Arg	Arg	Ser
				20					25					30
His	Leu	Asn	Glu	Asp	Thr	Gly	Arg	Phe	Val	Leu	Leu	Ala	Ala	Leu
				35					40					45
Ile	Gly	Leu	Tyr	Leu	Val	Ala	Gly	Ala	Thr	Val	Phe	Ser	Ala	Leu
				50					55					60
Glu	Ser	Pro	Gly	Glu	Ala	Glu	Ala	Arg	Ala	Arg	Trp	Gly	Ala	Thr
				65					70					75
Leu	Arg	Asn	Phe	Ser	Ala	Ala	His	Gly	Val	Ala	Glu	Pro	Glu	Leu
				80					85					90
Arg	Ala	Phe	Leu	Arg	His	Tyr	Glu	Ala	Ala	Leu	Ala	Ala	Gly	Val
				95					100					105
Arg	Ala	Asp	Ala	Leu	Arg	Pro	Arg	Trp	Asp	Phe	Pro	Gly	Ala	Phe
				110					115					120
Tyr	Phe	Val	Gly	Thr	Val	Val	Ser	Thr	Ile	Val	Arg	Glu	Glu	Ser
				125					130					135
Pro	Pro	Leu	Ala	Leu	Thr	Pro	Gly	Arg	Leu	Cys	Ser	Asn	Thr	Gly
				140					145					150
Arg	Leu	Cys	Asp	Leu	Thr	Phe	Lys	Ser	Tyr	Ile	Asn	Ile	Ala	Lys
				155					160					165
Glu	Gln	Glu	His	Pro	Ala	Ile	Gln	Gln	Ser	Phe	Pro	Arg	Val	Ser
				170					175					180
Thr	Val	Ser	Ser	Glu	Asn	Arg	Lys	Glu	Gly	Phe	Gly	Met	Thr	Thr
				185					190					195
Pro	Ala	Thr	Val	Gly	Gly	Lys	Ala	Phe	Leu	Ile	Ala	Tyr	Gly	Leu
				200					205					210
Phe	Gly	Cys	Ala	Gly	Thr	Ile	Leu	Phe	Phe	Asn	Leu	Phe	Leu	Glu
				215					220					225

Arg	Ile	Ile	Ser	Leu	Leu	Ala	Phe	Ile	Met	Arg	Ala	Cys	Arg	Glu
				230					235					240
Arg	Gln	Leu	Arg	Arg	Ser	Gly	Leu	Leu	Pro	Ala	Thr	Phe	Arg	Arg
				245					250					255
Gly	Ser	Ala	Leu	Ser	Glu	Ala	Asp	Ser	Leu	Ala	Gly	Trp	Lys	Pro
				260					265					270
Ser	Val	Tyr	His	Val	Leu	Leu	Ile	Leu	Gly	Leu	Phe	Ala	Val	Leu
				275					280					285
Leu	Ser	Cys	Cys	Ala	Ser	Ala	Met	Tyr	Thr	Ser	Val	Glu	Gly	Trp
				290					295					300
Asp	Tyr	Val	Asp	Ser	Leu	Tyr	Phe	Cys	Phe	Val	Thr	Phe	Ser	Thr
				305					310					315
Ile	Gly	Phe	Gly	Asp	Leu	Val	Ser	Ser	Gln	His	Ala	Ala	Tyr	Arg
				320					325					330
Asn	Gln	Gly	Leu	Tyr	Arg	Leu	Gly	Asn	Phe	Leu	Phe	Ile	Leu	Leu
				335					340					345
Gly	Val	Cys	Cys	Ile	Tyr	Ser	Leu	Phe	Asn	Val	Ile	Ser	Ile	Leu
				350					355					360
Ile	Lys	Gln	Val	Leu	Asn	Trp	Met	Leu	Arg	Lys	Leu	Ser	Cys	Arg
				365					370					375
Cys	Cys	Ala	Arg	Cys	Cys	Pro	Ala	Pro	Gly	Ala	Pro	Leu	Ala	Arg
				380					385					390
Arg	Asn	Ala	Ile	Thr	Pro	Gly	Ser	Arg	Leu	Arg	Arg	Arg	Leu	Ala
				395					400					405
Ala	Leu	Gly	Ala	Asp	Pro	Ala	Ala	Arg	Asp	Ser	Asp	Ala	Glu	Gly
				410					415					420
Arg	Arg	Leu	Ser	Gly	Glu	Leu	Ile	Ser	Met	Arg	Asp	Leu	Thr	Ala
				425					430					435
Ser	Asn	Lys	Val	Ser	Leu	Ala	Leu	Leu	Gln	Lys	Gln	Leu	Ser	Glu
				440					445					450
Thr	Ala	Asn	Gly	Tyr	Pro	Arg	Ser	Val	Cys	Val	Asn	Thr	Arg	Gln
				455					460					465
Asn	Gly	Phe	Ser	Gly	Gly	Val	Gly	Ala	Leu	Gly	Ile	Met	Asn	Asn
				470					475					480
Arg	Leu	Ala	Glu	Thr	Ser	Ala	Ser	Arg						
				485										

<210> 16

<211> 1735

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1784775CB1

<400> 16

atgtgcctcc	ttgtcttccc	ccttgtcccc	aggagtccag	attacatcct	accctgcagt	60
cctggatggc	gcctccgact	tgcagcttcc	ttcctgcttt	ccgtcttccc	gctgctagac	120
cttcttccag	ttgctttgcc	accaggggca	ggcccaggac	ccatagggct	agaggtgttg	180
gcaggggtgc	tggcagctgt	ggcctggatc	agccacagcc	tggccctgtg	ggtgttggca	240
cattccccctc	atggccactc	ccgggggtccc	ttggccttgg	ccctggtagc	cttgctgcca	300
gctccagccc	tagtgctgac	cgtgttgtgg	cattgccagc	gaggcacact	tctgccccca	360
cttctccag	ggcccatggc	ccgcctatgc	ttgctcatcc	tgcagctggc	tgcactcttg	420
gcctatgcac	tgggatgggc	agctcctggg	ggaccacgag	aaccctgggc	tcaggagccc	480
ctcctgcccc	aggatcaaga	acctgaggtg	gctgaagatg	gggagagttg	gctgtcacgc	540
ttttcctatg	cctggctggc	acccttgcctg	gcccgtgggg	cctgtggaga	gctccggcag	600
cctcaggaca	tttgccgcct	ccccacaga	ctgcagccaa	cctacctggc	tcgtgtcttc	660
caggcacact	ggcaggaggg	ggcacggctg	tggagggcct	tgtatggggc	ctttggacgg	720
tgctatctgg	cacttggact	gctgaagctg	gtggggacca	tgttgggatt	ctcagggccc	780
ctgttgctct	ccctactggg	gggcttctctg	gaagaggggc	aggagccact	aagccacggc	840
ctgctctatg	ctctggggct	agccggtggg	gctgtgctgg	gtgctgtgct	gcagaatcag	900
tatgggtatg	aggtatataa	ggtaacactt	caggcacggg	gggctgtgct	gaacatcctg	960

```

tactgcaagg ctttacagct ggggccagc cgcctccta ctggggaggc cctgaacct 1020
ctaggcactg actctgaacg gctgcttaac tttgctggga gcttccatga agcctggggc 1080
ctggccctgc aactggccat caccctctac ctgctgtacc agcaggtagg cgtggccttc 1140
gtgggtggtc tcatcttggc actgctgctg gtaccctgca acaaagtgat tgccaccgc 1200
atcatggcca gcaaccagga aatgctacag cacaaggatg cgcgggttaa gcttgtgaca 1260
gagctgctga gtggcattcg ggtcatcaag ttctgcggtt gggagcaggc actgggagcc 1320
cgagtagagg cctgccgggc tcgagagctg gggcgactcc gggtcacaa atacctggat 1380
gcgccctgtg tatacctgtg ggctgcccta ccggttgtca tctccatcgt tatcttcac 1440
acctatgtcc tcatggggca ccagctcact gccaccaagg tgaggaccag gaaggaagg 1500
gaccagcatc aaggagactt cagcgaagtg aagacagagg cttggggcct cagtgtggc 1560
tgagaaggag ggagggatcc ctgactgcct catctctcaa ccaagggaaa actgaagaaa 1620
cctttttgtg ggggccttgg atatataacc ctcccctctg tgaaggagtt cctttctttc 1680
ctctcctcta cctttcactc cagcttctat tcagttccag gcttggggtt aggtc 1735

```

<210> 17

<211> 1041

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473034CB1

<400> 17

```

atggttcaag catctgggca caggcgggtcc acccgtgggt ccaaaatggt ctctgggtcc 60
gtgatagcaa agatccagga aatatgggtgc gaggaagatg agaggaagat ggtgcgagag 120
ttcttggccg agttcatgag cacatatgtc atgatgggtat tcggccttgg ttctgtggcc 180
catatgggtc taaataaaac atatgggagc taccttgggt tcaacttggg ttttggcttc 240
ggggtcacca tgggagtcca cgtggcaggc cgcactctctg gagccacat gaatgcagct 300
gtgaccttca ctaactgtgc gctgggcccgc gtgccctgga ggaagtttcc agtccatgtg 360
ctggggcagt tcttgggtc ctctctggca gctgccacca tctacagtct ctctacagc 420
gccattctcc acttttcggg tggagagctg atggtgaccg gtccctttgc tacagtggc 480
atttttgcca cctaccttcc tgatcacatg acattgtggc ggggcttctt gaatgaggag 540
tggtgacca ggatgtctca gctgtgtctc ttcaccatca cggaccagga gaacaacca 600
gcaactgccg gaacacacgc gctggtgata agcatcctcg tggtcacat cagggtgtcc 660
catggcataa acacaggata tgcatcaat ccatcccggg acccggccc cagcatcttc 720
accttcattg ctggctgggg caaacaggtc ttcagcgatg gggagaactg gtggtgggtg 780
ccagtgggtg caccacttct ggggtgcctc ctagggtggc tcatctacct ggtcttcatt 840
ggctccacca tcccacggga gccctgaaa ttggaggact ctgtggcgta tgaagaccac 900
gggataaccg tattgcccaa gatgggatct catgaacca tgatctctcc cctcaccctc 960
atctccgtga gccttgccaa cagatcttca gtccactctg cccaccctt acatgaatcc 1020
atggccctag agcatttcta a 1041

```

<210> 18

<211> 2367

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1878581CB1

<400> 18

```

ggacgcgctc cggggacgcg cgaggctgcc gtggcgggag acgcgtttcc ggtggcggcg 60
gaggctgcac tgagcgggac ctgcgagcag cgcgggaggc agcccggggg aagcgtccgg 120
gaccatgtct ggagaactac caccaaacta taacatcaag gaacctcgat gggatcaaag 180
cactttcatt ggacgagcca atcatttctt cactgtaact gacccagga acattctgtt 240
aaccaacgaa caactcgaga gtgcgagaaa aatagtacat gattacaggc agggaattgt 300
tctcctggt cttacagaaa atgaattgtg gagagcaaag tacatctatg attcagcttt 360
tcactctgac actggtgaga agatgatttt gataggaaga atgtcagccc aggttcccat 420
gaacatgacc atcacagggt gtatgatgac gttttacagg actacgccgg ctgtgctgtt 480
ctggcagtgg attaaccagt cttcaatgc cgtcgtcaat tacaccaaca gaagtggaga 540
cgcaccctc actgtcaatg agttgggaac agcttacgtt tctgcaacaa ctggtgccgt 600

```

```

agcaacagct ctaggactca atgcattgac caagcatgtc tcaccactga taggacgttt 660
tgttcccttt gctgccgtag ctgctgctaa ttgcattaat attccattaa tgaggcaaaag 720
ggaactcaaa gttggcattc ccgtcacgga tgagaatggg aaccgcttgg gggagtcggc 780
gaacgctgcg aaacaagcca tcacgcaagt tgctgtgtcc aggattctca tggcagcccc 840
tggcatggcc atccctccat tcattatgaa cacttttgaa aagaaagcct ttttgaagag 900
gttcccatgg atgagtgcac ccattcaagt tgggttagtt ggcttctggt tgggtgtttgc 960
tacacccctg tgttgtgcc tgtttccctca gaaaagttcc atgtctgtga caagcttggg 1020
ggccgagttg caagctaaga tccaagagag ccattcctgaa ttgcgacgcg tgtacttcaa 1080
taagggtattg taaagcaggg aggaaacctc tgcagctcat tctgccactg caaagctggg 1140
gtagccatgc tgggtgagaaa aatcctgttc aacctgggtt ctcccagtta cggaaacctt 1200
ttaaagatcc acattagcct tttagaataa agctgctact ttaacagagc acctggcggt 1260
ggccaagtgc ctgatactcc cttacactga atcatgttat gatttataga aatacctttc 1320
ctgtagcttt tatagtcatt gtttttcaaa gacgatatac cagccctcac ccagggttta 1380
aaaaagcact ggtaggcata gaataggtgc tcagtatatg gtcagtaaat gttctattga 1440
ttatcaatca gtgaaaaaag aaatctgttt aaaatactga attttcatct cactcccat 1500
gcaaatacaag gagatctcag cagtgaactg ggaaaataca aaagctctgg gctaacttat 1560
aaaaacttac cctgaaatat taagggcagt ttgcttctag ttggggatt gcgctagccc 1620
aatgaagggtg atgaagcttt tggatttggg gggtaaaagc tccttcacac cccttccaaa 1680
agtcagtcac agaccactgc aacatgcctt ccctgctgga tcattatata cattcagatt 1740
gtgagtggat tgccttgggt gacttttaat ttattgtttt ttgttcttat aaagatgata 1800
atcttacctt gcagttattg actttatatt caattattta catcaaataa tgaataaact 1860
gaaatgtaca aatgtcaaat tttggaagta tattcaatac caatgctgta tgagtgggct 1920
gaatccagtt cattgttttt tttttggtaa gaagtgcagc tacagttcca gctacctaca 1980
tgtcttttct tgtcatcctt atagatctct ttggctttca gaaagataca gtgataatgt 2040
gtgtatgaat cagtcacaat gaattttact tgaatattgt atgttgcat ccacttcatt 2100
tgaaaataat gaaaccatgt accactgttt acatcatctg tagtgatttc atagataata 2160
tatttaatat gcagattat gtttcaactc tgtagatgtt taacgtcata gacagttggc 2220
cctctgtatc cgtgagctct atatctgtga attcaaccaa gtttggatgg aaaatttttt 2280
tttttttttt tttttttgag acggagtctc gctctgtcac ccaggctgga gtgcagtggc 2340
gtagtctcgg ctactgcaa gctccgc 2367

```

<210> 19

<211> 3343

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2346292CB1

<220>

<221> unsure

<222> 57

<223> a, t, c, g, or other

<400> 19

```

cttgacgagg cgcacgcggg atgggagggc gggaggagca gcgggaagag cggacgngcg 60
accgcgtccg gcgcagtcct caatgagcag cgcggaact gcacccaga cccgagcctg 120
ctgcgcgccc cctcccagag ctacactggg gccaggtaac aggcctggcc tcgcccgtgt 180
gatgatgatg gccttgcccc cgtgagctac aacctggcct tcagcacccg cccacctcca 240
accagcagga tgcggctgtg gaaggcgggt gtggtgactt tggccttcat gagtgtggac 300
atctgcgtga ccacggccat ctatgtcttc agccacctgg accgcagcct cctggaggac 360
atccgccact tcaacatctt tgactcgggt ctggatctct gggcagcctg cctgtaccgc 420
agctgcctgt tgcctgggagc caccattggg gtggccaaga acagtgcgct ggggccccgg 480
cggtgcgggg cctcgtggct ggcatcagc ctcgtgtgcc tcttcgtggg catctatgcc 540
atggtgaagc tgcgtctctt ctgagagggt cgcaggccca tccgggaccc ctggttttgg 600
gccctgttcg tgtggacgta catttcaact gcgcatacct tcctgctctg gtggctgctg 660
tccaccgtgc ggccaggcac ccaggccctg gaggcagggg cggccaccga ggctgagggc 720
ttccctggga gcggccggcc accgcccagc caggcgtctg gggccacgct gcagaagctg 780
ctctcctaca ccaagccgca cgtggccttc cctgtggccg cctccttctt cctcatcggt 840
gcagctctgg gagagacctt cctgccctac tacacgggcc gcgccattga tggcatcgct 900
atccagaaaa gcatggatca gttcagcacg gctgtcgtca tcgtgtgcct gctggccatt 960
ggcagctcat ttgccgcagg tattcggggc ggcattttta ccctcatatt tgccagactg 1020

```

```

aacattcgcc ttcgaaactg tctcttccgc tctactggtg cccaggagac aagcttcttt 1080
gatgagaacc gcacagggga cctcatctcc cgctgacct cggacaccac catggtcagc 1140
gacctggtct ccagaaacat caatgtcttc ctgcggaaca cagtcaaggt cacgggcgtg 1200
gtggtcttca tgttcagcct ctcatggcag ctctccttgg tcaccttcat gggcttcccc 1260
atcatcatga tgggtgtccaa catctacggc aagtactaca agaggctctc caaagagggtc 1320
cagaatgccc tggccagagc gagcaacacg gcggaggaga ccatcagtgc catgaagact 1380
gtccggagct tcgccaatga ggaggaggag gcagaggtgt acctgcggaa gctgcagcag 1440
gtgtacaagc tgaacaggaa ggaggcagct gcctacatgt actacgtctg gggcagcggg 1500
tccgtgggct cegtctacag tggcctgatg cagggagtgg gggctgctga gaaggtgttc 1560
gagttcatcg accggcagcc gacctggtg cagcatggca gcttggcccc cgaccacctg 1620
gagggccggg tggactttga gaatgtgacc ttcacctacc gactcggcc ccacaccagg 1680
gtcctgcaga atgtctcctt cagcctgtcc cccggcaagg tgacggccct ggtggggccc 1740
tcgggcagtg ggaagagctc ctgtgtcaac atcctggaga acttctaccc cctggagggg 1800
ggccgggtgc tgctggacgg caagcccatc agcgctacg accacaagta cttgcaccgt 1860
gtgatctccc tggtagacca ggagcccggt ctgttcgccc gctccatcac ggataacatc 1920
tcctacggcc tggccactgt gcctttcgag atggtggtgg aggccgcaca gaaggccaat 1980
gcccacggct tcatcatgga actccaggac ggctacagca cagagacagg ggagaagggc 2040
gcccagctgt caggtggcca gaagcagcgg gtggccatgg cccgggctct ggtgcggaac 2100
ccccagctcc tcatcctgga tgaagccacc agcgctttgg atgccgagag cgagtatctg 2160
atccagcagg ccatccatgg caacctgcag aagcacacgg tactcatcat cgcgccaccg 2220
ctgagcaccg tggagcacgc gcacctcatt gtggtgctgg acaagggccg cgtagtgcag 2280
cagggcacc caccagcgt gctggcccag ggcggcctct acgccaagct ggtgcagcgg 2340
cagatgctgg ggcttcagcc cgccgagacg ttcacagctg gccacaacga gcctgtagcc 2400
aacggcagtc acaaggcctg atggggggcc cctgcttctc ccggtggggc agaggaccgg 2460
gtgcctgcct ggcagatgtg cccacggagg ccccagctg ccctccgagc ccaggcctgc 2520
agcactgaaa gacgacctgc catgtcccat ggatcacccg tctctgcatac ttgcccttgg 2580
tccctgcccc attcccaggg cactccttac ccctgctgcc ctgagccaac gccttcacgg 2640
acctccctag cctcctaagc aaaggtagag ctgccttttt aaacctagggt cttaccaggg 2700
tttttactgt ttggtttgag gcaccccagt caactcctag atttcaaaaa ctttttctta 2760
attgggagta atggcgggca ctttcaccaa gatgttctag aaacttctga gccaggagtg 2820
aatggccctt ccttagtagc ctgggggatg tccagagact aggcctctcc cctttacccc 2880
tccagagaag gggcttccct gtcccggagg gagacacggg gaacgggatt ttccgtctct 2940
ccctcttgcc agctctgtga gtctggccag ggcgggtagg gagcgtggag ggcactctgtc 3000
tgccatcgcc cgctgccaat ctaagccagt gctactgtga accacacgaa acctcaactg 3060
ggggagttag gggctggcca ggtctggagg ggctcagggt gtgccccag cccggcacc 3120
agcgctttcg cccctcgctc accaccccct ggctggcagc ctccctcccc acaccgccc 3180
ctgtgctctg ctgtctggag gccacgtgga tgttcatgag atgcattctc ttctgtcttt 3240
ggtggatggg atggtggcaa agcccaggat ctggctttgc cagagggtgc aacatgttga 3300
gagaaccggg tcaataaagt gtactacctc ttacccttaa aaa 3343

```

<210> 20

<211> 3517

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 5151730CB1

<400> 20

```

cccgaccgcg ctgggctggg ctgggctggg ctggggcggg cgcagggcgc agggggcggg 60
gcgcggggga agacgcacgg gcgggctcgg ctctcccggg gagcgggccg ggactgcacc 120
gggaccagcg cctccccgct tcgcgctgcc ctcgccctcg ccccgggccc ggggtggatga 180
gccgcgcgcc cgggggacat ggaagcgctg acgctgtggc ttctcccctg gatatgccag 240
tgctgttcgg tgcgggccga ctccatcatc cacatcggtg ccatcttcga ggagaacgg 300
gccaaggacg acaggggtgt ccagttggcg gtatccgacc tgagcctcaa cgatgacatc 360
ctgcagagcg agaagatcac ctactccatc aaggctcatg aggccaaaca ccattccag 420
gctgtgcagg aagcctgtga cctcatgacc caggggattt tggccttggg caggtccact 480
ggctgtgcat ctgccaatgc cctgcagtcc ctacggatg ccatgcacat cccacacctc 540
tttgctcagc gcaaccgggg agggtcgcca cgcaccgat gccacctgaa cccagcccc 600
gatgggtgag cctacacact ggcttcgaga ccaccgctcc gcctcaatga tgtcatgtct 660
aggctggtga cggagctgcg ctggcagaag ttcgtcatgt tctacgacag cgagtatgat 720
atccgtgggc ttcaaagctt tctggaccag gcctcgcggc tgggccttga cgtctcttta 780

```

```

caaaaggtgg acaagaacat tagccacgta ttcaccagcc tcttcaccac gatgaagaca 840
gaggagctga atcgctaccg ggacacgctt cgccgcgcca tcctgctgct cagcccacag 900
ggagcccact ccttcatcaa cgaggccgtg gagaccaacc tggcttccaa ggacagccac 960
tgggtctttg tgaatgagga aatcagtgac ccggagatcc tggatctggt ccatagtggc 1020
cttggaaagga tgaccgtggt ccggcaaatc tttccgtctg caaaggacaa tcagaaatgc 1080
acgaggaaca accaccgcat ctctccctg ctctgcgacc ccaggaagg ctacctccag 1140
atgctgcaga tctccaacct ctatctgtat gacagtgttc tgatgctggc caacgccttt 1200
cacaggaagc tggaggaccg gaagtggcat agcatggcga gcctcaactg catacggaag 1260
tccactaagc catggaatgg tgggaggtcc atgctggata ccatcaaaaa gggccacatc 1320
actggcctca ctggggtgat ggagtttcgg gaggacagtt cgaatcccta tgtccagttt 1380
gaaatccttg gcactaccta tagtgagact ttggcacaag acatgcgcaa gttggcgaca 1440
tgggactcag agaagggtt gaatggcagc ttgcaagaga ggcccatggg cagccgcctc 1500
caaggattga ctcttaaagt ggtgactgtc ttggaagagc ctttcgtgat ggtggctgag 1560
aacatcctag gacagcccaa gcgctacaaa gggttctcca tagatgtcct ggatgcactg 1620
gccaaggctc tgggctttaa atatgagatt taccaagccc ctgatggcag gtacggtcac 1680
cagctccata acacctcctg gaacgggatg atcggggagc tcacagcaa gagagcagac 1740
ttggccatct ctgccatcac catcacccca gagaggaga gcgttgaggga cttcagcaag 1800
cgggtacatgg actattcagt ggggattcta attaagaagc ccgaggagaa aatcagcatc 1860
ttctccctct ttgctccatt tgatttcgct gtgtgggcct gcattgcagc agccatccct 1920
gtggttggtg tgctgatatt tgtgttgaa aggatacagg ctgtgagggc tcagagtgtc 1980
gccagccca ggccgtcagc ttctgccact ctgcacagcg ccatctggat tgtctatgga 2040
gccttcgtac agcaagggtg cgaatcttcc gtgaactcca tggccatgcg catcgtgatg 2100
ggcagctggt ggctcttcac gctcattgtg tgctcctcct acacagccaa ccttctgtgc 2160
ttctcacag tgtccaggat ggacaacccc ataaggactt tccaggacct gtccaaacaa 2220
gtggaatgt cttatggcac tgtccgggat tctgctgtat atgagtactt ccgagccaag 2280
ggcaccaacc ccctggagca ggacagcagc tttgttgaa tctggcggac catcagcaag 2340
aacggagggg ctgacaactg cgtgtccagt ccttcagaag gcacaggaag ggcaaagaag 2400
gggaactacg ccttctgtg ggatgtggcc atcagcagca agggttacgg gattgccctg 2460
gactgctcgg tgactgtcat cggcaacagc atcagcagca agggttacgg gattgccctg 2520
cagcatggca gccctacag ggacctcttc tcccagagga tcctggagct gcaggacaca 2580
ggggacctgg atgtgctgaa gcagaagtgg tggccgcaca tgggcccgtg tgacctcacc 2640
agccatgcca gcgcccaggc cgacggcaaa tccctcaagc tgcacagctt cgccggggtc 2700
ttctgcatcc tggccattgg cctgctcctg gcctgcctgg tggctgcctt ggagtgtggt 2760
tggaacagca accggtgcca ccaggagacc cccaaggagg acaaagaagt gaacttgagg 2820
caggtccacc ggcgcatgaa cagcctcatg gatgaagaca ttgctcaca gcagatttcc 2880
ccagcgtcga ttgagctctc ggccctggag atgggggggc tggctccca cccagacctt 2940
gagccgacac gggagtacca gaacacccag ctctcgggtc gcacctttct gccagagcac 3000
agcagccatg gcaccagccg gacactctca tcagggccca gcagcaacct gccgtgccc 3060
ctgagcagct cggcgacatc gccctccatg cagtgcacaa acaggtcacc caacgggggg 3120
ctgttccggc agagcccggt gaagaccccc atccccatgt ccttccagcc cgtgcctgga 3180
ggcgtccttc cagaggctct ggacacctcc cagcggacct ccatctgact gcgccgctg 3240
ccctcctgcc caccctccca cccacccgac cagcagagct ttttaataca agaaaaacaa 3300
aacacaaacc acacacactc gcacacacac acatacacag agactctttc atttttctg 3360
tacatatgtg taaataatga cagaatggag tggggtaaaa gtgtattttg aatattccca 3420
attttcgaag tcagtaaaaa aacacaaaaa ctgtatgaat gactttgtaa attttgttct 3480
atatgaataa aaaggcaaat tacttgtgaa aaaaaaa 3517

```

<210> 21

<211> 1248

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472584CB1

<400> 21

```

atgaagaggc agaacgtgcg gactctgtcc ctcatcgtct gcaccttcac ctacctgctg 60
gtgggcgcgc ccgtgttcga cgccctcgag tcggaccacg agatgcgcga ggaggagaaa 120
ctcaaagccg aggagatccg gatcaagggg aagtacaaca tcagcagcga ggactaccgg 180
cagctggagc tggatgacct gcagtcggaa ccgcaccgcg ccggcgtcca gtggaaattc 240
gccggctcct tctactttgc gatcacggtc atcaccacca taggttatgg gcacgctgca 300
cctggcaccg atgcccggca ggccttctgc atgttctacg ccgtgctggg catcccgtg 360

```

```

acactgggtca tgttccagag cctggggcgag cgcataaaca ccttcgtgcg ctacctgctg 420
aagcgcatta agaagtgctg tggcatgctg aacactgacg tgtctatgga gaacatgggtg 480
actgtgggct tcttctcctg catggggacg ctgtgcatcg gggcgccgcg cttctcccag 540
tgtgaggagt ggagcttctt ccacgcctac tactactgct tcatcacgtt gactaccatt 600
gggttcgggg actacgtggc cctgcagacc aaggggtgcc tgcagaagaa gccgctctac 660
gtggccttta gctttatgta tatcctgggt gggctgacgg tcatcggggc cttcctcaac 720
ctggctcgcc tcaggttctt gaccatgaac agtgaggatg agcggcgagg tgctgaagag 780
agggcatccc tcgccgaaa ccgcaacagc atggtcattc acatccctga ggagccgcg 840
cccagccggc ccaggtacaa ggcggacgtc cgggacctgc agtctgtgtg ctcctgcacc 900
tgctaccgct cgcaggacta tggggcgccg tcggtggcac cgcagaactc cttcagcgcc 960
aagcttgccc cccactactt ccactccatc tcttacaaga tcgaggagat ctcaccaagc 1020
acattaaaaa acagcctctt cccatcgctt attagctcca tctctcctgg gttacacagc 1080
tttaccgacc accagaggct gatgaaacgc cgggaagtccg tttaggggaa ctaactgcac 1140
attcaagaga ggcgtccgtg gatgctgggt ctcactgcc aagccgaaca cgcttcggg 1200
atttcttgcc ttctcaagtg gacctcttgc tgtgctgggc ggaatgcc 1248

```

<210> 22

<211> 1770

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7472536CB1

<400> 22

```

atgtctgcag tcctcacccc tggcctgttc ctccccctcc caggggccct cccggcctct 60
ctacataaag cggggggtac tgggcctcag gtcaggccta tggccatggc cttcacagac 120
ctgctggatg ctctgggcag catggggcgc ttccagctca accacacagc cctgctgctg 180
ctgccttgcg gcctgctggc ctgccacaac ttctgcaga acttcaccgc cgctgtcccc 240
ccccaccact gccggggccc tgccaaccac actgaggcct ccaccaacga ctcggggggc 300
tggctgaggg ccaccatacc cctggaccag cttggggccc ctgagccctg ccggcgcttc 360
accaagcctc agtgggcccc gctgagcccc aactcctcca tcccgggcgc ggccacggag 420
ggctgcaagg acggctgggt ctataaccgc agtgttttcc cgtccaccat cgtgatggag 480
cagtgggatc tgggtgtgtg gggccgcact ctccagagac tggcgagtc cgtctacatt 540
gccgggtgct tgggtggggc tgccgtgttt ggcagcttgg cagacaggct gggtgcaag 600
ggccccctgg tctggctcta cctgcagctg gcagcttcgg gggccgccac agcgtatttc 660
agctccttca gtgcctattg cgtcttcagg ttctgtatgg gcatgacctt cctcggcatc 720
atcctcaact ccgtctccct ggtggagtgg atgccacac ggggcccggc tgtggcgggt 780
atthtctgg ggtattcctt caccctgggc cagctcatcc tggctggggg agcctacctg 840
attcgccctt ggcgggtgct gcagtttgcc atctctgctc ctttctgat ctttttctc 900
tattcttggt ggcttcaga gtcacccgc tggtcctcc tgcattggaa gtcccagtta 960
gctgtacaga atctgcagaa ggtggctgca atgaacggga ggaagcagga aggggaaagg 1020
ctgaccaagg aggtgatgag ctctacatc caaagcgagt ttgcaagtgt ctgcacctcc 1080
aactcaatct tggacctctt ccgaaccccg gccatccgca aggtcacatg ctgtccggcg 1140
ctgaggttct ccaactctgt ggcttactat ggcctggcca tggacctgca gaagtttggg 1200
ctcagcctat acctggtgca ggccctgttt ggaatcatca acatcccggc catgctgggtg 1260
gccaccgcca ccatgattta cgtgggcccg cgtgccacgg tggcctcctt cctcatcctg 1320
gccgggctca tgggtgatgc gccatgttt gtgccagaag gcacgcagat cctgtgcaca 1380
gccaggcag cgctgggcaa aggtgcctg gccagctcct tcatctgtgt gtacctgttt 1440
accggcgagc tgtacccccc ggagatcagg cagatgggga tgggctttgc ctctgtccac 1500
gcccgctctg ggggcctgac ggcgcccctg gttaccacac ttggggaata cagcaccatc 1560
ctgccacccg tgagctttgg ggccaccgca atcctggctg ggctggccgt ctgcttcttg 1620
actgagaccc gcaacatgcc cctgggtggag accatcgag ccatggagag gagggtcaaa 1680
gaaggctctt ccaagaaaca tgtagaagag aagagtgaag aaatttctct tcagcagctg 1740
agagcatctc cctcaaaga gaccatctaa 1770

```

<210> 23

<211> 2544

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473422CB1

<400> 23

```

atgacgatcc gccccgaacc gctgatgcgt accttggccg ccgccgtgct gagcctggtc 60
atcggcgctc cgcccgccat ggcagacgca ccggtcaccc tgaccatgta caacggtcag 120
cacaaggaaa tcggcgaagc catcgccaag gcctacgagg ccaagaccgg catccacatc 180
gatatccgca agggcagcag caaccagctg gccagccaga tcatcgagga gggcgaccgt 240
tcgccagccg acctcatcta caccgaagag tccccgcccc tgaacaacct gggcgaaactg 300
ggcctgctgg cgaagatcga cgacgccacc ggaacatgg tgcccaagga gtatgtgggc 360
gccaacggga cctggatggg catcaccgcg cgcacgcgca tcgtggtgta caaccgaaag 420
aaggctcgatg aaaaagacct gccgaccaca gtgatggact tcgccaacct tgagtgggaa 480
ggcccgctcg gctacgtacc caccagcggg gcattccagg agcaggccgt ggccatcctg 540
aagatgcatg gtcgtgaagc caccgaagaa tggctgaccg gccttaaagc cttcggcaaa 600
acatacacca acaacatggt cgccctcaaa gccgtggaaa aagggtgaagt ggctgcggtg 660
ctggtgaaca actactactg gtacgcactt gaacgcgaac gcggcaagct cgacaccaag 720
ctctactacc tggcagatgg cgatgccggc aacctggtga ccatctctgg cgccgctgtg 780
gtcaaggcca gcaagcacc gaaagaagcc caggcactgc tcaactggat ggccagcgaa 840
gaaggccaac gtgtgatcac ccagaccacc gccagtgacc cgctgcacaa gggcatggtt 900
tccgaccggg gcctcaagcc gttcgaagac ctgcccgcgc cgaaaatctc gccagccgac 960
ctgggcaatg ccgaggaagc catcgagctt gaacgcgagc cggcgcgggt acgcttcgta 1020
ccgcgcgcga agcgccectc catctgggtg gtgctgctct tgctggcgatg 1080
agcttgctgc cgtgctgta tgtcgccatc aaagcctggg aagccggctg gcgtgaagcc 1140
ttgcacctgc tgtggcgccc ctttgtctgg gggctgatgc gcaataccct gatgctgatg 1200
gtcggggtga cattggcctg catggtggtc gggctggccc tggcctggct gctggagcgc 1260
agcaacctgg ctggccgccc gctgtggggc gtggtgcttt gcctgcccct cgctgtgccc 1320
tcgttcgtca gcagtttcac ctgggtgtcg ctgagctcgg acttcgaagg gctgggcccg 1380
gccatcctgg tcatggccct gtccaagtac ccattggtgt tectgccggt ggccgcccac 1440
ctgcgcaacc tcgacacctc gctggaggag tggcgcgca ccctgggttg tagccgctgg 1500
ggcgtgttca tcaaggtcac cttgccgctg ctgtggccct cgatgctcgg cgagcgcgtg 1560
ctgatcgccc tgcacatgct ggtggagttc ggtgcgttgt cgatcctcgg cctgcagacc 1620
ttcaccacgg cgatctacca gcagttcgaa ctggaattca gcaatgccaa cgcggccatg 1680
gtgtctgccc tgctgttggc gatgtgcctg gtgatgctgt ggctggaatt gcgtgtacgt 1740
ggcaaagccc gccatgtgcy catcgggccag ggcgtggcac gccgcgcgca acccgtgcga 1800
ctgcgtggct gggccgtacc ggcgcagcta ctctgcgtgg ccctggcagt gctgggcagc 1860
ggtatcccac tggccatgct cggctactgg ctgagcgtgg gttcgtcggc agccttcccg 1920
gtgggagcca tctccaaggc gctgttcacc tcgctgtcgg tgtcgcttgg cggtgccggt 1980
ttctgtgtgc tgctggcgct accgataagc ttctgggtgg tgcgctacaa aggccgtctt 2040
gcgatctggg ccgagcgctt gccgtacctg ctgcacgccc tgcccggcct ggtgattgca 2100
ctgaccttgg tgttcttcgc cctgcactac gtgccggcgc tgtaccagac cacggcgttg 2160
ctgctcttgg cgtatgcgct gctgttcctg ccattggcgc agtcaccggt gcgcaccgcy 2220
ctgaacaagg cctcgccaac actggaggaa gccgcgcgca ccctgggtgc cagcagcttc 2280
acggcattct gccgggtgac cctgccgatc atcttcccgg ccattggcggc agcatttgcy 2340
ctggtgtttc tggatgccat gaaagaactg acagctaccc tgctgctcag cccgaccggg 2400
atgaccaccc tggctaccga ggtgtgggcy catacggcca acgtcgagtt cgcggcgccg 2460
gcgcctatg cagccttgct gatcgtgggt tcaggcctgc cggtttatct gctgaccacg 2520
cggatgtacc tgaacaaggc ataa 2544

```

<210> 24

<211> 2871

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 2864715CB1

<220>

<221> unsure

<222> 2847

<223> a, t, c, g, or other

<400> 24

```

gcttctgccc tgcctgctgt gtgcggagcc gtccagcgac caccatgggtg aggctcgtgc 60
tgcccaaccc cggcctagac gcccgatcc cgccctggc tgagctggag accatcgagc 120
aggaggaggc cagctcccgg ccgaagtggg acaacaaggc gcagtacatg ctcacctgcc 180
tgggcttctg cgtgggcctc ggcaacgtgt ggcgcttccc ctacctgtgt cagagccacg 240
gaggaggagc cttcatgata ccgttccctca tcctgctggg cctggagggc atccccctgc 300
tgtacctgga gttcgccatc gggcagcggc tgcggcgggg cagcctgggt gtgtggagct 360
ccatccaccc ggccctgaag ggccctagcc tggcctccat gctcacgtcc ttcattgggtg 420
gactgtatta caacaccatc atctcctgga tcatgtggta cttattcaac tccttccagg 480
agcctctgcc ctggagcgac tggccgctca acgagaacca gacagggtat gtggacgagt 540
gcgccaggag ctcctctgtg gactacttct ggtaccgaga gacgctcaac atctccacgt 600
ccatcagcga ctcgggctcc atccagtggg gtagctgctg tgccctggcc tgcgcatgga 660
gcgtcctgta catgtgcacc atccgcggca tcgagaccac cgggaaggcc gtgtacatca 720
cctccacgct gccctatgtc gtccctgacca tcttctctat ccgaggcctg acgtgaagg 780
gcgccaccaa tggcatcgct ttcctcttca cgcccaacgt cagggagctg gccagccgg 840
acacctggct ggacgcgggc gcacaggtct tcttctcctt ctccctggcc ttcggggggcc 900
tcattctcct ctcagctac aactctgtgc acaacaactg cgagaaggac tcggtgattg 960
tgtccatcat caacggcttc acatcggtgt atgtggccat cgtggtctac tccgtcattg 1020
ggttccgcgc cagcgagcgc tacgacgact gcttcagcac gaacatcctg accctcatca 1080
acgggttcga cctgcctgaa ggcaacgtga ccaggagaa ctttgtggac atgcagcagc 1140
ggtgcaacgc ctcggacccc gcggcctacg cgcagctggg gttccagacc tgcgacatca 1200
acgccttct ctcagaggcc gtggagggca caggcctggc cttcatcgct ttcaccgagg 1260
ccatcaccaa gatgcggtg tccccactgt ggtctgtgct cttcttctt atgctcttct 1320
gcctggggct gtcattctatg tttgggaaca tggagggcgt cgtgtgtccc ctgcaggacc 1380
tcagagtcac ccccccgaag tggcccaagg aggtgtcac aggcctcatc tgcctgggga 1440
cattcctcat tggcttcatc ttcacgctga actccggcca gtactggctc tccctgctgg 1500
acagctatgc cggctccatt cccctgctca tcatcgctt ctgcgagatg ttctctgtgg 1560
tctacgtgta cgggtgtggc aggttcaata aggacatcga gttcatgac gccacaagc 1620
ccaacatctt ctggcaagtc acgtggcgcg tggtcagccc cctgctcatg ctgcatctc 1680
tcctcttctt cttcgtggta gaggtcagtc aggagctgac ctacagcatc tgggaccctg 1740
gctacgagga atttcccaa tcccagaaga tctcctaccc gaactgggtg tatgtgtgg 1800
tgggtattgt ggctggagtg ccctccctca ccatccctgg ctatgccatc tacaagctca 1860
tcaggaacca ctgccagaag ccaggggacc atcaggggct ggtgagcaca ctgtccacag 1920
cctccatgaa cggggacctg aagtactgag aaggcccatc ccacggcgtg ccatacactg 1980
gtgtcaggga aggaggaacc agcaagacct gtgggggtgg gggcgggctg cacctgcacg 2040
tgtgtaagcg tgagtgtatg ctctgtgtgt agtgtgtgt ttgtacacgc atgtgccatg 2100
tgtgcagata tgtatcgtgt gtgcatgtac atgcatgggc actgtgagtg tgcacgtgta 2160
tgcacacata tacatgtgtg tgggtgtgtg tattgtatgt gcatgtgcca tgtgtgcaga 2220
tgtgtcatgt tgtgtgtgtg catgtacatg tatggacatt gtgtgagtg gcaagtgtgc 2280
atgcataata atgtgtgcga tatttgcctg ccgtgtgtgt gcatgtatat atagacatac 2340
atgcctatgt tgtgtgtgtg gtgcatatgt gtgaacacac acgtgtatac atgcatgcac 2400
atgtgctcgt acaatgggtg tccacatgca cgtgtatatg tatactctgt agtgtatata 2460
catgcatgca attgtgtgta tgtgtgttct gtgtgtgctg ttgcaagtat atatgcacat 2520
gtgtatatgt acatgtatgc ctgtgtgacg tgtgtatatg tgagcatgtg tacgtgtgtg 2580
tatactgtgt ttgtgtatat gtgtgtgtct gtacctgttt gtgtatatgt gtgtgatgtg 2640
tgctcgtgtg tgtgcatatt caggcagggtg tgcatttgtg catcccagtg tgtatgtatg 2700
tgcgcatatg gacacgcagc gacacgcata tggacacata tggacacaca tatggacacg 2760
tgtggatatg tgtgcgtaca cgtcgtggg acacatgcct gccactcggg gccagctga 2820
ccctctgtgt ttggggatcc actattntaa gcgcgccacc gcgtgactcc a 2871

```

<210> 25

<211> 2141

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1734724CB1

<400> 25

```

gcggcgaccg cgggacggcg agaggcacgc ggcgggaggg gaccggaatc cgcagctccg 60
gccgcgccat ggacggcaac gacaacgtga cctgtctctt cgccctctg ctgcgggaca 120
actacaccct ggcgccaat gccagcagcc tgggccccgg caccgaacct gccctcgccc 180
ctgcctccag cgccggcccc ggccctgggc tcagcctcgg gccggtaccg agcttcggct 240

```

```

tcagccccgg ccccaactccg accccggagc ccacgaccag cggcctcgcg ggcggcgcg 300
cgagccacgg ccttcccccg gttccctcgg ccctggggcg cccacgcgct cccgttctgg 360
gacacgccgc tgaaccacgg gctgaacgtg ttcgtggggc cgcctgtgct atcaccatgc 420
tgggcctggg ctgcacgggtg gacgtgaacc acttcggggc gcacgtccgt cggcccgtgg 480
cggcgctgct ggcagctctg ccagttcggc ctccctgcgc tgctggcctt cctgtggcc 540
ctcgccctca agctggacga ggtggccgct gtgggctgct cctgtgtggc tgctgtccc 600
gcggaatct ctccaatctt atgtccctgc tgggtgacgg cgacatgaac ctgagcgtg 660
ctgctctctt ggcactctcc tcggatgtag gttctgcca gacttcaacc cgggacttg 720
cagtctcccc gttccacctc tactcaacat acaagaaaaa ggttagctgg ctgtttgact 780
caaagctcgt tctgatttct gcacattccc ttttctgcag catcatcatg accatctcct 840
ccacgcttct ggcctcgtc ttgatgcccc tgtgcctgtg gatctacagc tgggcttgg 900
tcaacacccc tatcgtgcag ttactacccc tagggaccgt gaccctgact ctctgcagca 960
ctctcatacc tatcgggttg ggcgtcttca ttcgctacaa atacagccgg gtggctgact 1020
acattgtgaa gggttccctg tgggtctctgc tagtgactct ggtggctcct ttcataatga 1080
ccggcactat gttaggacct gaactgctgg caagtatccc tgcagctggt tatgtgatag 1140
caatttttat gcctttggca ggctacgctt caggttatgg tttagctact ctcttccatc 1200
ttccacccaa ctgcaaggg actgtatgtc tggaaaacag tagtcagaat gtgcagctct 1260
gtacagccat tctaaaactg gcctttccac cgcaattcat aggaagcatg tacatgtttc 1320
ctttgctgta tgcacttttc cagtctgcag aagcggggat ttttgtttta atctataaaa 1380
tgtatggaag tgaatgtttg cacaagcgag atcctctaga tgaagatgaa gatacagata 1440
tttcttataa aaaactaaaa gaagaggaaa tggcagacac ttcctatggc acagtgaag 1500
cagaaaatat aataatgatg gaaaccgctc agacttctct cttaaagtgg agatacacag 1560
gagcttctat cttgctgaaa tattgcttca tttttatggc ctgtggtagt gcacatggtt 1620
aacataaaag ataactctgg ttcacatcat acatgtaaca attctgatct ttttaagggt 1680
cactgggtgta ttaaccaaac gttgtcacaa attacaaatc aatgctgtaa tataatttgc 1740
acctggaatg gctaactgta agcctgaatt aaatgtgggt tttagttttt accatcacca 1800
atttctatga ctgttgcaaa tacagaatct attagaaaac agggctcttg aaatgtagaa 1860
ttttggcgca ctatgaggaa aaacaagcta tctttgtaaa gcataattga gtttaattga 1920
attgttgtaa aaaaaaaagt gtgcttgctc tacttaaaat tcctcacaat gttgaatttt 1980
gacctgtatt cagaagaatt ccaaaacagg tcagttaaat aaggaaatat agtatttgct 2040
aaaccagtat cagagaaaag ttacattaat gtatttgatt acttgatctg gtatctactt 2100
attaatgaat aatcaacatt tttctagtga aaaaaaaaaa a 2141

```

<210> 26

<211> 1902

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1563237CB1

<400> 26

```

ccgggtagtg agcggaggga caggaagggt agggcaagaa agggagaggg gacaggaggg 60
aagggtgggc caaagcgggt agaaaggagg gccagccagt tgcgtggggg agagtggccg 120
aggcccgggg gcaggagtgc agggctctga ggcggggaga ggagaggaga gaagagccgc 180
ggggggccca gcccgagacc aggatgcccg cgcgcgcgc ccgggagcag cccgcgctgc 240
ccggggagcg ccagccgctg ctgcctcgcg gtgcgcgggg ccctcgacgg tggcgccggg 300
cggcgggcgc ggccgtgctg ctgggtggaga tgctggagcg cgccgccttc ttcggcgta 360
ccgccaacct cgtgctgtac ctcaacagca ccaacttcaa ctggaccggc gagcaggcga 420
cgcgcgccgc gctggtatcc ctgggcgcct cctacctgct ggcccccgtg ggcggctggc 480
tggccgacgt gtacctgggc cgctaccgcg cggctcgctc cagcctgctg ctctacctgg 540
ccgcctcggg cctgctgccc gccaccgctt tccccgacgg ccgcagctcc ttctgcggag 600
agatgcccg gtcgcgctg ggacctgect gccctcggc cgctgcccgc cgtcctcgc 660
ccagcccta ctgcgcgcc gtccctctac cgggcctgct gctactcggc ctggccgcca 720
gctccgtccg gagcaacctc acctccttcg gtgccacca ggtgatggat ctcgcccgcg 780
acgccaccgg ccgcttcttc aactggtttt actggagcat caacctgggt gctgtgctgt 840
cgctgctggt ggtggcggtt attcagcaga acatcagctt cctgctgggc tacagcatcc 900
ctgtgggctg tgtgggcctg gcatttttca tcttctctt tggcaccocc gtcttcatca 960
ccaagcccc gatgggcagc caagtgtcct ctatgcttaa gctcgctctc caaaactgct 1020
gccccagct gtggcaacga cactcgcca gagaccgtca atgtgcccgc gtgctggccg 1080
acgagaggtc tcccagcca ggggcttccc cgcaagagga catcgccaac ttccaggtgc 1140
tggtgaagat cttgcccgtc atggtgaccc tgggtgccta ctggatggtc tacttccaga 1200

```

```

tgcagtcac ctatgtcctg cagggtcttc acctccacat cccaaacatt ttcccagcca 1260
acccggccaa catctctgtg gccctgagag ccagggcag cagctacacg gagtcctgga 1320
gatggagcgc cttacactac atccaccaca acgagaccgt gtcccagcag attggggagg 1380
tcctgtacaa cgcggcacca ctgtccatct ggtggcagat ccctcagtac ctgctcattg 1440
ggatcagtga gatctttgcc agcatcccag gcctggagtt tgccactca gagggcccgc 1500
gctccatgca gggcgccatc atgggcatct tcttctgcct gtcgggggtg ggctcactgt 1560
tgggctccag cctagtggca ctgctgtcct tgcccggggg ctggctgcac tgccccaagg 1620
atthttgggaa catcaacaat tgccggatgg acctctactt ctctctgctg gctggcattc 1680
aggccgtcac ggctctccta tttgtctgga tcgctggacg ctatgagagg gcgctccagg 1740
gcccagcctc ccacagccgt ttcagcaggg acaggggctg aacagggcct attccagccc 1800
ccttgcttca ctctaccgga cagacggcag cagtcaccag tctggtttcc ttctcggttt 1860
attctgttag aatgaaatgt tcccataaat aagggcattg tc 1902

```

<210> 27

<211> 4125

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473443CB1

<400> 27

```

atggggaaaa aacagtgcac aaaggctaaa aattccaaaa accagaatgc ctcttctcct 60
ccaaaggatc acaactcctc gccagcaggg gaacaaaact ggatggagaa tgaattgaca 120
gaagcaggct tcagaagggtg ggtggtaata aactcctgca agctaaagga gcatgtttta 180
acccaatgta aggaagccaa gaaccttgaa aaaagggttag gcgaattgct aactagaata 240
accagtttag agaagaacat aaatgacctg atggagctga aaaacacagc acgagaactt 300
cgtgatgcat acataagtat cagtagccga attgatcaag cagaaaaaag gatatacagag 360
attgaagatc aacttaatat aataaagcgt gaagacaaga ttagagaaaa aaatgaaaag 420
gatgaacaag gcctccaaga aatatgggac tatgtgaaaa gaccaaactt acatttgatt 480
ggtgtacctg gcctgctcta ttcagacatg tgccgcctcc tcccttctcc aagaaatcag 540
cctgccttgc aggccttgga acgtggagtc atcttgaggg tcaaatgcgt cgtttgcagc 600
acgcaggctg gggcagcgcg gcgtggtgta aagataagta tcaaggggaa aggattttct 660
gtgggtgtag tcgtaggaac cttgcaatgg ttgctttggg ccagagccgc gcatgctcca 720
cactggcggt ttctacgttg gatggcagcc ctgtgggatg tgccaggcaa aactggccct 780
tccccatca gcctcacggg tcagagaggg aaccgggggtc cggagtctct ctctatcctc 840
cgaggcgtgc ccaaggattt cagcacggga acatcagccc aactaaggcg agccatgggg 900
ctggcccttg agggcgaggg tttccaggcc ttcttcccca ggccaccat gcctgcaact 960
cccaacttcc tcgcaaacc cagctccagc agcgcgtgga ttccctcca gccaatgcc 1020
gtggcctggg cctttgtgca gaagacctcg gccctcctgt ggctgtgct tctaggcacc 1080
tcctgtccc ctgctgaggg acaggccaag attcctctgg aaacagtga gctatgggct 1140
gacaccttcg gcggggacct gtataacact gtgacaaaat actcaggctc tctcttgctg 1200
cagaagaagt acaaggatgt ggagtccagt ctgaagatcg aggagtgga tggcttgagg 1260
ctgggtgagga agttctcaga ggacatggag aacatgctgc ggaggaaagt cgaggcggtc 1320
cagaatctgg tggagctgc cgaggaggcc gacctgaacc acgaattcaa tgaatccctg 1380
gtggaacctg gcgtgggagt tggcgtgggg atgtccgtga cgcagtccgg cgtgggagtt 1440
ggcgtgggga tgtccgtgac gcagtccggc gtgggagttg gcgtggggat gtccataacg 1500
ctggtccggc tgggagttgg cgtggggatg tccgtgaggc agtccggcgt gggagttggc 1560
gtggggatgt ccgtgacgca gtccggcggt ggagttggcg tggggatgtc cgtgacgcag 1620
tccggcgtgg gagttggcgt ggggatgtcc gtgaggcagt ccggcgtggg agttggcgtg 1680
gggatgtccg tgacgcagtc ctgggggggtg ttcagtgcgc agcgcgccgc cgcgggtgct 1740
tgtgtagact ctgatggccg cccggccccg gccctctcgt cctctcaact gcgccgtttc 1800
tcttctctc tctccgcctg tcccgggtgt cgggcgcct cgtggggcct caccgtcca 1860
ccccagttcg actattacaa ctccgtcctg atcaacgaga gggacgagaa gggcaacttc 1920
gtggagctgg gcgccgagtt cctcctggag tccaatgctc acttcagcaa cctgccggtg 1980
aacacctcca tcagcagcgt gcagctgccc accaacgtgt acaacaaaga cccagatatt 2040
ttaaattggg tctacatgtc tgaagccttg aatgctgtct tcgtggagaa ctccagaga 2100
gaccacaagt tgacctggca atattttggc agtgcaactg gattcttcag gatctatcca 2160
gggtataaat ggacacctga tgagaatgga tgcattactt ttgactgccg aaaccgcggc 2220
tggtacattc aagctgctac ttctcccaag gacatagtga ttttggtgga cgtgagcggc 2280
agtatgaagg ggctgaggat gactattgcc aagcacacca tcaccaccat cttggacacc 2340
ctgggggaga atgacttcat taatatcata gcgtacaatg actacgtcca ttacatcgag 2400

```

```

ccttggtttta aagggatcct cgtccaggcg gaccgagaca atcgagagca tttcaaactg 2460
ctgggtggagg agttgatggt caaagggtgt ggggtcgtgg accaagccct gagagaagcc 2520
ttccagatcc tgaagcagtt ccaagaggcc aagcaaggaa gcctctgcaa ccaggccatc 2580
atgctcatca gcgacggcgc cgtggaggac tacgagccgg tgtttgagaa gtataactgg 2640
ccagactgta aggtccgagt tttcacttac ctcatggga gagaagtgtc ttttctgac 2700
cgcatgaagt ggattgcatg caacaacaaa ggtactata cgagatctc aacgtggcg 2760
gacacccagg agaacgtgat ggaatacctg cacgtgctca gccgcccat ggtcatcaac 2820
cacgaccacg acatcatctg gacagaggcc tacatggaca gcaagctcct cagctcgag 2880
gctcagagcc tgacactgct caccactgtg gccatgccag tcttcagcaa gaagaacgaa 2940
acgcatccc atggcattct cctgggtgtg gtgggctcag atgtggccct gagagagctg 3000
atgaagctgg cgccccgta caagcttgga gtgcacggat acgcctttct gaacaccaac 3060
aatggctaca tcctctccca tcccgcactc cggccccgtg acagagaggg gaagaaacta 3120
aaacccaaac ctaactacaa cagtgtggat ctctccgaag tggagtggga agaccaggct 3180
gaatctctga gaacagccat gatcaatagg gaaacaggta ctctctgat ggatgtgaag 3240
gttccgatgg ataaagggaa gcgagtctct ttcctgacca atgactactt cttcacggac 3300
atcagcgaca cccctttcag tttgggggtg gtgctgtccc ggggccacgg agaatacatc 3360
cttctgggga acacgtctgt ggaagaaggc ctgcatgact tgcttcaccc agacttggcc 3420
ctggccggtg actggatcta ctgcatcaca gatattgacc cagaccaccg gaagctcagc 3480
cagctagagg ccatgatccg cttcctcacc aggaaggacc cagacctgga gtgtgacgag 3540
gagctggtcc gggagggtgct gtttgacgcg gtggtgacag ccccatgga agcctactgg 3600
acagcgtgg ccctcaacat gtccgaggag tctgaacacg tgggtggacat ggccttctctg 3660
ggcacccggg gtggcctcct gagaagcagc tggttctggg gctccgagaa ggtctccgac 3720
aggaagtccc tgacacctga ggacgaggcc agcgtgttca ccctggaccg cttcccgtg 3780
tggtaccgcc aggcctcaga gcatcctgct ggcagcttct tcttcaacct ccgctgggca 3840
gaaggaccag gacgcccttc tgccaaaggc cttccaccac cactttgcca aaccatctc 3900
aagcgtcgtg atggaaaaat gtcctggagc tgatggctgg ggaggcccag gatccccggg 3960
atcctcctgg gaccaggaca ggggaaggca acagcaggga ggagctccac ccgccccct 4020
cgggaatccc gccttctca cctggtgcta tgccttact ccacctgtg ctgttccctc 4080
cacacacgtg caaataacta ctatgcttca caaaacaaaa aaaaa 4125

```

<210> 28

<211> 2460

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 7473438CB1

<400> 28

```

gggaggagg gatggggaaa ggagtgaag gaaggaagga aggaaaggag ggaggagg 60
aggaaggcag gggaccgggg aggggaggga gggtaaaagg aaggaaggaa ggacggaagg 120
aaggacggaa gactggcacg aggtcacaaac atgagttagt ggcggaaca ggacttctgc 180
aggcccgggg tttgggcctt tgcttcagat ctactattc acagacacat gaaccccg 240
caggcgagt ggaggcggac aggggagcgg tcttccggc cccacccgt ggcgatccca 300
gcctccaggt tcccggcagt cggccgcct cggccgtcac aaccctgccg cgtggggccg 360
gggttgagg gggcgaggcg cgcggtcccg gcacacggag caggttggga ccgcgcggg 420
taccggggc gggcgccat gcggaggcc agcgtgcgc cgccgggct ggtcctgtgc 480
accctgtgtt acctgctggt gggcgctgct gtcttcgac cgctcgagtc cgaggcgga 540
agcgcccgcc agcgactgct ggtccagaag cggggcgctc tccggaggaa gttcggcttc 600
tcggccgagg actaccgca gctggagcgc ctggcgctcc aggtgagcc ccaccgccc 660
ggccgccagt ggaagtcccc cggtccttc tacttcgcca tcaccgtcat cactaccatc 720
gagtacggcc acgcgcgcc gggtagggac tccggcaagg tcttctgcat gttctacgcg 780
ctcctgggca tcccgtgac gctggtcact ttccagagcc tggcggaacg gctgaacgcg 840
gtggtgcggc gcctcctgtt ggcggccaag tgctgcctgg gcctgcggtg gacgtgcgtg 900
tccacggaga acctggtggt ggccgggctg ctggcggtg ccgccacct ggccctcggg 960
gccgtcgctt tctcgactt cgagggtggt accttcttcc acgcctacta ctactgcttc 1020
atcacctca ccaccatcgg cttcggcgac ttcgtggcac tgagagcgg cgaggcgctg 1080
cagaggaagc tcccctacgt ggccttcagc tctctctaca tctcctggg gctcacggctc 1140
attggcgctt tcccaacct ggtggtcctg cgcttctcgc ttgccaagcgc cgactggccc 1200
gagcgcgctg cccgcacccc cagcccgcgc ccccggggg cgcccgagag ccgtggcctc 1260
tggtgcgcc gccgcccggc ccgctccgtg ggctccgct ctgtctctg ccacgtgcac 1320
aagctggaga ggtgcgcccc cgacaacctg ggcttttcgc cccctcgag cccgggggtc 1380

```

```

gtgcgtggcg ggcaggctcc caggcttggg gcccggtgga agtccatctg acaacccac 1440
ccaggccagg gtcgaatctg gaatgggagg gtctggcttc agctatcagg gcaccctccc 1500
cagggattgg aaacggatga cgggcctcta ggcggtcttc tgccacgagc agtttctcat 1560
tactgtctgt ggctaagtc cctccctcct ttccaaaaat atattacagt cacaccataa 1620
gcacaaacca ggctccaggg tcaccctgta ggagcaaatt ccttgtagtc caaattgtat 1680
gagggcgtgg ccacatcagc acttaggaga ggctctgcac aggtccacct cagagccgac 1740
cctccagagc aacttttctg ttgtgaagag gctgggtttc tgagtaacgg ttgaaatgtg 1800
caactttcaa cactggaatc ttcgctgcaa ttagtgaggt cagatgctca cactacgaga 1860
agcatgggga acaaagggtg accaaatggg accgtgtaca gtccagtgtt gacaaggggg 1920
tcaatctctt gcgctaaacg atctcattct ctgccagtg tatagagtgg aatcacgcca 1980
tgtgtgaatg atggcctctt tccccagac agctgatgct ctttgtccct ggccagcccc 2040
acttcaggat gagggaggcc ttgctgtcac ccacccacca tgtaactggg gccacttggg 2100
cacagcagaa tgccatggga cgagctctct tccgggtcct gtcaatcacc agcaatatga 2160
ccttgagaaa tcgcatectc tcccagggcc tcagtttcca catctgtaga atgacggggg 2220
tcatccagaa ccctgctccc tcttacgcac ctctggcagg actttctgga acaggccctc 2280
gcaccataag ggggcagaga caaagcccga cgtgtggcat cctggcacc cgtggcacc 2340
agccacttcc cctggcttcc cagatagggc tgtctcaaca caaagcatga acgagccagg 2400
ttagaaaagc caaaaacttt aatttcaaca tgagctacat ggtcatgaac acaatgcaac 2460

```

<210> 29

<211> 896

<212> DNA

<213> Homo sapiens

<220>

<231> misc_feature

<223> Incyte ID No: 7474286CB1

<400> 29

```

gggaaactga gtccctcacc cccttcaaga cccagggccg ctctctgctc ccgcccctcg 60
aggcccttcg ccggctctgc ctctctcccc tccccgacct caccggccat aagatgatgt 120
gggtccactt cttcctgcaa gaggagaacc ggccggcggg gcccgcgggc cggcgcgggg 180
cgcacgggca gggcaggctc gggtgacgc ccgagcgcgga ggggaagggtg aagctggcgc 240
tgctgtctgg ccgcgtgggc gccacgctgg cgggtgctgtc cgtgggcacc gagttctggg 300
tgagctcaa cacctacaag gccaacggca gcgcgctgtg cgaagcgggc cacttggggc 360
tgtggaaggc gtgcaccaag cggctgtggc aggcggacgt gccggtggac agggacacct 420
gcggcccccgc ggagctgccc ggagaagcaa actgcacctt ttttaaattc ttcaccacgg 480
gggagaatgc acgcatcttt cagagaacca caaagaaaga ggtgaatctg gcagctggcg 540
tgatagcagt gctgggcctg gcagtcattg ccttgggggtg cctctgtatc atcatgggtc 600
tcagtaaagg tgcagagttc ctgctccgag ttggagccgt ctgctttggc ctctcaggcc 660
tgctgtctct ggtgagcctg gaggtgttcc ggcatctcgt gagggccctg ctgcagagag 720
tcagcccgga gcctccccgc gccccacgcc tcacctacga gtactcctgg tccctgggct 780
gcggcggtgg ggcgggcctg atcctgctgt tggggggcgg ctgctttctg ctgctcacac 840
tgccttctct gccctggggg tccctctgtc ccaagcgggg gcaccggggc acctag 896

```

<210> 30

<211> 2080

<212> DNA

<213> Homo sapiens

<220>

<231> misc_feature

<223> Incyte ID No: 7472589CB1

<400> 30

```

gaaaggagcg cttccccgga ctcggtctcg ctccgaggct ccgaagccga cgccgccagc 60
tcagccccgg gggcgggagc aggactgccc gcacagcccc cacttaggag gcgccgatcc 120
cgaacgcctc atgggacgcc ccggggggct ctctccacgc cttgctgccc cgtcccggtc 180
ctaggcgccc gggatccacg gcccaccccg cccgcagccc gcggcctgtc tggagaggag 240
tatgaggccc ggggccccgc ggacgcgggc caccggggcg cagggcgcct agctgcggag 300
ccccgcgccc gagagcgggc ggtaaggagc cgcggggagc ggagagcggt cggggcgcg 360
agaggagcgc ccctgccccg ggcacccgct gggccacggg actcgcgtgt ggctgagcg 420
ccggggagga ggcggaggcg cccctctgtc cgggctctgt gaaggcgacg aggggctctg 480

```

```

cgaaggcggc gaggggctcc ggggcgcccc cggaaccctg gccaccatcc tcaegctcct 540
gctcccgcgc gggggatgtc gtggcccggg ccccgagcgc cggcccggcc ccggggctga 600
gctccggacc atgtcctccc gcagcccccg gccccgcgcc cgccgtagcc gccgccgcct 660
gccgcgcccc tcctgctgct gctgctgctg ccgccgttcg cacctcaacg aggacaccgg 720
ccgcttcgtg ctgctggcgg cgtcatcgg cctctacctg gtggcggtg ccacagtctt 780
ctcggcgctc gagagccccg gcgagggcga ggcgcgggcg cgctggggcg ccacgctgcg 840
caacttcagc gctgcgcacg gcgtggccga gccagagctg cgcgccttcc tccggcacta 900
cgaggccgcg ctggccgcgc gcgtccgcgc cgacgcgctg cggccgcgct gggacttccc 960
cggcgcttc tacttcgtgg gcaccgtggt gtcaaccata gtgagggag aaagcccacc 1020
tctggcgctc accccgggcc gcctgtgctc caaactggc cggctctgtg atctgacctt 1080
taagagttac atcaatattg ccaaagaaca ggagcaccca gcaatacagc agagcttccc 1140
acgggtttct acagtgtctt cagagaaccg caaggagggt ttcggcatga ccacccccgc 1200
gacggtgggc ggggaaggcct tcctcatcgc ctacgggctg ttcggctgcg ctgggacctt 1260
cctgttcttc aacctcttcc tggagcgcat catctcgctg ctggccttca tcatgcgcgc 1320
ctgccgggag cgccagctgc gccgcagcgg cctgctgccc gccaccttcc gccgcggctc 1380
cgcgctctcg gaggccgaca gcctggcggg ctggaagccc tcggtgtacc acgtgctgct 1440
catcctgggc ctgttcgccc tgctgctgtc ctgctgcgcc tcggccatgt acaccagcgt 1500
ggagggctgg gactacgtgg actcgctcta ctctgcttc gtcaccttca gcaccatcgg 1560
cttcggggac ctggtgagca gccagcacgc cgcctaccgg aaccaggggc tctaccgcct 1620
gggcaacttc ctcttcatec tgctcggcgt gtgctgcatt tactcgctct tcaacgtcat 1680
ctccatctc atcaagcagg tgctcaactg gatgctgcgc aagctgagct gccgctgctg 1740
cgcgcgctgc tgcccggtc ctggcgcgcc cctggcccg cgcaatgcc tccccagg 1800
ctcccggtg cgccgcgcgc tggccgcgct cggtgccgac cccgcggccc gcgacagcga 1860
cgccgagggc cgccgcctct cgggcgagct catctccatg cgcgacctca cggcctccaa 1920
caaggtgtcg ctggcgctgc tgcagaagca gctgtcggag acggccaacg gctaccgcg 1980
cagcgtgtgc gtcaacacgc gccagaacgg cttctcgggc ggcgtgggcg cgctgggcat 2040
catgaacaac cggctggccg agaccagcgc ctccaggtag 2080

```

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/077174 A3(51) International Patent Classification⁷: C07K 14/47,
C12N 15/12, 5/10, A01K 67/027, C07K 16/18, C12Q
1/68, A61K 38/16, 39/00

(21) International Application Number: PCT/US01/11206

(22) International Filing Date: 6 April 2001 (06.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/195,595 6 April 2000 (06.04.2000) US
60/196,872 12 April 2000 (12.04.2000) US
60/199,020 20 April 2000 (20.04.2000) US
60/200,552 28 April 2000 (28.04.2000) US
60/202,348 5 May 2000 (05.05.2000) US
60/203,495 11 May 2000 (11.05.2000) US(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier applications:US 60/195,595 (CIP)
Filed on 6 April 2000 (06.04.2000)
US 60/196,872 (CIP)
Filed on 12 April 2000 (12.04.2000)
US 60/199,020 (CIP)
Filed on 20 April 2000 (20.04.2000)
US 60/200,552 (CIP)
Filed on 28 April 2000 (28.04.2000)
US 60/202,348 (CIP)
Filed on 5 May 2000 (05.05.2000)
US 60/203,495 (CIP)
Filed on 11 May 2000 (11.05.2000)(71) Applicant (for all designated States except US): INCYTE
GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo
Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): REDDY, Roopa
[IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA
94086 (US). THORNTON, Michael [US/US]; 9 Medway
Road, Woodside, CA 94062-2612 (US). BOROWSKY,
Mark, L. [US/US]; 122 Orchard Avenue, Redwood City,
CA 94061 (US). TANG, Y., Tom [US/US]; 4230 Ranwick
Court, San Jose, CA 95118 (US). KHAN, Farrah, A.
[IN/US]; 333 Escuela Avenue, #221, Mountain View, CA
94040 (US). TRIBOULEY, Catherine, M. [FR/US];
1121 Tennessee Street, #5, San Francisco, CA 94107 (US).GANDHI, Ameena, R. [US/US]; 837 Roble Avenue,
#1, Menlo Park, CA 94025 (US). YAO, Monique, G.
[US/US]; 111 Frederick Court, Mountain View, CA 94043
(US). SANJANWALA, Madhu, S. [US/US]; 210 Sylvia
Court, Los Altos, CA 94024 (US). BAUGHN, Mariah, R.
[US/US]; 14244 Santiago Road, San Leandro, CA 94577
(US). NGUYEN, Danniell, B. [US/US]; 1403 Ridgewood
Drive, San Jose, CA 95118 (US). POLICKY, Jennifer,
L. [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US).
YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA
94087 (US). SEILHAMER, Jeffrey, J. [US/US]; 12555
La Cresta, Los Altos Hills, CA 94022 (US). WALIA,
Narinder, K. [US/US]; 890 Davis Street, #205, San
Leandro, CA 94577 (US). LAL, Preeti [IN/US]; P.O. Box
5142, Santa Clara, CA 95056 (US). KEARNEY, Liam
[IE/US]; 50 Woodside Avenue, San Francisco, CA 94127
(US). WALSH, Roderick, T. [IE/GB]; 8 Boundary Court,
St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB).
LU, Dyung, Aina, M. [US/US]; 233 Coy Drive, San
Jose, CA 95123 (US). LU, Yan [CN/US]; 3885 Corrina
Way, Palo Alto, CA 94303 (US). GREENE, Barrie, D.
[US/US]; 1332 10th Avenue, #104, San Francisco, CA
94122 (US). RAUMANN, Brigitte, E. [US/US]; 5801
South Dorchester Avenue, #3B, Chicago, IL 60637 (US).
PATTERSON, Chandra [US/US]; 490 Sherwood Way,
#1, Menlo Park, CA 94025 (US).(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics,
Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 October 2002

[Continued on next page]

(54) Title: HUMAN TRANSPORTERS AND ION CHANNELS

(57) Abstract: The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and en-
code TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also
provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.

WO 01/077174 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/11206

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 C12N15/12 C12N5/10 A01K67/027 C07K16/18
C12Q1/68 A61K38/16 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A01K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EMBL [Online] 26 May 1999 (1999-05-26) KA0: "Homo sapiens mRNA for multidrug resistance-associated protein 7, partial" retrieved from EMBL, accession no. HSA238889 Database accession no. AJ238889 XP002192367 * See the sequence; standard codes for conversion of alternatives (unfinished sequencing; this fragment may be the first half of the claimed sequence) * --- -/--</p>	1-19,22, 25-45,60

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 April 2002

Date of mailing of the international search report

17. 07. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Korsner, S-E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/11206

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EMBL [Online] 3 March 2000 (2000-03-03) OHARA ET AL: "Homo sapiens mRNA for FLJ00002 protein, partial cds" retrieved from EMBL, accession no. AK000002 Database accession no. AK000002 XP002192368 * See the NA sequence (99.9% overlap 27-1482 [of SA]: 371-1826) *</p> <p>-----</p>	<p>1-19,22, 25-45,60</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/11206

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 20-21, 23-24
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-19,22,25-44,45,60(PART., AS APPLICABLE)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19, 22, 25-44, 45, 60 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 1 and 16, respectively, and dependent
claims as long as they relate to said sequences.

2. Claims: 1-19, 22, 25-44, 46, 61 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 2 and 17, respectively, and dependent
claims as long as they relate to said sequences.

3. Claims: 1-19, 22, 25-44, 47, 62 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 3 and 18, respectively, and dependent
claims as long as they relate to said sequences.

4. Claims: 1-19, 22, 25-44, 48, 63 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 4 and 19, respectively, and dependent
claims as long as they relate to said sequences.

5. Claims: 1-19, 22, 25-44, 49, 64 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 5 and 20, respectively, and dependent
claims as long as they relate to said sequences.

6. Claims: 1-19, 22, 25-44, 50, 65 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 6 and 21, respectively, and dependent
claims as long as they relate to said sequences.

7. Claims: 1-19, 22, 25-44, 51, 66 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 7 and 22, respectively, and dependent
claims as long as they relate to said sequences.

8. Claims: 1-19, 22, 25-44, 52, 67 (partially, as applicable)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 8 and 23, respectively, and dependent
claims as long as they relate to said sequences.

9. Claims: 1-19, 22, 25-44, 53, 68 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 9 and 24, respectively, and dependent
claims as long as they relate to said sequences.

10. Claims: 1-19, 22, 25-44, 54, 69 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 10 and 25, respectively, and dependent
claims as long as they relate to said sequences.

11. Claims: 1-19, 22, 25-44, 55, 70 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 11 and 26, respectively, and dependent
claims as long as they relate to said sequences.

12. Claims: 1-19, 22, 25-44, 56, 71 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 12 and 27, respectively, and dependent
claims as long as they relate to said sequences.

13. Claims: 1-19, 22, 25-44, 57, 72 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 13 and 28, respectively, and dependent
claims as long as they relate to said sequences.

14. Claims: 1-19, 22, 25-44, 58, 73 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 14 and 29, respectively, and dependent
claims as long as they relate to said sequences.

15. Claims: 1-19, 22, 25-44, 59, 74 (partially, as applicable)

TRICH polypeptide and nucleic acid as specified by
SEQ ID NOS 15 and 30, respectively, and dependent
claims as long as they relate to said sequences.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although Claims 32, 34 are directed to a diagnostic method practised on the body, the search has been carried out and based on the alleged effects.

Although Claim 18 is directed to a method of treatment of the body, the search has been carried out and based on the alleged effects.

Continuation of Box I.2

Claims Nos.: 20-21, 23-24

Present Claims 20-21, 23-24 relate to undefined compounds (and their use) as identified by screening methods. Since the compounds are not defined, no meaningful search can be carried out - and no factual support can be found in the Description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.